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Abstract
The major pathways of human pharmaceuticals into the environment are
from their use by individuals either at home or under medical supervision in
hospitals, and to a lesser extent by the disposal of unwanted or out of date
drugs.
The administered pharmaceuticals will be excreted as the parent com-
pound, metabolite or conjugate and will be transported to sewage treatment
works. In sewage treatment, the compound may be degraded or partially
degraded, adsorbed to sludge if lipophilic, be deconjugated or pass through
sewage treatment unchanged. Once in the environment the substance will be
subject to further degradation processes.
The first part of this research is dedicated to the occurrence and fate of
five substances widely consumed in Switzerland: Clofibric acid (metabolite),
Ibuprofen, Ketoprofen, Mefenamic acid and Diclofenac (Chapter 2). These
acidic drugs were analyzed in three sewage treatment plants (STPs) over four
to seven consecutive days. Ibuprofen, Ketoprofen, Mefenamic acid and Di-
clofenac are non-steroidal anti-inflammatory drugs (NSAIDs). Clofibric acid
is an active metabolite of Clofibrate, Etofibrate, Etofyllinclofibrate which are
drugs used as blood lipid regulators. The anti-inflammatory drug Ibuprofen
and Mefenamic acid are the most sold substances of this study with 17 tons
per year and per substance in Switzerland.
Recoveries after filtration, extraction, derivatisation and clean-up gener-
ally exceeded 70%. Limits of detection (5-15 ng/l) and quantification (15-50
ng/l) were in a range which allows the detection and the quantification of
these compounds in wastewaters.
The results of samples analysis point out that the five substances were
persistent in wastewater eﬄuents after municipal wastewater treatment. At
the most, half of Mefenamic acid was eliminated. Ibuprofen was well removed
(80%) by one sewage treatment plant. The removal of Ibuprofen is depending
on the residence time of wastewater in the STPs. A long raining period in-
duce a important decrease of removal of Ibuprofen and Ketoprofen. Removal
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rates showed a great variability according to sewage treatment plants and
types of treatments (e.g. biological, physico-chemical). The concentrations of
Ibuprofen, Mefenamic acid and Diclofenac were relatively high in the eﬄuents
(150-2000 ng/l), showing a potential contamination of surface water.
An environmental risk assessment is presented. Mefenamic acid seems to
present the most important risk, followed by Ibuprofen, Clofibric acid, Di-
clofenac and Ketoprofen. But the risk ratio for surface water calculated with
a dilution factor was above one only for Mefenamic acid. Since that toxicity
of a single drug might be enhanced by the occurrence of other pharmaceuti-
cals with similar activity, the overall risk of these drugs could be significant.
To our knowledge, chronic ecotoxicity data are available only for Diclofenac
and Clofibric acid. These kind of data are needed for the other chemicals to
confirm our results.
The second part of this thesis is dedicated to anticancer drugs (Chapter
3).
Since the occurrence of anticancer drugs in the environment are few stud-
ied and that these substances are extremely toxic (teratogen, mutagen, etc.),
it was interesting to evaluate the contamination of wastewaters by two of the
most used anticancer drugs.
Two methods were set up to analyse Tamoxifen and 5-Fluorouracil in
wastewaters. A Liquid-liquid extraction (LLE) followed by a purification on
OASISr MCX cartridge and gas chromatography and mass spectrometry de-
tection (GC-MS) were used for the analysis of Tamoxifen. 5-Fluorouracil was
extracted with an ENV+ (Isolute) cartridge (solid-phase extraction), deriva-
tised with pentafluorobenzyl bromide (PFBBr) and detected by GC-MS.
Both methods showed good recoveries (>70%), reproducibility (RSD<10%)
and limits of detection (LOD615 ng/l).
Wastewaters from a residential area, an hospital, and two sewage treat-
ment plants (STPs) were analysed with the analytical methods developed in
this study. Tamoxifen was detected in wastewaters of the hospital, residential
area and influent of STPs, but not in treated wastewaters. All wastewaters
showed no contamination with 5-Fluorouracil.
The risk evaluation was not possible for these drugs, since no ecotoxicity
data (even acute data) is available.
The third part of this research is dedicated to toxicity and mutagenicity
of wastewaters (Chapter 4).
As pharmaceutical compounds, including anticancer drugs that are geno-
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toxic, are discharged in wastewaters, the mutagenic potential of wastewaters
from various origins (hospital, two different sewage treatment plants (STPs)
and a residential area) was evaluated using the Ames test.
The samples were not concentrated prior the analysis to determine the
overall effects of these waters. The survival and the reversion frequencies of
strains TA98, TA100, TA102 and TA1538 following treatment with the dif-
ferent wastewaters were determined. Survival was obtained by two methods.
The first method was by comparing the number of reversions induced by
a known mutagen in the presence and absence of wastewater. The second
was by determining the colony forming ability of dilutions of treated and
non-treated cultures.
The samples from the hospital were on the whole more toxic than sam-
ples from the STPs and residential area. The different strains showed varying
sensitivities to the toxic effects of the wastewater, with TA98 exhibiting the
highest sensitivity (<5% survival). The results from the reversion assays in-
dicated that TA102 was the most sensitive, followed by TA1538 and TA100.
More hospital wastewater than influents of sewage treatment plants were
mutagenic, indicating a higher mutagenic activity in the wastewater of the
hospital. These wastewaters have not to be released in the environment with-
out an adequate treatment. Comparison of the mutagenicity of the influents
and eﬄuents of the STPs showed that less eﬄuent samples were mutagenic.
This result indicates that biological treatments were relatively efficient in
decreasing the mutagenicity of wastewaters.
Due to their beneficial health effects and economic importance, the actions
taken to reduce inputs of drugs into the environment are much debated. The
use of pharmaceutical compounds is expected to grow with the increasing age
of the population. A solution for pollution control is to add sewage treatments
in hospital and to avoid that municipal wastewaters are released without any
treatment. Another solution is to focus on reduction at source, by developing
a clear labeling on medicinal products, guidelines for the disposal and aware-
ness campaign. These recommendations would have the potential benefit of
improved consumer health (by minimizing the intake of active substances),
as well as reduced health care spending.
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Version abre´ge´e
La contamination de l’environnement par les substances pharmaceutiques
est lie´e a` leur utilisation (a` la maison ou dans les hoˆpitaux) ainsi qu’a`
l’e´limination des produits non utilise´s ou de´passe´s de date.
Les stations d’e´purations (STEPs) sont des sources importantes d’apport
de me´dicaments, car une partie de la dose du me´dicament administre´ est ex-
cre´te´e via l’urine ou les matie`res fe´cales sous forme inchange´e, sous forme con-
jugue´e ou de me´tabolites. Dans les STEPs, les substances peuvent eˆtre par-
tiellement ou entie`rement de´grade´es, absorbe´es aux particules en suspension
formant les boues d’e´puration, de´conjugue´es ou alors elles peuvent passer sans
modification au travers des diffe´rents traitements. Une de´gradation de ces
substances peut aussi survenir lorsqu’elles se trouvent dans l’environnement
aquatique.
Dans la premie`re partie de cette recherche, la pre´sence et le devenir de
cinq me´dicaments tre`s utilise´s (Acide Clofibrique, Ibuprofe`ne, Ke´toprofe`ne,
Acide Me´fe´namique et Diclofe´nac) ont e´te´ analyse´s dans trois STEPs durant
quatre a` sept jours conse´cutifs (Chapitre 2). L’Ibuprofe`ne, le Ke´toprofe`ne,
l’Acide Me´fe´namique et le Diclofe´nac sont des anti-inflammatoires (NSAIDs).
L’Ibuprofe`ne et l’Acide Me´fe´namique sont les me´dicaments les plus vendus de
cette e´tude: 17 tonnes par an et par substance en Suisse. L’Acide Clofibrique
est un me´tabolite du clofibrate, de l’e´tofibrate et du clofibrate d’e´tofylline.
Ces substances hypolipe´miantes sont utilise´es pour abaisser les concentrations
plasmatiques e´leve´es de choleste´rol et de triglyce´rides.
La me´thode analytique de´veloppe´e pour analyser ces cinq me´dicaments
permet de re´cupe´rer ge´ne´ralement plus de 70% de ces compose´s. Les limites
de de´tection (5-15 ng/l) permettent la de´tection de ces substances dans les
e´chantillons d’eaux use´es.
Les re´sultats de l’analyse des e´chantillons montrent que ces cinq sub-
stances e´taient persistantes et se retrouvaient dans les eﬄuents des STEPs. La
moitie´ de l’Acide Me´fe´namique e´tait e´limine´e au travers des STEPs e´tudie´es.
L’Ibuprofe`ne e´tait bien e´limine´ (80%) dans une STEP. L’e´limination de l’ibu-
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profe`ne e´tait de´pendante du temps de re´sidence des eaux use´es dans les
STEPs. Une importante pe´riode de pluie a induit une diminution de l’e´limination
de l’Ibuprofe`ne et du Ke´toprofe`ne. Les taux d’e´limination e´taient tre`s vari-
ables en fonction des STEPs et du type de traitement (p.ex. biologique,
physico-chimique). Les concentrations d’Ibuprofe`ne et d’Acide Me´fe´namique
mesure´es dans les eﬄuents e´taient relativement e´leve´es (150-2000 ng/l), pou-
vant induire une contamination non ne´gligeable des eaux de surface.
Une e´valuation du risque pour l’environnement est pre´sente´e dans ce tra-
vail. L’Acide Me´fe´namique semble pre´senter le risque le plus important suivi
par l’Ibuprofe`ne, l’Acide Clofibrique, le Diclofe´nac et le Ke´toprofe`ne. Mais le
risque pour les eaux de surfaces n’est probable que pour l’Acide Me´fe´namique.
La toxicite´ d’une substance peut eˆtre augmente´e par la pre´sence d’autres
me´dicaments avec des modes d’actions similaires, ainsi le risque ge´ne´ral de
ces substances pharmaceutiques dans l’environnement pourrait eˆtre signifi-
catif. Des donne´es d’e´cotoxicite´s chroniques ne sont disponibles que pour le
Diclofe´nac et l’Acide Clofibrique. Ce type de donne´es est absolument ne´ces-
saire pour les autres substances afin de confirmer nos re´sultats.
La deuxie`me partie de cette the`se est consacre´e aux substances utilise´es
pour le traitement des cancers (Chapitre 3).
E´tant donne´e que la pre´sence dans l’environnement des me´dicaments con-
tre le cancer est tre`s peu e´tudie´e et que ces substances sont extreˆmement
toxiques (te´ratoge`ne, mutage`ne, etc.), il e´tait inte´ressant d’e´valuer la con-
tamination des eaux use´es par quelques’uns de ces me´dicaments.
Deux me´thodes d’analyse chimique ont e´te´ de´veloppe´es pour analyser
la pre´sence du Tamoxife`ne et de 5-Fluorouracil dans les eaux use´es. Une
extraction liquide-liquide (LLE) suivie par une purification sur une cartouche
OASISr MCX et une analyse par chromatographie en phase gazeuse avec une
de´tection par spectrome´trie de masse (GC-MS) ont e´te´ utilise´es pour l’analyse
du Tamoxife`ne. 5-Fluorouracil a e´te´ extrait graˆce a` une cartouche ENV+
(extraction en phase solide), derivatise´ avec du bromide de pentafluorobenzyl
(PFBBr) et de´tecte´ par GC-MS. Ces me´thodes permettent de re´cupe´rer plus
de 70% de ces substances dans les eaux use´es et les limites de de´tection
(LOD615 ng/l) sont bonnes.
Des eaux use´es d’une zone re´sidentielle, d’un hoˆpital et de deux STEPs
ont e´te´ analyse´es avec les me´thodes de´veloppe´es. Le Tamoxife`ne a e´te´ de´tecte´
dans les e´chantillons de l’hoˆpital, de la zone re´sidentiel et des influents des
STEPs, mais pas dans les eaux traite´es (eaux de sortie de STEPs). Aucun des
e´chantillons d’eaux use´es n’e´tait contamine´ par le me´dicament 5-Fluorouracil.
L’e´valuation du risque pour l’environnement n’a pas e´te´ possible pour ces
me´dicaments, car aucune donne´e sur leur e´cotoxicite´ n’e´tait disponible.
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La troisie`me partie de ce travail est consacre´e a` la toxicite´ et a` la mu-
tage´nicite´ des eaux use´es (Chapitre 4).
E´tant donne´ que certains me´dicaments mutage`nes, comme ceux utilise´s
contre les cancers, sont excre´te´s dans les eaux use´es, il e´tait inte´ressant
d’e´valuer le pouvoir mutage`ne (avec le test de Ames) des eaux use´es de dif-
fe´rentes origines (hoˆpital, deux STEPs, et une zone re´sidentielle).
Les e´chantillons n’ont pas e´te´ concentre´s avant l’analyse afin de de´ter-
miner l’effet global de ces eaux. Les souches TA98, TA100, TA102 et TA1538
ont e´te´ utilise´es pour de´terminer les taux de survie et les fre´quences de
re´version induites par les e´chantillons. La survie a e´te´ mesure´e graˆce a` deux
me´thodes. La premie`re me´thode consistait a` comparer le nombre de re´ver-
tants induits par une substance mutage`ne connue en pre´sence ou en l’absence
des e´chantillons. La deuxie`me me´thode de´terminait la capacite´ a` former des
colonies a` partir des cultures dilue´es, traite´es ou non-traite´es par les e´chan-
tillons.
Les e´chantillons d’hoˆpitaux e´taient plus toxiques que ceux des STEPs et
de la zone re´sidentielle. La sensibilite´ a` la toxicite´ variaient en fonction des
diffe´rentes souches, TA98 e´tait la souche la plus sensible (<5% de survie).
Les re´sultats du test de mutage´nicite´ montrent que TA102 e´tait la souche
la plus sensible, suivie par TA1538 et TA100. Les eaux use´es de l’hoˆpital
e´taient plus souvent mutage`nes que les eaux use´es des STEPs. Il est par
conse´quent tre`s important que les eaux use´es d’hoˆpitaux ne soient jamais
de´verse´es dans l’environnement sans un traitement ade´quat. La comparaison
de la mutage´nicite´ des eaux use´es et des eaux traite´es des STEPs montre
qu’un nombre plus faible d’eaux traite´es e´taient mutage`nes. Ces re´sultats
indiquent que les traitements biologiques des STEPs e´taient relativement
efficaces pour diminuer la mutage´nicite´ des eaux use´es.
A cause de l’effet be´ne´fique pre´sume´ et de l’importance e´conomique, les
actions e´labore´es pour re´duire les rejets de me´dicaments dans l’environnement
sont souvent conteste´es. De plus, l’utilisation des substances pharmaceutiques
va tre`s probablement augmenter avec l’accroissement de l’age de la popula-
tion. Une solution pour limiter la pollution par ces substances serait d’ajouter
des traitements d’eaux use´es a` la sortie des hoˆpitaux et d’e´viter tout de´borde-
ments dans les STEPs communales. D’autres solutions seraient de diminuer
la pollution a` la source, en de´veloppant un label clair sur les me´dicaments, des
directives pour l’e´limination des me´dicaments non-utilise´s et des campagnes
de sensibilisation de la population a` l’(e´co)-toxicite´ de ces substances. Ces
recommandations pourraient ame´liorer la sante´ de la population en diminu-
ant l’ingestion de substances actives, et diminuer les couˆts de la sante´ lie´s a`
cette sur-consommation.
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Glossary of Terms
Acute exposure Contact with a substance that occurs once or for only a
short time (compare with chronic exposure).
Additive effect A biologic response to exposure to multiple substances
that equals the sum of responses of all the individual substances added
together (compare with antagonistic effect and synergistic effect).
Aneuploid Having a chromosome number that is not a multiple of the
haploid number for the species.
Antineoplastic Drugs that control or kill neoplastic cells; used in chemother-
apy to kill cancer cells.
Cancer Group of diseases that occur when cells in the body become ab-
normal and grow or multiply out of control.
Carcinogen A substance, factor or situation that causes or induces cancer.
Chronic exposure Contact with a substance that occurs over a long time
(more than 1 year for humans).
DNA Deoxyribonucleic acid. DNA constitutes the molecules inside cells
that carry genetic information and pass it from one generation to the
next.
Cytostatic Inhibiting or suppressing cellular growth and multiplication.
Ecotoxicology The science that deals with the possible impact of chemicals
on the environment.
Eﬄuent Wastewater that flows out of a treatment plant, sewer, or indus-
trial outfall. Generally refers to wastes discharged into surface waters.
Endocrine disruptor A natural or man-made chemical that can interfere
with endocrine glands and their hormones or where the hormones act
- the target tissues.
xxiii
Glossary of Terms
Frameshift mutation Type of mutation consisting of the insertion or dele-
tion of one or more nucleotides in the nucleic acid structure of a gene,
when the number of base pairs inserted or deleted is not a multiple of
three. If the addition or deletion occurs in multiples of three, the unaf-
fected nucleotides in the genome remain in the proper order (“frame”)
to be correctly translated into protein; in such cases of insertions or
deletions not causing a frame shift, a functional though altered protein
may be produced by the organism. Frameshift mutations cause more
profound changes in the composition of the protein resulting from trans-
lation of the mutated gene.
Gene The functional and physical unit of heredity passed from parent to
offspring. Genes are pieces of DNA, and most genes contain the infor-
mation for making a specific protein.
Genotoxic (genotoxicity) Toxic (damaging) to DNA. Substances that
are genotoxic may bind directly to DNA or act indirectly leading to
DNA damage by affecting enzymes involved in DNA replication, thereby
causing mutations which may or may not lead to cancer or birth de-
fects (inheritable damage). Genotoxic substances are not necessarily
carcinogenic.
Germ cell a spermatozoon or an ovum.
Haploid Having the same number of sets of chromosomes as a germ cell or
half as many as a somatic cell.
Influent Water, wastewater, or other liquid flowing into a reservoir, basin,
or treatment plant.
In vitro In an artificial environment outside a living organism or body. For
example, some toxicity testing is done on cell cultures or slices of tissue
grown in the laboratory, rather than on a living animal.
Mutagen (mutagenic, mutagenicity) A substance or physical agent that
causes mutations, i.e. permanently alters the DNA of a cell.
Mutation (gene mutation, genetic mutation, chromosomal mutation)
Any permanent change in the DNA of a cell. Mutations may be caused
by mistakes during cell division, or they may be caused by exposure to
DNA-damaging agents in the environment. Mutations can be harmful,
beneficial, or have no effect. If they occur in cells that make eggs or
sperm, they can be inherited; if mutations occur in other types of cells,
xxiv
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they are not inherited. Certain mutations may lead to cancer or other
diseases.
Nucleotide One of the structural components, or building blocks, of DNA
and RNA. A nucleotide consists of a base (one of four chemicals: ade-
nine, thymine, guanine, and cytosine) plus a molecule of sugar and one
of phosphoric acid.
Oncogene A gene that is capable of causing the transformation of normal
cells into cancer cells.
Prodrug An inactive precursor of a drug, converted into its active form in
the body by normal metabolic processes.
Somatic cells All body cells, except the reproductive cells.
Strain A group of organisms of the same species, having distinctive char-
acteristics but not usually considered a separate breed or variety.
Synergy (synergistic or synergic effect) A biologic response to multi-
ple substances where one substance worsens the effect of another sub-
stance. The combined effect of the substances acting together is greater
than the sum of the effects of the substances acting by themselves.
Teratogen A substance that causes defects in development between con-
ception and birth. A teratogen is a substance that causes a structural
or functional birth defect.
Tumor (tumour, solid neoplasm) An abnormal mass of tissue that re-
sults from excessive cell division that is uncontrolled and progressive.
Tumors perform no useful body function. Tumors can be either benign
(not cancer) or malignant (cancer).
xxv

Abbreviations
ACN Acetonitrile
CA Clofibric acid
CH Switzerland
CHUV Centre Hospitalier Universitaire Vaudois / University hos-
pital of Lausanne
d day
DE Deutchland
DK Denmark
DNA DeoxyriboNucleic Acid
EC50 median Effect Concentration or 50% effective concentration
ECOSAR Ecological Structure Activity Relationships
eﬄ eﬄuent (treated wastewater)
5-FU 5-Fluorouracil
GC Gas Chromatography
h hour
HC5 Hazardous Concentration for 5% of the species
IHA Institut fu¨r Haushaltsanalysen
inf influent (wastewater)
inh inhabitants
LC Liquid chromatography
LD50 lethal dose 50% kill
LLE Liquid-liquid Extraction
LOD limit of Detection
LOEC Low Observed Effect Concentration
LOQ Limit of Quantification
MEC Measured Environmental Concentration
MeOH Methanol
MR Mutagenicity Ratio
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Abbreviations
MS Mass spectrometry
ND Not Detected
NOEC No Observed Effect Concentration
NSAID Non-Steroidal Anti-Inflammatory Drug
OFEFP Office Fe´de´ral de l’Environnement, des Foreˆts et du Paysage
/ Swiss Agency for the Environment, Forests and Landscape
(SAEFL)
PEC Predicted Environmental Concentrations
PNEC Predicted No Effect Concentration
RA Residential area
RSD Relative Standard Deviation
SD Standard Deviation
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Chapter 1
General introduction
Nowadays tons of pharmacologically active substances are consumed yearly
in human medicine for diagnosis, treatment, or prevention. In animal and fish
farming there is greater reliance on drugs for preventing illness, as growth pro-
moters, or as parasiticides. Consequently, pharmaceuticals are continuously
being released into the environment, mainly as a result of excreta, disposal
of unused or expired products, and manufacturing processes.
The contamination of the environment by drugs is partly a function of the
quantity administered, the excretion efficiency of the parent compound and
metabolites, propensity of the drug to adsorb to solids, and the biodegrada-
tion in sewage treatments (or in landfill).
Since drugs are used to“take care”of humans, drugs were rarely viewed as
potential environmental pollutants, even tough they can be toxic. Neverthe-
less, recent studies have shown a wide contamination of water environments
by pharmaceutically active substances [for reviews see Halling-Sorensen et al.,
1998; Daughton & Ternes, 1999]. Thus, the occurrence of drugs in the envi-
ronment is now a subject of concern.
1.1 Usage and Consumption
Several thousands of active ingredients are used for drugs, which are rep-
resented in even more products. For example, 6 900 human pharmaceuticals
and 820 veterinary products were authorized to be sold in Switzerland in
2002 [Swissmedic, 2003]. More than half of them were only delivered with
prescription. In Belgium and Luxembourg, more than 11 000 drugs but only
2 200 active substances were registered for human used, and 2 700 brand
name were available on the market1. In Germany, about 50 000 drugs were
1www.aventispharma.be
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registered for human use, 2 700 of which accounted for 90% of the total con-
sumption and which, in turn, contained about 900 different active substance
[Ku¨mmerer, 2001b].
Large quantities of pharmaceutical substances are prescribed in human
medical care, and they are sold in high amounts without prescription or in
internet-available products. In Switzerland, the Institut fu¨r Haushaltsanal-
ysen (IHA) - IMS HEALTH produces precise statistic in term of quantities
of pharmaceutical and active compounds sold. Some of these data are pre-
sented in Tables 2.1 and 3.1 and in Appendices A.17 and A.17. For most
of the countries, the estimation of drug consumptions were less precise. A
synthesis of the literature data is presented in Table 1.1.
The highest consumed drugs were the analgesics, e.g. paracetamol and
acetylsalicylic acid (Aspirinr). In UK analysis, it was estimated that parac-
etamol was used between 1130 to 2000 tonnes per annum in 2000 and 1995,
respectively, followed by aspirin with 770 tonnes in 1995 and 79 tonnes in
2000 [Webb, 2001a; Sebastine & Wakeman, 2003]. Ibuprofen was used in UK
at 163 tonnes and in Switzerland at 18 tonnes. The consumption of acid
mefenamic was the same level in Switzerland and in UK.
The antibiotics, as amoxycillin and penicillin V, are also highly prescribed.
According to Halling-Sorensen et al. [1998], antibiotics were the most con-
sumed group in human therapy in UK (see Table 1.2). In addition, a total of
110 tonnes of antibiotics in UK were used as growth promoters in livestock
production, as feed additives in fish farms or as coccidiostatica in poultry
production. Therefore the risk that the antibiotics may end up in the envi-
ronment is not negligible.
Synthetic steroids are frequently prescribed as oral contraceptives but be-
cause of their high pharmacological potency the total amounts annually sold
are relatively low. Indeed, the annual prescriptions of 17α-ethinylestradiol in
Germany amount only to approximately 50 kg [Ternes et al., 1999b].
There is significant differences in the type of drugs which are prescribed
in differing countries (see Table 1.1). For example, in the UK amoxycillin
is the highest prescribed antibiotic whereas in Denmark this drug is rarely
used with penicillin V being the most prescribed antibiotic [Ayscough et al.,
2000].
While already used in vast quantities, the consumption of drugs is ex-
pected to increase for the following reasons: expanding population, increas-
ing age of the population, increased per capita consumption, expiration of
patents.
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1.2. Source and fate
Table 1.2: Consumption in UK of medical substances per therapeutic
groups [Halling-Sorensen et al., 1998]
Substances Applied weight [t/year]
Antibiotics 38
Analgesics (NSAID-type) 28
Diuretics 3.8
Anti-asthmatics 1.7
Psychleptics 7.4
1.2 Source and fate
1.2.1 Source
The main routes for human pharmaceuticals to reach the environment are
expected to be through the use by patients in hospitals, medical centres or
at home, and disposal of unwanted or out-of-date drugs by users (see Figure
1.1). Another way that drugs enter the environment are as waste eﬄuents of
the manufacturing processes and from accidental spills during manufacturing
or distribution.
Following its use, a medical substance will be excreted in urine or faeces
as a mixture of unchanged substance, metabolites or conjugated products.
Metabolism is partly depending on the type of pharmaceutical compound
and on the individual patient. The conjugates (i.e. glucuronide and sulphate
formation) are more soluble forms. There is some evidence that conjugates
entering the sewage treatment plants may be hydrolysed and reactivated
to the parent drug or metabolite [Heberer, 2002a], via enzymatic, acidic or
alkaline hydrolysis (see Appendix C.2 on page 208).
The substances then enter the sewage system and pass through sewage
treatment before release via sludge, or eﬄuent discharge to surface waters.
Sewage treatment plants (STPs) therefore serve as an important pathway of
pharmaceutical contaminations.
Veterinary products vary considerably from human pharmaceuticals in
their pathways to the environment. For example, fish farm chemicals pass
directly to water and are not subject to STP processes; antibiotics are added
to cattle feed as growth enhancers which are then excreted and dispersed
on fields in manure [Hirsch et al., 1999]. The fate of veterinary products
is discussed in more detail in several papers [Halling-Sorensen et al., 1998;
Hirsch et al., 1999].
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Hospital use At home use
Sludge dispersed 
on fields a
Excretion in urine 
and feces
Effectis on 
aquatic organisms
Sewage system
Aquatic environment
Effects on 
terrestrial organisms
Disposal of surplus 
dugs
Sewage treatment plant
(STP)
Runoff
SOURCE
FATE
EFFECTS
Incineration
Minor Major
Figure 1.1: Possible pathways of human pharmaceuticals in the environ-
ment
a In Switzerland, the agriculture use of sewage sludge is no more allowed (Ordinance on
substances)
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1.2.2 Fate in sewage treatment plants (STPs)
The aim of a sewage treatment plants (STPs) is to remove suspended and
degradable material from the wastewater. STPs that function on a biological
principle are the most widespread. The various treatments are (see Figure
1.2):
Screens: remove large and medium sized clogging constituents.
Sand trap: remove sand and other heavy sediments.
Fat separator: remove floating substances as fats or oils.
Primary sedimentation tank: is used for settling of a significant portion of
the organic solids. This settled material is called sludge and follow
several treatments (e.g. thickening, digestion).
Biological and chemical treatment: use a large population of microorgan-
isms or chemical (e.g. FeCl3) to convert the remaining organic material
into other forms which can easily settled in the secondary sedimentation
tank.
Biological (activated sludge) and chemical (FeCl$_{3}$) treatment
Influent
Effluent
Screen Sand trap Fat 
separator 
Sludge
treatments
Primary 
sedimentation 
tank 
Biological and 
chemical 
treatments
Secondary 
sedimentation 
tank 
Figure 1.2: Description of a sewage treatment plant
In a sewage treatment plant, a pharmaceutical compound and its metabo-
lites can follow one of three patterns in behaviour (see Figure 1.1):
• Hydrophilic (often formed by metabolism, e.g. clofibric acid) and per-
sistent substances, remain in the aqueous phase and may pass though
the STP and therefore reach the aquatic environment.
• Degradable substance, transformed into smaller molecular entities or
into carbon dioxide and water. During the treatments of the STP,
chemical and biological degradation could occur extensively. Aerobic
6
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degradation by microorganisms could lead to biotransformation of the
drug substance and its metabolites, with a conversion into breakdown
products and some mineralisation could occur (conversion into CO2 +
H2O). Hydrolysis and photolysis, two main chemical degradation pro-
cesses, could lead to chemical transformation of the drug. Some pharma-
ceutical substances are susceptible to these chemical and/or biological
degradation processes while others are not.
• Part of the lipophilic and not readily degradable substances will be set-
tled in the tanks of the STPs and retained in the sludge. Hydrophobic
compounds are concentrated (by several orders of magnitude) in the
sludge compared with the sewage from which the sludge was derived.
When the sludge is used as fertiliser and dispersed on fields, pollu-
tants or drugs, or their biologically active metabolites, may threaten
the ground water (depending on their mobility in the soil system) and
hence affect terrestrial and aquatic organisms. For this reason, the agri-
culture use of sewage sludge is no more allowed in Switzerland (ordi-
nance on substances).
1.2.3 Disposal
Large quantities of drugs are never consumed and many of these are even-
tually disposed down the toilets or via domestic refuse [Daughton & Ternes,
1999]. If a patient should have any medicines left over, the correct procedure
is to return them to the pharmacy, which is then responsible for disposal. In
the Canton of Vaud, 20 tonnes of unused and out-of-date pharmaceuticals
are collected annually by pharmacies (pers. comm. of E. Maillefer, CRIDEC
SA, Eclepens). Nevertheless, according to Kuspis & Krenzelok [1996], the
majority of people in the United States will either flush unused drugs down
drain or dispose of them in domestic refuse which will be incinerated.
The disposal of waste pharmaceuticals is subject to control in the cases
of manufacturers, wholesalers and retailers of such products, and hospitals.
In the case of pharmacies and hospitals, disposal is done through the use
of special containers to be collected by licensed waste disposal contractors.
Depending on the nature of the waste, it may then undergo incineration,
sent to STPs or be taken to designated landfill sites. In Switzerland, these
containers are incinerated.
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1.2.4 Manufacture
Wastage from manufacturing units (to landfill, incinerators or sewage
treatment plants (STPs)) is minimal due to the careful handling and pack-
aging of expensive pharmaceutical products. For example, it has been es-
timated that a manufacturer or packer of a pharmaceutical will only incur
1-5% wastage of their product [Richardson & Bowron, 1985]. Similarly, the
distribution of pharmaceutical products is likely to lead to releases to the
environment only in exceptional circumstances (e.g. an accident).
1.3 Occurrence and fate in the environment
Pharmaceutical substances were detected in hospital eﬄuents, sewage ef-
fluents, surface waters and even in ground and drinking waters. The occur-
rence of pharmaceuticals has been investigated in several countries: Brazil
[Stumpf et al., 1999], Canada [Ternes et al., 1999a], England [Ashton et al.,
2004], France [Andreozzi et al., 2003], Germany [Heberer et al., 2002; Ternes,
1998; Ternes et al., 2001], Greece [Koutsouba et al., 2003], Italy [Calamari
et al., 2003], Spain [Farre´ et al., 2001], Switzerland [Soulet et al., 2002; Golet
et al., 2002; Buser et al., 1998a], Sweden [Andreozzi et al., 2003] and US
[Kolpin et al., 2002].
The occurrence of pharmaceuticals in different environmental compart-
ments, especially water, were reviewed by Halling-Sorensen et al. [1998];
Daughton & Ternes [1999]; Ku¨mmerer [2001a]; Jones et al. [2001]; Heberer
[2002a], among others.
Where pharmaceuticals have been detected in sewage eﬄuents or surface
waters, the levels are in trace amounts at the ng/l or, at most, low µg/l level.
Only a few studies looked for the presence of pharmaceuticals in ground-
water [Heberer et al., 1997; Sacher et al., 2001; Heberer, 2002b]. Most of-
ten these have been associated with contamination via older landfills over
vulnerable aquifers and therefore may represent isolated and rather specific
circumstances. No quantitative data were located on concentrations of phar-
maceuticals in sewage sludge.
The groups of pharmaceuticals detected are broad e.g. contraceptive hor-
mones, lipid regulators, pain killers, antibiotics, anticancer drugs, antiepilep-
tic drugs and those regulating blood pressure. The occurrence of drug metabo-
lites has not been studied in detail apart from a few specific compounds (e.g.
clofibric acid, fenofibric acid and salicylic acid) [Buser et al., 1998b; Ahrer
et al., 2001; Koutsouba et al., 2003; Farre´ et al., 2001] and, therefore, current
knowledge of metabolites contamination is limited.
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1.3.1 Analgesics and anti-inflammatory drugs
As a pro-drug, Aspirinr (acetylsalicylic acid) is easily degraded into its
more active form salicylic acid. This metabolites is detected in sewage influ-
ent, eﬄuent and river samples at concentration up to 54 µg/l [Farre´ et al.,
2001; Ternes, 1998; Heberer, 2002b]. Ternes [1998] observed that Aspirinr
was efficiently removed by the municipal STPs. According to Henschel et al.
[1997], salicylic acid is biodegradable.
To a lesser extent, the pain killer paracetamol (acetaminophen) is also
easily biodegraded [Henschel et al., 1997; Richardson & Bowron, 1985]. Ternes
[1998] and Kolpin et al. [2002] detected paracetamol in less than 24% of all
samples at a maximum concentration up to 10 µg/l.
Ibuprofen, diclofenac and ketoprofen has been detected in STP influents
and eﬄuents and in surface water samples [Soulet et al., 2002; Buser et al.,
1999; Sacher et al., 2001; O¨llers et al., 2001; Stumpf et al., 1999]. Ibuprofen
showed high removal rates with biological treatment measured by several
authors [Ternes, 1998; Buser et al., 1999; Stumpf et al., 1999]. For diclofenac,
Heberer et al. [2002] showed a removal rate of 17% in different STPs in
Berlin. On the other hand, in the STPs studied by Stumpf et al. [1999] and
Ternes [1998], up to 75% of diclofenac was removed. In addition, diclofenac
was sensitive to photodegradation [Buser et al., 1998a; Andreozzi et al., 2003]
and ozone [Zwiener & Frimmel, 2000; Huber et al., 2003; Ternes et al., 2002].
Stumpf et al. [1999] measured a removal rates of 48% for ketoprofen with an
activated sludge treatment.
Several other analgesics such as, for instance, codeine and naproxen, have
also been detected in sewage and surface water samples [Ternes, 1998; Kolpin
et al., 2002; O¨llers et al., 2001; Rodriguez et al., 2003a; Tixier et al., 2003].
These drugs were non-biodegradable [Richardson & Bowron, 1985].
Phenazone, diclofenac or ibuprofen, have also been detected in some
ground water or drinking water samples [Heberer et al., 1997; Sacher et al.,
2001; Heberer et al., 2001; Ternes, 2001a].
The Chapter 2 is focused on mefenamic acid, ibuprofen, diclofenac and
ketoprofen.
1.3.2 Antibiotics
Hirsch et al. [1999] combined overviews on antibiotics in water with re-
sults from their own investigations and Thiele-Bruhn [2003] reviewed the
contamination of soils.
Kolpin et al. [2002] detected a high number of antibiotics in U.S. sur-
face water samples. Golet et al. [2001] found ciprofloxacin and norfloxacin in
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wastewater sample at a maximum concentrations up to 400 ng/l. Ciprofloxacin
has been detected at high concentrations (3 to 87 µg/l) in hospital eﬄu-
ents [Hartmann et al., 1998]. Golet et al. [2002] detected ciprofloxacin and
norfloxacin in surface water, but less consumed antibiotics as fleroxacin or
lomefloxacin were not detected.
The occurrence of sulfamethoxazole, dehydroerythromycin and sulfamet-
hazine in groundwater samples in Germany was reported by Sacher et al.
[2001] and Hirsch et al. [1999].
Most of the tested antibiotics (ciprofloxacin, ofloxacin, metronidazole, ery-
thromycin, tetracycline and sulphamethoxazole) were biodegradable, with
the exception of penicillin G [Richardson & Bowron, 1985; Ku¨mmerer et al.,
2000; Al-Ahmad et al., 1999].
1.3.3 Antiepileptic drugs
The antiepileptic drugs carbamazepine and primidone have frequently
been detected in wastewater and surface water samples [O¨llers et al., 2001;
Ahrer et al., 2001; Heberer, 2002b; Ternes, 1998]. Several studies showed
that carbamazepine was not significantly removed during sewage treatment
[Heberer, 2002b; Ternes, 1998] and can be detected in groundwater and drink-
ing waters [Sacher et al., 2001; Ternes, 2001a].
1.3.4 Beta-blockers
Several beta-blockers (metoprolol, propanolol and bisprolol) have been
found in sewage eﬄuents and in surface waters [Hirsch et al., 1996; Ternes,
1998]. Sotalol was detected in three groundwater samples by Sacher et al.
[2001].
1.3.5 Blood lipid regulators
The first detections of clofibric acid, the active metabolite of the blood
lipid regulators clofibrate, etofyllin clofibrate and etofibrate, in wastewaters
from STPs have already been reported in the 1970s [Hignite & Azarnoff,
1977]. Since then, this substance was one of the most frequently reported
pharmaceuticals in monitoring studies. It has been detected in waste, sur-
face, ground and drinking water samples [Stan et al., 1994; Buser et al.,
1998b; Heberer, 2002b; Stumpf et al., 1996]. Several studies showed no or lit-
tle removal rate by different STPs [Heberer et al., 2002; Ternes, 1998; Stumpf
et al., 1999]. Winkler et al. [2001] and Richardson & Bowron [1985] found
10
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no evidence for biotic degradation of clofibric acid and clofibrate. The oc-
currence and behaviour of clofibric acid are discussed in detail in Chapter
2.
Bezafibrate and gemfibrozil have been detected in wastewater and in sur-
face water samples [Stumpf et al., 1999; Ahrer et al., 2001; Farre´ et al., 2001].
Ternes [2001a] and Heberer [2002b] detected gemfibrozil in groundwater sam-
ples.
1.3.6 Anticancer drugs
Ifosfamide and cyclophosphamide have been found in sewage samples from
hospitals and STPs [Ternes, 1998; Steger-Hartmann et al., 1997, 1996; Ku¨m-
merer et al., 1997]. 5-Fluorouracil has been detected at high concentration
(900 ppm) in wastewater from a 5-Fluorouracil plant [Anheden et al., 1996].
Until now, cytostatics have not been detected in surface water [Ternes, 1998].
Ifosfamide, cyclophosphamide and methotrexate exhibited poor biodegrad-
ability [Steger-Hartmann et al., 1997; Ku¨mmerer et al., 1997; Henschel et al.,
1997]. Chapter 3 is focused on anticancer drugs.
1.3.7 Oral contraceptives
17α-ethinylestradiol and mestranol were detected at trace-level concen-
tration (<1-3 ng/l) in sewage eﬄuents, surface waters and ground waters
in various countries [Ternes et al., 1999a; Hohenblum et al., 2004; Adler
et al., 2001]. Baronti et al. [2000] measured a removal rate of 85% for 17α-
ethinylestradiol with an activated sludge treatment.
1.4 Effect to the environment
The evidence supports the case that pharmaceutical compounds, refrac-
tory to degradation and transformation, do indeed have the potential to reach
the environment. What is not known, however, is whether these chemicals
and their transformation products can elicit physiologic effects on biota at
low concentrations at which they are observed to occur.
1.4.1 Ecotoxicity
Although pharmaceutical chemicals receive considerable pharmacological
and clinical testing, information on the ecotoxicity of these biologically active
substances is generally limited. Acute toxicity values are in the mg/l range
11
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for most of the pharmaceuticals detected in the environment [for reviews see:
Halling-Sorensen et al., 1998; Webb, 2001a]. But, reported levels in surface
water are at least three orders of magnitude below the mg/l levels which
cause acute toxicity. It is more difficult to assess whether there is any en-
vironmental significance with regard to long-term effects as chronic toxicity
data are lacking [for review see Webb, 2001a].
1.4.2 Antibiotic resistance
Antibiotics have a different effect than common xenobiotics, because bac-
teria are the target organism of antibiotics. The increased use of antibiotics
during the last five decades has caused a genetic selection of more harm-
ful bacteria [Jorgensen & Halling-Sorensen, 2000]. Moreover, it seems that
development of antibiotics resistance is favoured by pollution or concentra-
tions of antibiotics in waters or sediments [Ku¨mmerer & Henninger, 2003;
Leff et al., 1993; Attrassi et al., 1993]. Nevertheless, according to Ku¨mmerer
[2004], there is insufficient information available to reach a final conclusion
on the impact of antibiotics on bacterial populations in the environment.
1.4.3 Endocrine disruption
Endocrine disrupters, i.e., chemicals which can disturb the normal func-
tion of hormones, cause environmental damages even if they are found in
very low concentration. As several pharmaceuticals (17α-ethinyloestradiol or
tamoxifen) show hormonal activities, it might not be excluded that this type
of effect is associated with the use of drugs [Jorgensen & Halling-Sorensen,
2000].
1.4.4 Genotoxicity
In recent years there have been an increasing interest in the genotoxi-
cological effect connected to the release of genotoxins in the environment.
Genotoxicity is a measure of the ability of a substances to damage the DNA
and chromosomes of cells. Several pharmaceutical substances are genotoxic,
for instance cytostatic substances [for review see Sorsa et al., 1985] and an-
tibiotics [Ehlhardt et al., 1988; Giuliani et al., 1996]. The Section 1.6 (page
14) is focused on a description of genotoxicity tests.
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1.5 Choice of pertinent pharmaceuticals
Given the large number of pharmaceuticals in use, it is impractical to
monitor samples for all the active substances involved. The use of informa-
tion on metabolism/excretion, environmental fate and toxicity in addition
to pharmaceutical use data would help us to make our choice on pertinent
pharmaceuticals.
1.5.1 Acidic drugs: NSAIDs and clofibric acid
This work has been first focused on several pharmaceutical substances
widely consumed in Switzerland and not readily biodegradable: Ibuprofen,
Mefenamic acid, Diclofenac and Ketoprofen (see Table 1.1). They are non-
steroidal anti-inflammatory drugs (NSAIDs) and possess analgesic and an-
tipyretic activities. They are used for relief of the signs and symptoms of
rheumatoid arthritis and osteoarthritis and are indicated for relief of mild to
moderate pain. They are also indicated for treatment of primary dysmenor-
rhea.
This work has also been focused on the first and highly persistent sub-
stance detected in the environment: Clofibric acid. Clofibric acid is an active
metabolite of Clofibrate, Etofibrate, Etofyllinclofibrate, which are drugs used
as blood lipid regulators. These substances are used to decrease the plasmatic
concentration of cholesterol and triglycerides.
Description sheets of these pharmaceutical substances were presented in
the Appendices A.1 to A.5 (pages 120 to 132).
1.5.2 Anticancer drugs
According to Daughton & Ternes [1999] and Heberer [2002a], antineoplas-
tics is a class of drugs of potential concern for environmental effects, not only
for their acute toxicity but for their ability to effect subtle genetic changes.
Indeed such compound often exhibit carcinogenic, mutagenic or embryotoxic
properties.
Drugs used to treat cancer inhibit the mechanisms of cell proliferation.
There is approximatively 50 active substances which are classified in sev-
eral groups depending of their modes of action [Pratt et al., 1994; Atkins &
Gershell, 2002]. For instance:
Alkylating agents (e.g. cyclophosphamide, busulfan, carboplatin) add alkyl
groups to DNA bases, causing cross-linking of DNA strands, abnor-
mal base pairing, or DNA strand breaks, thus preventing the cell from
dividing.
13
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Anticancer antibiotics (e.g. daunorubicin) intercalate between the DNA base
pairs, preventing DNA replication.
Steroid hormones (e.g. prednisolone, tamoxifen), via receptor binding, in-
terfere with DNA synthesis and alter intracellular metabolism.
Antimetabolites (e.g. methotrexate, 5-fluorouracil) is an analog of a normal
metabolite. By being mistaken for a metabolite during the synthesis of
DNA, they inhibit nucleotide biosynthesis, preventing cell division or
DNA synthesis.
The anticancer drugs interfere with the function of cancer cells, but also
with healthy cells, inducing an important toxicity.
To select several anticancer drugs, description sheets of the ten most used
cytostatic drugs were prepared and are available in the Appendices A.6 to
A.15 (pages 135 to 170). The usage of cytostatic drugs in Switzerland and in
the university hospital of Lausanne (CHUV) are presented in the Appendices
A.17 and A.18 (pages 175 and 177).
Hydroxycarbamide (Appendix A.6) could be a substance with a high
potential of contamination. Nevertheless, this compound is not stable [Havard
et al., 1992] and loss of 40% after 72h in water was observed [Iyamu et al.,
1998]. It is degraded to pyridine by pyrolyse [Elyazigi & Alrawithi, 1992].
5-Fluorouracil (Appendix A.8) is an interesting substance, since it was one
of the most used anticancer drug. In addition Capecitabine (the most used) is
metabolised to 5-Fluorouracil in the tumor. Adjei [1999] presented a review
of Capecitabine and 5-Fluorouracil metabolism. According to Ku¨mmerer &
Al-Ahmad [1997], 5-Fluorouracil was not biodegradable. Capecitabine and 5-
fluorouracil are recommended for the treatment of skin, breast and colo-rectal
cancers.
Tamoxifen (Appendix A.7) is the second anticancer drug which is cho-
sen, seeing its high consumption and its classification as human carcinogen.
Tamoxifen is recommended for the treatment of breast cancers.
Cyclophosphamide (Appendix A.10) and Ifosfamide (Appendix A.9) were
already studied by several scientists in Switzerland (pers. communication of
H.-R. Buser, Wa¨denswil) and in Germany [Steger-Hartmann et al., 1996]. It
is the reason why these substances were not chosen in this work.
1.6 Genotoxicity
Genetic toxicity assays are used to identify germ and somatic cell mu-
tagens and potential carcinogens. These assays can complement chemical
14
CHAPTER 1. GENERAL INTRODUCTION
analysis because genotoxic chemicals are usually present as complex mix-
tures [Theodorakis et al., 2000]. Measuring the concentrations of all geno-
toxic chemicals is impossible, and the additive or synergistic effects of com-
plex mixtures are largely unknown. In addition, there may be unknown or
unsuspected genotoxic chemicals present.
Human health effects commonly associated with exposures to genotoxic
compounds include cancer, birth defects and heart disease [Houk, 1992]. DNA
damage has been associated with perturbations in fecundity, longevity and
growth of affected organisms [Shugart & Theodorakis, 1994; Barja, 2002;
Steinert et al., 1998].
Genotoxicity assays detect diverse kinds of genetic alterations that are
relevant for human health:
Mutagenesis refers to gene (or point) mutations, which are changes in the
DNA sequence within a gene.
The assays developed to measure mutagenicity are: Ames test, Es-
cherichia coli reversion assay, mouse lymphoma tk assay, HPRT assay.
Chromosomal aberration refers to changes in chromosome structure, usu-
ally resulting in a gain, loss, or rearrangement of chromosome pieces
(clastogenesis) or in a gain or loss of intact chromosomes (aneuploidy).
Chromosomal aberration test or micronucleus test in human or animal
cells are examples of tests.
DNA Damages refers for instance to DNA fragmentation (Comet assay) and
to activation of cellular system as stress or repair (UmuC test, SOS
chromotest).
1.6.1 The Salmonella Mutagenicity Test
Developed by B.N. Ames and coworker in the early 1970s, the Salmonella
mutagenicity assay (Ames test) has been used worldwide to evaluate the
mutagenicity of pure chemicals and complex environmental mixtures. Of
the numerous genetic bioassays available, the Salmonella assay is selected
most often to evaluate the genotoxicity of industrial eﬄuents, wastes and
discharges.
The assay uses Salmonella typhimurium strains carrying a defective (mu-
tant) gene (His−) that prevents them from synthesising the essential amino
acid histidine from the ingredients in standard bacterial culture medium.
Therefore, these strains (His−) can only survive and grow on medium that
contains excess histidine. However, in the presence of a mutagenic chemical,
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the defective histidine gene may be mutated back to the functional state
(His+), allowing the bacterium to grow on standard medium that does not
contain supplemental histidine:
His−︸ ︷︷ ︸
no growth without histidine
mutations−−−−−−→ His+︸ ︷︷ ︸
growth without histidine
These mutations, which lead to a regaining of normal activity or func-
tion, are called “back” or “reverse” mutations and the process is referred to
as “reversion”. The mutant colonies, which can make histidine, are called
“revertants”.
To increase the susceptibility of the Salmonella tester strains to mutagens,
various modifications to the wild-type strains have been made (see Table
1.3). Modifications include the removal of the bacteria’s DNA excision repair
system (∆uvrB) resulting in a decrease in the ability of the bacteria to correct
DNA damage and the partial loss of the lipopolysaccharide structure of the
bacteria cell wall (rfa), permitting large mutagens (such polycyclic aromatic
hydrocarbons) to penetrate the cell. In addition, an extra-chromosomal piece
of DNA called a plasmid (pKM101), which codes for error-prone DNA repair
enzymes, has been inserted into some of the tester strains. Plasmid-containing
strains incorrectly repair certain types of DNA damage and are more likely to
express a mutation. Some of the Salmonella tester strains contain frameshift
mutations (the addition or deletion of nucleotides). Other strains contain
base pair substitution mutations. Frequently used strains are TA97, TA98,
TA100, TA102, TA104, TA1535, TA1537, and TA1538. During the past 15
years, two strains (TA98 and TA100) have emerged as the most sensitive for
analysing the mutagenicity of both pure chemical compounds and complex
environmental mixtures.
Table 1.3: Commonly used Salmonella tester strains and their characteris-
tics
Stain Target allele rfa ∆uvrB Plasmid Mutations
TA98 hisD3052 + + pKM101 Frameshifts
TA100 hisG46 + + pKM101 Base-pair substitutions
TA102 hisG428 + - pKM101,
pAQ1
Base-pair substitutions,
oxidative and alkylating
mutagens
TA1538 hisD3052 + + none Frameshifts
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Thus each strain is genetically different, so using several strains in a test
increases the opportunity of detecting a mutagenic sample.
Many chemicals are not mutagenic (or carcinogenic) in their native forms,
but they are converted into mutagenic substances by metabolism in the liver.
The bacteria do not have many of the metabolic enzymes present in mam-
mals. Mammalian metabolism can be imitated in vitro by adding rodent
liver homogenate (called S9). This permits to determine if a chemical must
be metabolised to express mutagenic activity.
To perform the Salmonella assay, the tester strains are exposed to in-
cremental doses of the test substance or to the environmental sample. The
solution are poured onto a selective agar medium plate without histidine that
allows only the revertants (His+) to grow and form colonies. Spontaneous mu-
tations (not induced by chemical treatment) will appear as colonies on the
control petri dishes, where the sample is replaced by purified water. If the
sample was mutagenic, the number of colonies of revertants arising on those
plates will be significantly greater than the control plate.
2-fold rule
It is frequently recommended that, for an agent or sample to be judged as
positive, it should result in at least a doubling of the spontaneous mutation
rate. This 2-fold rule has the advantage to be simple. However, there are
several limitations. Indeed, the results of several authors show that use of
the 2-fold rule can be too radical for a low spontaneous reversion frequency
(e.g. TA1538) [Cariello & Piegorsch, 1996], but also too conservative for a
large spontaneous reversion frequency (TA100) [Cariello & Piegorsch, 1996;
Takanashi & Urano, 1998; Hamada et al., 1994; Mahon et al., 1989; Helma
et al., 1996]. Thus the use of the 2-fold rule can increase the number of “false
positive” and of “false negative” results with the strains with low or large
spontaneous mutations, respectively [Chu et al., 1981]. Instead of using the
2-fold rule and to avoid these false results, all our results are tested with
statistical analysis.
Predicting carcinogenicity
Nearly all of the agents determined to be human carcinogens are muta-
genic in the Salmonella assay, except hormones, metal and fibers [Shelby &
Zeiger, 1990]. In comparison to four assays for genetic toxicity (Salmonella ty-
phimurium, mutagenesis in mouse lymphoma cells, chromosome aberrations
and sister chromatid exchanges in Chinese hamster ovary cells), Salmonella
Ames test performed best, achieving a 66% concordance, an 89% positive
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predictivity, and a 55% negative predictivity with regard to rodent carcino-
genicity [Haseman et al., 1990].
The rapidity and the low cost of the test make it an important tool for
screening substances or samples for potential carcinogenicity.
1.7 Objective and outline
The occurrence of drugs in the environment are now a subject of con-
cern. This thesis aimed at investigating the potential of contamination of
wastewaters by several of the most frequently used and several of the most
toxic pharmaceuticals and at estimating the environmental risk associated
with these contaminations. The first general aim was to develop or to im-
prove analytical methods to measure the concentration of these substances in
wastewaters. These methods were applied on influents and eﬄuents of two or
three sewage treatment plants (STPs). The second aim was to adapt a geno-
toxicity assay for environmental samples as wastewaters, and to evaluate the
contamination by genotoxins in wastewaters of hospital and of municipal
STPs.
Chapter 2 presents the article “Occurrence of several acidic drugs in
sewage treatment plants in Switzerland and risk assessment”. This chap-
ter discusses the wastewater contamination by four anti-inflammatory drugs
(Mefenamic acid, Ibuprofen, Ketoprofen and Diclofenac) and one metabolite
of blood lipid regulators (Clofibric acid). The efficiency of different STPs to
remove these substances was investigated. In addition, the environmental risk
that these substances may pose for the aquatic environment was assessed.
Chapter 3 presents the article “Trace determination of Tamoxifen and 5-
Fluorouracil in hospital and urban wastewaters”. This article describes the
method developments for the analyse of Tamoxifen and 5-Fluorouracil in
wastewaters. These methods were applied to evaluate the contamination of
hospital and municipal wastewaters, and the removal efficiency of STPs for
those two compounds.
Chapter 4 presents the article “Mutagenicity of hospital and sewage treat-
ment plants wastewaters”. This chapter discusses the mutagenicity and the
bacterial toxicity of hospital and municipal wastewaters. The sensitivity of
different strains of Salmonella typhimurium was compared. Two tests of tox-
icity evaluation using Salmonella were developed and compared.
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Chapter 2
Occurrence of several acidic
drugs in sewage treatment
plants in Switzerland and risk
assessment
Authors: A. Tauxe-Wuersch, L. F. De Alencastro, D. Grandjean, J. Tar-
radellas.
Published by Water Research (2005, Vol. 39, pp. 1761-1772)
Motivations
The present chapter discusses the wastewater contamination by highly
used drugs and by one of the first drug found in the environment. Since the
consumption of these substances are important, the probability to detect these
compound is high. The efficiency of different STPs to remove these substances
during a relative long period of time was few studied. In addition, the aquatic
risk in Switzerland that these substances may pose was not yet investigated.
The protocol of the developed method, the chromatographical condition
and the regression lines are available in the Appendix B.1 (page 181). As
these substances are also excreted in a conjugated form, an additional step of
hydrolysis was tested (see Appendix C.2, page 208).
One sample of Geneva Lac was also analysed, the results are shown in
Appendix C.3 (page 210).
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Abstract
The occurrence and fate of five acidic drugs (Mefenamic acid, Ibuprofen,
Ketoprofen, Diclofenac and Clofibric acid) were analyzed in three sewage
treatment plants (STP) over 4-7 consecutive days. The results point out
that the five substances were persistent in wastewater eﬄuents after munic-
ipal wastewater treatment. At the most, half of Mefenamic acid was elim-
inated. Ibuprofen was well removed (80%) by one sewage treatment plant.
The removal of Ibuprofen is depending on the residence time of wastewater
in the STPs. A long raining period induce a important decrease of removal
of Ibuprofen and Ketoprofen. Removal rates showed a great variability ac-
cording to sewage treatment plants and types of treatments (e.g. biological,
physico-chemical). The concentrations of Ibuprofen, Mefenamic acid and Di-
clofenac were relatively high in the eﬄuents (150-2000 ng/l), showing a po-
tential contamination of surface water. An environmental risk assessment is
presented. Mefenamic acid seems to present a risk for the aquatic environ-
ment, with a ratio PEC/PNEC higher than one.
Keywords pharmaceutical, non-steroidal anti-inflammatory drugs, lipid
regulation agent metabolite, wastewater, sewage treatment plant
2.1 Introduction
The occurrence of drugs in the environment is a subject of concern from
several years. In comparison with the quantity of authorized drugs to be sold
in Switzerland (7753 in 2002, Swissmedic [2003]), relatively few substances
were analysed in the Swiss aquatic environment or in wastewaters: several
antibiotics [Hartmann et al., 1998; Golet et al., 2002; Giger et al., 2003]
and anti-inflammatory drugs [Soulet et al., 2002; Tixier et al., 2003; Buser
et al., 1998a, 1999], one antiepileptic agent [Tixier et al., 2003], and one
metabolite of some blood lipid regulators [Soulet et al., 2002; Buser et al.,
1998b]. The contamination is due to the consumption (up to several ten
tons) and the excretion via urine and feces in wastewaters. Indeed, many
of ingested pharmaceutical is excreted in the same form or in a conjugated
or slightly transformed form. The unused part of medicine could be also a
source of sewage contaminations. Indeed, according to a survey conducted
in the USA [Kuspis & Krenzelok, 1996], 35% of people flushed medications
down the toilet or sink. However the portion of drugs marketed which are not
used are not known [Jorgensen & Halling-Sorensen, 2000; Halling-Sorensen
et al., 1998].
This study focused on five substances widely consumed in Switzerland:
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Clofibric acid (metabolite), Ibuprofen, Ketoprofen, Mefenamic acid and Di-
clofenac (for structures see Figure 2.1). The anti-inflammatory drug Ibupro-
fen and Mefenamic acid are the most sold substances of this study with 17
tons per year and per substance in Switzerland (pers. comm. of Institut fu¨r
Haushaltsanalysen (IHA) - IMS HEALTH, Switzerland; see Table 2.1 and
Appendix A.16).
Table 2.1: Quantity of substance sold in Switzerland from July 2001 to June
2002 and excretion in the urine and in the bile of glucuronide and unchanged
drugs
Substances Amount sold Excretion
[kg/year]a [% of the dose]b
Clofibric acid Etofibrate 67
Clofibrate 42 95-99%
Etofylline
clofibrate
34 8.5% (8h after administration)
Ibuprofen 17 982 15% (1% unconjugated)
Ketoprofen 254 80%
Mefenamic acid 17 275 11% (<5% unconj.)
Diclofenac 3 883 10-15% (little unconj.)
a From Institut fu¨r Haushaltsanalysen (IHA) - IMS in Switzerland
b From rxlist (http://www.rxlist.com/)
Clofibric acid is an active metabolite of Clofibrate, Etofibrate, Etofyllinclofi-
brate which are drugs used as blood lipid regulators. These substances are
used to decrease the plasmatic concentration of cholesterol and triglycerides.
Clofibric acid has already been detected in sewage treatment plant (STP)
influents and eﬄuents, in German river waters, in Swiss lakes and in ground-
water wells [Soulet et al., 2002; Stumpf et al., 1996; Ternes, 1998; Buser et al.,
1998b; Heberer et al., 1997].
Ibuprofen, Ketoprofen, Mefenamic acid and Diclofenac are non-steroidal
anti-inflammatory drugs (NSAIDs). They possess analgesic and antipyretic
activities. These drugs have been detected in STP influents and eﬄuents and
in surface water samples [Soulet et al., 2002; Buser et al., 1999; Sacher et al.,
2001; O¨llers et al., 2001; Stumpf et al., 1999], except for Mefenamic acid
which concentrations and behaviour in STPs has never been reported.
Description sheets of these pharmaceutical substances were available in
Appendices A.1 to A.5 (pages 120 to 132).
21
2.2. Experimental section
OCl C
CH3
CH3
C
O
OH
 
Clofibric acid
C 
H2
CH
H3C
H3C
C
CH3
H
C
O
OH
 
Ibuprofen
C
O
CH
CH3
C
O
OH
 
Ketoprofen
Mefenamic acid Diclofenac
 
N
H
C
OH
O
H3C CH3
N 
H
Cl
Cl
H2C
C
O
OH
 
Figure 2.1: Structures of studied pharmaceuticals
Variations of the behaviour in various STPs and in different seasons are
little known. Therefore, the first aim of our study was to analyze the occur-
rence of these drugs during a representative amount of days in three STPs.
The second aim was to investigate the removal in summer and winter for
one STP. The third aim was to measure the removal during different steps
of the sewage treatment process. And the fourth aim was to assess the envi-
ronmental risk that these substances may pose for the aquatic environment
in Switzerland.
2.2 Experimental section
2.2.1 Standards and reagents
Ibuprofen, Ketoprofen, Diclofenac sodium salt, Clofibric acid, Mefenamic
acid and Pentafluorobenzyl bromide (PFB-Br) were all purchased from Sigma-
Aldrich (Steinheim, Germany). Supelclean ENVI-18 (6 ml, 1 g) solid phase
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extraction (SPE) cartridges were purchased from Supelco (Bellefonte, USA).
SiOH cartridges (3 ml) containing 500 mg of unmodified silica were ob-
tained from Macherey-Nagel Chromabond (Du¨ren, Germany). All solvents
were super-purity quality from Romil (Cambridge, England) or analytical-
grade from Merck (Dietikon, Switzerland). Stock solutions of all compounds
were prepared in methanol.
2.2.2 Analytical procedure
2.2.2.1 Filtration and Solid phase extraction (SPE)
With a Millipore Hazardous Waste Filtration System, 250 ml portions of
each sample were filtered (0.45 µm). The pH was adjusted to 2 with HCl.
Subsequent extraction of solid matter retained by the 0.45 µm filter with
diethyl ether did not show any presence of analytes of interest [Soulet et al.,
2002]. Extraction was performed by percolation through a ENVI-18 reverse
phase packed tube at a flow rate of approximately 3 ml/min by applying a
low vacuum. The solid phase was previously conditioned by flushing with 3
ml acetone, followed by 3 ml methanol and 3 ml of water adjusted to pH <2.
At the end of percolation, erlenmeyer flasks were washed with 3 x 15 ml of
acidified water, which are also passed through the cartridge. After drying the
solid phase for one hour under vacuum, the analytes were eluted with 6 ml of
methanol. The methanol extract was evaporated till dryness under a gentle
stream of nitrogen.
2.2.2.2 Derivatisation and Clean-up
Derivatisation was performed as described by Heberer et al. [1994], at
90◦C for one hour using 400 µl of pentafluorobenzyl bromide (2% in toluene)
and 4 µl of triethylamine. The derivatised extract was passed through a SiOH
cartridge conditioned with toluene. The analytes were eluted with 15 ml of
toluene. The eluate volume was reduced under a gentle stream of nitrogen
between 100 and 1500 µl, to be inside the range of concentration tested in
the calibration curve. If higher/smaller concentration were found, the samples
were diluted/concentrated and analyzed a second time.
2.2.3 Gas Chromatography and quantification
GC/MS system (Varian CP 3800 gas chromatograph / Varian 1200L mass
spectrometer) was used for quantitative analysis.
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The gas chromatograph was equipped with a 60 m x 0.25 mm i.d. x 0.25
µm RTX-5 capillary column connected to a 5 m deactivated fused silica 250
pre-column. Constant column flow mode was chosen.
GC injection parameters: 1 µl on-column; injection port: 250◦C; 80◦C for
1 min; 30◦C/min to 150◦C; 3.5◦C/min to 280◦C; 280◦C isothermal 30 min.
MS parameters: Transfer line temperature: 250◦C; EI mode, electron en-
ergy: 70 eV. For quantification in SIM mode, three characteristic ions were
selected for each compound [Soulet et al., 2002] and scanned using corre-
sponding time windows. External standards were used for quantification.
Calibration curves were obtained with four to seven standard concentrations
(linear regression: R2 > 0.99). Concentration of samples did not differ more
than 20% from the concentration of the standard used for quantification. The
results were corrected for recovery. The identity of substances in samples was
confirmed by checking the relative abundances of the characteristic ions.
2.2.4 Reproducibility, determination of recoveries and
detection limits
To determine the initial concentration and to quantify the reproducibil-
ity of the whole method, an unspiked sample was analyzed four times. The
relative standard deviations are shown in Table 2.2.
To determine the recoveries, samples of wastewater were spiked with the
pharmaceutical substances at four concentrations: 50%, 100%, 150% and
200% of the initial concentration or about 5, 10, 15 and 20 times the limit
of detection for compounds not found in the wastewater tested (Clofibric
acid). Samples were taken through the analytical procedure. The experimen-
tal quantities expressed as a function of the theoretical quantities enabled
to determine a regression line (see Figure B.5 of the Appendix B.1; page
187). The recovery rate was then derived from the slope. Deviation stan-
dards of slopes were calculated with the method of least squares and are
also shown in Table 2.2. Recoveries after filtration, SPE, derivatisation and
clean-up generally exceeded 70%. Seeing that relative standard deviations on
the reproducibility and standard deviation on recoveries varied from 2% to
16%, the precision is sufficient. These results point out that the analytical
procedures were suitable for the analysis of these five substances.
Limits of detection (signal/noise ratio of 3) and limits of quantification
(s/n ratio of 10) of the entire analytical procedure were calculated with a
spiked sample and were corrected for recovery. Limits of detection and quan-
tification (Table 2.2) were in a range which allows the detection and the
quantification of these compounds in wastewaters.
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Table 2.2: Relative standard deviations (RSD) of the method reproducibil-
ity (n = 4), recoveries and their standard deviations (SD), limits of detection
(LOD) and limits of quantification (LOQ) per liter of wastewater for five
pharmaceutical compounds
Substances Reproducibility Recovery ± SD LOD LOQ
(RSD) [ng/l] [ng/l]
Clofibric acid 75% ± 4% 15 50
Ibuprofen 3% 74% ± 2% 8 30
Ketoprofen 16% 76% ± 5% 8 30
Mefenamic acid 11% 91% ± 5% 5 15
Diclofenac 3% 68% ± 3% 6 20
The samples of the STP of Mittleres Emmental were frozen before anal-
ysis. To test the stability of the substances during congelation, four freezed
samples were analyzed and compared with four non-freezed samples. The
freezed samples showed a lower quantity of substances (maximum decrease
of 12%). This small decrease was no statistically significative for the five sub-
stances (level of significance was evaluated with the non-parametric Mann-
Whitney U test: p above 0.05), so it was not taken into account.
2.2.5 Sampling
Eighty-six samples of wastewater were collected: in April 2002 at the STP
of Mittleres Emmental in Hasle (Berne, central Switzerland), in January 2003
at the STP of Lausanne and in February and June 2003 and January 2004
at the STP of Morges (Western Switzerland, on Lake Geneva). The char-
acteristics of these STPs are shown in Table 2.3. Seeing that sewer systems
were combined for the three STPs, the eﬄuent flow rates depend on the
rain. Table 2.3 also shows the wastewater residence time during each of the
treatment stages. The STPs of Mittleres Emmental and Morges have a quite
similar treatment process (activated sludge and chemical precipitation with
FeCl3). In the STP of Lausanne, 70% of wastewater of Lausanne are treated
by a chemical (FeCl3) and biological (activated sludge) treatment followed
by a secondary clarifier and 30% are treated by a physico-chemical treatment
(FeCl3 and sedimentation) followed by a biological filtration on coal.
The samples (24h composite) were collected each day during 4-7 con-
secutive days, with a flow proportional automatic sampler for the STPs of
Mittleres Emmental and Morges and during 5 days with a time-related auto-
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matic sampler for the Lausanne STP (30 ml every 15 minutes). The samples
were kept at 4◦C during the collection and until the analysis, excepted the
samples of Mittleres Emmental which were frozen.
From the STPs of Mittleres Emmental and Morges, we analyse three
samples (influent, sample after primary treatment and eﬄuent) per day of
the sampling period. Two eﬄuent samples were analysed at the Lausanne
STP, one treated by biological treatment and one treated by physico-chemical
treatment and bio-filtration.
2.2.6 Risk assessment
The environmental risk assessment aims to evaluate the potential impact
of individual substances on the environment by examining both exposures
and effects on the ecosystem of such emissions [EC, 2003]. For pharmaceu-
tical products exposures result principally from excretion in wastewaters of
active drugs and/or its metabolites by patients, so only the effects on aquatic
compartment are taken into account.
The environmental risk was assessed as described by several authors
[EMEA, 2001; Stuer-Lauridsen et al., 2000; Ferrari et al., 2003]. Risk quo-
tients were calculated between the predicted environmental concentrations
(PECs) or measured environmental concentration (MEC) and the predicted
no effect concentration (PNEC), which is the concentration of the substance
for which adverse effects are not expected to occur.
PNEC values of the literature are used in our study. For Clofibric acid
and Diclofenac, Ferrari et al. [2003] estimated the PNEC values from chronic
No Observed Effect Concentration (NOEC) values and a statistical extrap-
olation model providing an estimate of hazardous concentration for 5% of
the species (HC5). For Ibuprofen, Stuer-Lauridsen et al. [2000] calculated the
PNEC value with the lowest environmental toxicity data and with a safety
factor of 1000. For Mefenamic acid, Jones et al. [2002] propose a PNEC ex-
trapolated with the Ecological Structure Activity Relationships (ECOSAR)
model. For Ketoprofen, the lowest EC50 (median Effect Concentration) pro-
posed by Farre´ & Barcelo´ [2003] and Robin & Soulet [1999] were used to
derive a PNEC with a safety factor of 1000 as recommended with short-term
toxicity data [EC, 2003].
The estimation of the concentrations in influent (PECinf ), in eﬄuent
(PECeffl) and in surface water (PECsw) were calculated from the following
equation
PEC =
A× (100−R)× E
365× P × V ×D × 10 000 (2.1)
where A is the predicted amount used per year (kg/yr) (Table 2.1), R the
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removal rate in percent (due to loss by adsorption to sludge particles, by
hydrolysis, by biodegradation during sewage treatment, etc.), E the maximal
excretion of the glucuronide and unchanged drug in percent (Table 2.1), P
the number of inhabitants of the geographic area considered (in Switzerland:
7 261 000 in 2001), V the volume of wastewater per capita and day (0.3
m3/capita-day), and D the factor for dilution of wastewater by surface water
flow. We have chosen four scenarios:
PECinfa: Worst case scenario. The removal rate (R) was set to zero, the
excretion (E) to 100 and the dilution factor (D) to 1.
PECinfb: Scenario considering the metabolization rate (excretion) and ac-
counts for free and conjugated parent drugs. We calculated a more
realistic influent concentration which was compared to the measured
influent concentrations.
PECefflc: Scenario with excretion and STP removal (R), which was deter-
mined from the results of the present study.
PECswd: Scenario proposed by EMEA [2001] for a prediction of an envi-
ronmental concentration in surface water. The removal rate (R) was set
to zero, the excretion (E) to 100 and the dilution factor (D) to 10.
The scenarios b and c did not consider the ecotoxic risk of metabolites. The
scenario a and d considered that metabolites are no more ecotoxic than the
parent drugs. In presence of toxic metabolites, the risk could be underesti-
mated.
Measured environmental concentrations (MECs) correspond to the max-
imal concentrations measured in influents or eﬄuents obtained during the
present study. The maximal values were chosen to be the most protective in
the evaluation of the risk.
2.3 Results and discussion
2.3.1 Clofibric acid
Clofibric acid was not degraded during the treatment process of Lausanne
and Morges, whatever the sampling period (Figure 2.2). In the same way,
Heberer et al. [2002] showed no removal rate in different STPs of Berlin, and
Winkler et al. [2001] found no evidence for biotic degradation of Clofibric
acid. On the other hand, the results of Ternes [1998] and Stumpf et al. [1999]
pointed out a relatively high removal rate of 15% (biological filtration), 34%
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Figure 2.2: Ranges of concentrations over 4-7 days (minimal, maximal and
average) of Clofibric acid in sewage treatment plants
(activated sludge) and 51% (activated sludge and FeCl3). Thus, Clofibric
acid is generally not eliminated from wastewater, but a removal can appear
in some sewage treatment plants, which used nevertheless the same treatment
processes as in our study.
With the daily flow rate of the eﬄuent during the sampling period, the
release in surface water was calculated. The annual release was estimated by
making the hypothesis that the sampling period was representative of the
whole year. In a large STP as Lausanne, approximately 12 kg per year of
Clofibric acid was discharged into Lake Geneva.
This substance was not detected in wastewater of Mittleres Emmental and
detected but not quantified in sewage of Morges (Winter 2004). This pharma-
ceutical was also not detected in STPs of France, Greece and Italy [Andreozzi
et al., 2003; Ferrari et al., 2003]. According to these authors, fenofibrate and
gemfibrozil are probably alternative parent drugs of Clofibric acid in these
countries. For the area of our study, the diminution of the consumption of the
Clofibric acid parent drugs is confirmed by the relevant diminution of the load
of this pharmaceutical in wastewaters of Morges from 2003 to 2004 (Winter
2003: 0.09 mg/inhabitant/day; Summer: 0.05 mg/inh/d; Winter 2004: below
the limit of quantification). The load for a larger STP (Lausanne) was higher
(0.16 mg/inh/d). The concentrations of this substance in winter 2003 were
in the same order of magnitude than published by several authors [Ternes,
1998; Stumpf et al., 1999; Heberer et al., 2002].
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The Predicted Environmental Concentrations (PECs) for Switzerland cal-
culated from Equation 2.1 are close to the mean measured concentrations
(PECinf : 180 ng/l; mean MECinf : 230 ng/l; see Table 2.4 and Figure 2.2).
The worst case (100% excretion and no STP removal) risk quotient
(PEC/PNEC), calculated with the PNEC value of Ferrari et al. [2003], is
0.1. Considering that aquatic risks can be suspected when PEC/PNEC ratio
is above one, environmental concentrations of this substance do not seem to
cause a risk for aquatic ecosystems. According to Ferrari et al. [2003], the risk
ratio for Germany was close to one (0.92). This value, nine time higher than
in Switzerland is due to a no negligible difference in the PEC (3.85 µg/l),
calculated on the base of consumption data.
2.3.2 Ibuprofen
Ibuprofen was relatively well removed in the STPs of Mittleres Emmen-
tal: from 66 to 93%, mean: 79% (Figure 2.3). The primary sedimentation
tank removed already 32% (12-45%). The removal rate of Ibuprofen show an
important variation in the STP of Morges depending of the sampling period.
This STP was most efficient in summer 2003 (removal from 62 to 79%, mean:
72%) and absolutely no removal was observed during a raining week of winter
2004. The biological treatment of Lausanne decreases slightly the concentra-
tion of Ibuprofen (20-43%, mean: 27%), in comparison with concentration
after the primary sedimentation. The difference in efficiency between the bi-
ological treatment of these three STPs is due to the fact that they do not have
the same residence time of water in treatments tanks. Indeed, a linear regres-
sion on our data on biological treatment of the three STPs showed that an
increased residence time results in a significant increased Ibuprofen degrada-
tion (n=27, R2=0.70, P<0.01; see Appendix C.1). In addition, the residence
time is partly depending on the rain, that may have been presumably re-
sponsible for the observed decrease in drug elimination rates [Ternes, 1998].
The sampling period of the STP of Lausanne and Morges (winter 2004) was
very wet (> 5 mm every day, up to 30 mm), for instance, the flow rate was
sometimes three times higher than in a dry period. In our case, the rain in-
duced a dramatic decrease of removal rates, that enhance the contamination
potential. On the other hand, the small rainfall events (one or two consecu-
tive days, 3-15 mm), that had occurred during the sampling periods of the
STPs of Morges (winter and summer 2003) and Mittleres Emmental, had no
relevant effect on the removal rate (non-parametric Wilcoxon test: p>>0.05).
The higher removal rates for biological treatment measured by several au-
thors [Ternes, 1998; Buser et al., 1999; Stumpf et al., 1999] are probably due
to a relatively dry sampling period and good operating conditions as high
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Table 2.4: Predicted No Effect Concentration (PNECs), Predicted Envi-
ronmental Concentrations (PECs) estimated from Equation 2.1, Measured
environmental Concentration (MEC) and risk quotients
Substances PNEC PECinfa PECinfb PECefflc PECswd MEC
a b c d max
[ng/l] [ng/l] [ng/l] [ng/l] [ng/l] [ng/l]
Clofibric
acid
4200e 180 - 170 18 360
P(M)EC/PNEC 0.04 0.04 0.004 0.09
Ibuprofen 5000f 22620 3400 700-3400 2262 4620
P(M)EC/PNEC 4.5 0.7 0.1-0.7 0.5 0.9
Ketoprofen 15600g 320 255 125-255 32 570
P(M)EC/PNEC 0.02 0.02 0.01-0.02 0.002 0.04
Mefenamic
acid
430h 21730 2390 1200-2340 2173 4540
P(M)EC/PNEC 50 5.6 2.8-5.4 5 10.6
Diclofenac 116000e 4890 730 730 489 2940
P(M)EC/PNEC 0.04 0.01 0.01 0.004 0.03
inf: influent; eﬄ: eﬄuent
a Without metabolism and STP removal
b With metabolism (max)
c With metabolism (max) and STP removal (min-max)
d Without metabolism and STP removal but with dilution with surface water
e According to Ferrari et al. [2003]
f According to Stuer-Lauridsen et al. [2000]
g Based on ecotoxicity data of Farre´ & Barcelo´ [2003] and Robin & Soulet [1999] with a
safety factor of 1000
h According to Jones et al. [2002] (calculated with ECOSAR)
residence times.
Physico-chemical treatment of Lausanne had no effect on Ibuprofen, which
is consistent with the laboratory studies of Winkler et al. [2001], indicating
that abiotic degradation processes were not significant. The physico-chemical
treatment of Lausanne is followed by a biological filtration, which had also
only little effect (22%) in the study of Stumpf et al. [1999]. Indeed, con-
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Figure 2.3: Ranges of concentrations over 4-7 days (minimal, maximal and
average) and elimination rate of Ibuprofen in sewage treatment plants
tact times with microorganisms were certainly to short to be efficient for the
removal of such substances.
In our study, Ibuprofen was the most important substance discharged
into Lake Geneva by the STP of Lausanne: 140 kg/year (see hypothesis in
Clofibric acid section).
Concentrations in influents varied from 1 to 4.6 µg/l, which is in accor-
dance with the values of other Swiss STPs presented by Buser et al. [1999],
but higher than concentrations in a Brazilian STP [Stumpf et al., 1999]. The
variation of concentration from one day to another is very important, espe-
cially for the STP of Mittleres Emmental (from 1.7 µg/l for Monday up to
4.6 µg/l for Wednesday). These variations of concentrations are not due to
a variation of flow, which was relatively stable during the week (7000-9600
m3/day). Thereby the load between Monday and Wednesday varied also of
a factor three (0.6-1.6 mg/inhabitant/day).
Ibuprofen was measured in lower quantity in the STP of Morges in 1999
by Soulet et al. [2002]. In addition, from January 2003 to January 2004, a
relevant increase of the average load of Ibuprofen reached the STP of Morges
(Winter 2003: 1.2 mg/inhabitant/day; Summer: 1.1 mg/inh/d; Winter 2004:
2.3 mg/inh/d) was observed. The differences in concentrations and loads are
likely due to an increase of Ibuprofen consumption in this area. More analysis
covering a larger period (with various weather) will be necessary to confirm
this state. The load reaching the STP of Lausanne and Mittleres Emmental
were the same order of magnitude (1.4 and 1.0 mg/inh/d, respectively).
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The Swiss PEC estimated including metabolism (PECinfb: 3400 ng/l,
Table 2.4) was close to the influent concentrations (MECinf range of vari-
ous STP means: 2000-3300 ng/l, Figure 2.3). This shows that the values of
consumption and excretion rate used in Equation 2.1 are consistent.
PEC/PNEC ratio exceeded one for the worst case scenario (100% excre-
tion and no STP removal), remained close to one for the maximum measured
concentration, but was below one for the more realistic scenarios taking into
account metabolism or surface water dilution. Risk ratios for Denmark are
above one [Stuer-Lauridsen et al., 2000], showing that this substance could
pose a potential risk for freshwater ecosystems. Nevertheless, the elimina-
tion by sedimentation in the aquatic environment [Tixier et al., 2003], could
decrease this risk.
2.3.3 Ketoprofen
Half of Ketoprofen (from 15% to 72%) was removed from the influents
of Morges (winter and summer 2003) and Mittleres Emmental (Figure 2.4).
The most important part of the elimination took place during the primary
sedimentation in the STP of Morges, but after this treatment in the Mittleres
Emmental STP. This difference could be due to the fact that the residence
time of water in the primary sedimentation tank was higher in the STP of
Morges than in Mittleres Emmental (see Table 2.3). The physico-chemical
treatment of Lausanne removed 20% (5-36%) of this substance. For a similar
treatment, Stumpf et al. [1999] found slightly higher elimination rates in a
Brazilian STP (48%). During the rainfall events, the biological treatment
(Lausanne and Morges winter 2004) had nearly no effect on Ketoprofen.
Thus, STP efficiencies to remove Ketoprofen are very sensitive to external
perturbations, as pouring rain.
Lausanne sewage treatment plant released annually about 14 kg of Keto-
profen.
The concentrations of Ketoprofen in influents were in the same order of
magnitude than in other Swiss STPs [O¨llers et al., 2001; Soulet et al., 2002],
but lower than in a Brazilian STP [Stumpf et al., 1999]. The used water and
the consumption of this substance might be different in the area of the Brazil
STP than in Switzerland (Table 2.1). In addition, the consumption of Keto-
profen seems to increase from 2003 to 2004, indeed the reached quantity in the
STP of Morges increase continuously (winter 2003: 0.11 mg/inhabitant/day;
summer: 0.15 mg/inh/d; winter 2004: 0.26 mg/inh/d). The same quantity of
this drug was loaded in the STP of Mittleres Emmental (winter 2002: 0.12
mg/inh/day), with an approximatively equivalent number of connected in-
habitants. This value was slightly higher for a larger STP (Lausanne 2003:
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Figure 2.4: Ranges of concentrations over 4-7 days (minimal, maximal and
average) and elimination rate of Ketoprofen in sewage treatment plants
0.18 mg/inh/d).
The Predicted Environmental Concentrations (PECinfb: 255 ng/l and
PECefflc: 125-255 ng/l, see Table 2.4) estimated from Equation 2.1 were
very close to concentrations measured in the influents (means: 250-440 ng/l)
and eﬄuents (means: 160-250 ng/l).
Several ecotoxicty data were found in the literature (ToxAlert 100, V.
ficheri, EC50=15.6 µg/ml [Farre´ & Barcelo´, 2003]; Microtox
r, V. ficheri,
EC50=27 µg/ml;Daphnia magna 24h,EC50=101-138 µg/ml;Daphnia magna
48h, EC50=52-76 µg/ml [Robin & Soulet, 1999]). The test showing the most
toxicity (EC50=15.6 µg/ml) was used with a safety factor of 1000 [EC, 2003].
The risk quotients for Ketoprofen are the lowest of all studied substances,
but it has to be confirmed with chronic ecotoxicty data not yet available in
the literature.
2.3.4 Mefenamic acid
The Mittleres Emmental STP removed half (28-74%) of Mefenamic acid,
while biological and physico-chemical treatments of Lausanne STP showed
an elimination rate of 40% (30-50%) and 30% (21-36%), respectively (Figure
2.5). In spite of a high residence time of water in the STP of Morges (winter
2003), no removal was measured, which was already observed in this plant
for a limited number of samples [Soulet et al., 2002]. Under bad weather
conditions, during the sampling period of Morges 2004, this STP was able
to remove 43% of Mefenamic acid (16-69%), slightly less efficient than in
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summer (from 38% to 58%; mean: 49%). Thus, the STP of Morges improved
significantly its efficiency to remove Mefenamic acid, in spite of rainfall events,
which had no harmful effect on the removal of this pharmaceutical. We could
not find any data in the literature on the behaviour of this substance in
wastewater.
In the region of Lausanne, about 82 kg of Mefenamic acid were discharged
per year into Lake Geneva.
The concentrations of Mefenamic acid were as high as those of Ibuprofen.
Mefenamic acid is commonly used in Switzerland, (pers. comm. of IHA-IMS
in Switzerland, see Table 2.1). The Predicted Environmental Concentrations
(PECinfb: 2390 ng/l and PECefflc: 1200-2340 ng/l of Table 2.4) are very close
to the measured concentrations of influents (means: 1600-2400 ng/l) and ef-
fluents (means: 800-2400 ng/l). This shows that the values of consumption
and excretion rate used in Equation 2.1 are also consistent. From January
2003 to January 2004, we observed a slight increase of the average load of
Mefenamic acid reached the STP of Morges (Winter 2003: 0.9 mg/inh/day;
Summer: 1.1 mg/inh/d; Winter 2004: 2.0 mg/inh/d). This increase was rel-
evant for January 2004, due certainly to an important consumption of this
drug during such painful bad weather condition. This increase has to be con-
firmed by the analysis of more samples during a longer sampling period. The
load reaching the STP of Lausanne in winter 2003 was the same order of
magnitude (1.2 mg/inh/d), but the one reaching the STP of Mittleres Em-
mental one year before was less important (0.5 mg/inh/d). This difference
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Figure 2.5: Ranges of concentrations over 4-7 days (minimal, maximal and
average) and elimination rate of Mefenamic acid in sewage treatment plants
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could be due to the absence of hospital in the watershed of this STP. Indeed,
Mefenamic acid are the most sold substance by hospital (10%, only 3% for
Ibuprofen; pers. comm. of IHA - IMS HEALTH, Switzerland; see Appendix
A.16 on page 174).
There is no ecotoxicity data published in the literature, but Jones et al.
[2002] propose a PNEC value calculated with the Ecological Structure Ac-
tivity Relationships (ECOSAR) model. This program estimates the toxicity
of chemicals to aquatic organisms such as fish, invertebrates and algae in the
absence of test data, using structures activity relationships (SARs) to predict
the aquatic toxicity of chemicals based on the similarity of their molecular
structures to other compounds for which the aquatic toxicity is known. Thus,
a risk quotients could be estimated (See Table 2.4). PEC/PNEC ratios ex-
ceed one for all scenarios. Due to the high consumption of this substance in
Switzerland, the PEC is higher than in UK (440 ng/l, Jones et al. [2002]), on
that account the PEC/PNEC ratio for Switzerland is higher than the one pre-
sented by Jones et al. [2002] for UK (1.03). PEC/PNEC ratios for Mefenamic
acid are ten times higher than for Ibuprofen. On that account, this pharma-
ceutical seems to be the pharmaceutical of our study presenting the highest
risk for the aquatic environment. Since PNEC estimated with ECOSAR are
overconservative for a large amount of substances [Salvito et al., 2002; Cash,
1998] including several pharmaceuticals [Sanderson et al., 2003; Cleuvers,
2003], the risk estimated could be overprotective for this drug. In addition,
the validation and the statistical robustness of this model are debated [Kaiser
et al., 1999]. Thus, these estimations have to be imperatively confirmed in
future with ecotoxicity tests.
2.3.5 Diclofenac
None of the studied sewage treatment plants were able to remove Di-
clofenac from wastewater (Figure 2.6). In addition, the removal of this phar-
maceutical was not dependent on the sampling period. Heberer et al. [2002]
pointed out a slightly higher elimination rate of 17% in different STPs in
Berlin. On the other hand, in the STPs studied by Stumpf et al. [1999] and
Ternes [1998] with biological treatment, up to 75% of Diclofenac was removed.
Thereby, the removal of this substance was very variable between different
STPs studied by various authors.
The sewage treatment plant of Lausanne discharged 50 kg per year of Di-
clofenac, which are probably degraded in surface water by photodegradation
[Buser et al., 1998a; Andreozzi et al., 2003] or in drinking water treatment
plants by ozone [Zwiener & Frimmel, 2000; Huber et al., 2003; Ternes et al.,
2002].
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Figure 2.6: Ranges of concentrations over 4-7 days (minimal, maximal and
average) of Diclofenac in sewage treatment plants
The concentrations of Diclofenac were close to Ibuprofen and Mefenamic
acid, especially for the Mittleres Emmental STP, in spite of a lower consump-
tion (Table 2.1). Indeed, the measured concentrations of this STP (mean:
1900 ng/l) were about three times higher than the Predicted Environmen-
tal Concentrations (PECinfb and PECefflc: 730 ng/l, of Table 2.4). But the
measured concentrations for the STP of Morges during a dry sampling period
(mean: 1250 ng/l) are closer to the PECs. The loads of Diclofenac were the
same order of magnitude in the STPs of Lausanne and Mittleres Emmen-
tal (0.63 and 0.67 mg/inh/d, respectively). From January 2003 to January
2004, we observed no relevant difference of the average load reached the STP
of Morges (Winter 2003: 0.45 mg/inhabitant/day; Summer: 0.42 mg/inh/d;
Winter 2004: 0.47 mg/inh/d).
The risk quotients for Diclofenac were as low as the one calculated for
Clofibric acid (Table 2.4). The risk quotients calculated for France [Ferrari
et al., 2003] with the worst case scenario (100% excretion and no STP re-
moval) were identical to our value in Switzerland (0.04). Nevertheless, the
administration of this pharmaceutical had adverse effect on terrestrial ecosys-
tem. Indeed, Oaks et al. [2004] observed that vulture population decline was
directly due to the administration of this drugs on live stock that died and
left for scavengers to remove.
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2.4 Conclusion
The concentrations of Ibuprofen, Mefenamic acid and Diclofenac were
relatively high in the eﬄuents, and thus, the risk for surface water contami-
nation was important. None of these drugs were well removed (>80%), except
Ibuprofen in the STP of Mittleres Emmental. For Ibuprofen, the removal is
depending on the residence time of wastewater in biological treatment. The
removal of Ibuprofen and Ketoprofen were decreased during a raining period
of winter, in comparison to dry periods. None of the studied STPs were able
to remove Diclofenac and Clofibric acid of wastewater. For the other sub-
stances, the elimination rates depended on the type of treatment available in
the different sewage treatment plants. The biological and physico-chemical
treatments did not have the same impact. This study showed a high vari-
ability of concentrations (up to a factor three) and of removal rates during
the week. Thus, to obtain a reliable average removal rate, it is important to
analyse a representative amount of samples, which was done in this study by
analysing wastewater of four to seven consecutive days.
Mefenamic acid seems to present the most important risk, followed by
Ibuprofen, Clofibric acid, Diclofenac and Ketoprofen. But the risk ratio for
surface water calculated with a dilution factor was above one only for Mefe-
namic acid. Since that toxicity of a single drug might be enhanced by the
occurrence of other pharmaceuticals with similar activity [Cleuvers, 2003],
the overall risk of these drugs could be significant. To our knowledge, chronic
ecotoxicity data are available only for Diclofenac and Clofibric acid. These
kind of data are needed for the other chemicals to confirm our results.
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Motivations
Since the occurrence of anticancer drugs in the environment are few stud-
ied and that these substances are extremely toxic, the contamination of wastew-
aters by two of the most used anticancer drugs were evaluated. The removal
efficiency of STPs and the contamination of treated wastewaters were also a
subject of interest.
The present chapter and the Appendices C.4 to C.5 (pages 211 to 216) de-
scribe the method development for the analyse of Tamoxifen and 5-Fluorouracil
in wastewaters. The final protocols are presented in Appendices B.2 and B.3
(pages 189 to 193).
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Abstract
Tamoxifen and 5-Fluorouracil are widely used in cancer therapy. They
are highly toxic (teratogenic, mutagenic, etc.), as are most of the anticancer
drugs. Two methods were set up to analyse these drugs in wastewaters to
evaluate the potential for environmental contamination by anticancer drugs.
Liquid-liquid extraction (LLE) followed by purification on OASISr MCX
cartridge and gas chromatography with mass spectrometry detection (GC-
MS) were used for the analysis of Tamoxifen. 5-Fluorouracil was extracted
with an ENV+ (Isolute) cartridge (solid-phase extraction), derivatised with
pentafluorobenzyl bromide (PFBBr) and detected by GC-MS. Both methods
showed good recoveries (> 70%), reproducibility (RSD < 10%) and limits of
detection (LOD 6 15 ng/l). Wastewaters from a residential area, an hospi-
tal, and sewage treatment plants (STPs) were analysed using the analytical
methods developed in this study. Tamoxifen was detected in wastewaters of
the hospital, residential area and influent of STPs, but not in treated wastew-
aters. 5-Fluorouracil in all wastewaters was below the limit of detection of
the analytical method.
Keywords: Tamoxifen; 5-Fluorouracil; Cytostatic; Chemotherapy; Cancer;
Pharmaceuticals; Wastewaters; Sewage treatment plants
3.1 Introduction
Many drugs are detected in aquatic environments [for review see Ku¨m-
merer, 2001b; Halling-Sorensen et al., 1998]. Most of the studies are based
on widely used pharmaceutical compounds such as anti-inflammatory drugs
[See Chapter 2; Ternes, 2001b], which have a low toxicity. Few cytostatic
substances have been studied [Steger-Hartmann et al., 1997; Ku¨mmerer &
Al-Ahmad, 1997; Aherne et al., 1985] and no ecotoxicological data on cy-
tostatic have been published. However, antineoplastic drugs are very toxic
(mutagenic, carcinogenic or teratogenic) for humans [for review see Sorsa
et al., 1985] and it is a group of potential concern for environmental effects
[Daughton & Ternes, 1999].
Our study focused on Tamoxifen and 5-Fluorouracil, since they are two
of the most used anticancer drugs (see Table 3.1 and Appendices A.17 and
A.18). Tamoxifen is a non-steroidal antiestrogen that is used as adjuvant
therapy for breast cancer and it is undergoing several clinical trials as a
chemo-preventive agent in healthy women at risk of breast cancer. According
to Adjei [1999], colorectal cancer is the third leading cause of cancer deaths
in the United States and standard therapy is 5-Fluorouracil modulated with
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folinic acid. Capecitabine is a prodrug of 5-Fluorouracil approved in the treat-
ment of colorectal and breast cancer. Capecitabine allows more convenient
administration (oral), provides a quality-of-life and economic advantage and
offers the potential of less gastrointestinal toxicity as compared with intra-
venous 5-Fluorouracil chemotherapy [Adjei, 1999; Zufia et al., 2004; Diasio,
1999]. These advantages induce a higher consumption of Capecitabine than
5-Fluorouracil (see Table 3.1).
Table 3.1: The most sold antineoplastic drugs in Switzerland: quantities of
substances sold from July 2001 to June 2002 by hospitals, pharmacies and
self-dispensing doctors
Substances Amount sold [kg/year]a
Total Hospitals Pharmacies Doctors
Capecitabine 455 145 207 103
Hydroxycarbamide 352 44 216 92
Tamoxifen 156 10 108 38
5-Fluorouracil 81 60 11 10
Cyclophosphamide 34 22 8 5
Methotrexate 13 6 4 3
Ifosfamide 12 12 0.1 0.1
a From Institut fu¨r Haushaltsanalysen (IHA) - IMS in Switzerland
Tamoxifen causes liver cancer in rats [Greaves et al., 1993]. In Tamoxifen-
treated women there is an increase in endometrial abnormalities [Kedar et al.,
1994] and in the incidence of uterine endometrial tumours [Fisher et al., 1994].
Tamoxifen and its metabolite, 4-hydroxytamoxifen, exhibit both estrogenic
and antiestrogenic activities [Shelby et al., 1996; Jordan, 1995]. 5-Fluorouracil
is mutagenic, genotoxic and teratogenic [for reviews: Sorsa et al., 1985; Reif-
ferscheid & Hell, 1996].
Description sheets of these pharmaceutical substances were available in
Appendices A.7 and A.8 (pages 139 and 143).
There are several methods described in the literature for the analysis
of Tamoxifen. From wastewater, Tamoxifen has been extracted with a SPE
column but with low recovery (42%) and a high standard deviation (40%)
[Thomas & Hilton, 2004]. Tumor tissues were analysed with a C2 (Bond-
Elut) solid phase extraction (SPE) cartridge [MacCallum et al., 1997]. Liquid-
Liquid extraction (LLE) methods have been used for the extraction of Tamox-
ifen from plasma and horse serum [Lee et al., 2003; Manns et al., 1998]. High-
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performance liquid chromatography (HPLC) - UV [Jalonen, 1988], HPLC
with Fluorescence detection [MacCallum et al., 1997; Fried & Wainer, 1994],
LC-MS/MS [Thomas & Hilton, 2004], Gas chromatography (GC) and mass
spectrometry (MS) [Murphy et al., 1987; Mihailescu et al., 2000] and GC
with flame ionisation detection (FID) [Rodriguez et al., 2003b] have been
described for measuring levels of Tamoxifen.
Several methods have been reported for the quantitative analysis of 5-
Fluorouracil in various matrices. For environmental samples, Kiffmeyer et al.
[1998] proposed SPE with various sorbents (Amberlyste, C18 and ENV+).
But the limit of detection (LOD) was much higher than environmental con-
centrations of drugs. Occupational environmental samples (air, glove) were
analysed with a SPE cartridge (Isolute ENV+). LLE methods were used for
the extraction of 5-Fluorouracil from human or rat plasma and urine [Bruin
et al., 1983; Zambonin et al., 1996; Guerrieri et al., 1994; Matsushima et al.,
1997]. The extraction was followed either by HPLC and UV detection [Loos
et al., 1999; Debruijn et al., 1986; Kiffmeyer et al., 1998; Micoli et al., 2001]
or by GC-MS where appropriate derivatisation increases the sensitivity [An-
derson et al., 1997; Matsushima et al., 1997; Kok et al., 1985].
The first aim of our work was to set up efficient methods for the analysis of
Tamoxifen and 5-Fluorouracil in wastewater. The second aim was to analyse
the contamination of hospital wastewater, municipal sewage (residential area,
sewage treatment plant (STP) influents and eﬄuents) with these drugs, and
to evaluate the removal efficiency by STPs for the two compounds.
3.2 Experimental
3.2.1 Standards and reagents
Tamoxifen, 5-Fluorouracil and Pentafluorobenzyl bromide (PFBBr) were
purchased from Sigma-Aldrich (Steinheim, Germany). OASISr HLB and
MCX (150 mg, 6 ml, 30 µm) cartridges were purchased from Waters (Rup-
perswil, Switzerland). The OASISr HLB sorbent is a poly(divinylbenzene-
co-N-vinylpyrrolidone) copolymer. The OASISr MCX sorbent is OASISr
HLB sorbent with sulfonic groups. Isolute ENV+ (200 mg, 500 mg, 1 g, 6
ml) and C2 cartridges were purchased from Separis (Grellingen, Switzerland).
SiOH cartridges (3 ml) containing 500 mg of unmodified silica were obtained
from Macherey-Nagel Chromabond (Du¨ren, Germany). Supelclean ENVI-18
(6 ml, 1 g) solid phase extraction (SPE) cartridges were purchased from Su-
pelco (Bellefonte, USA). All solvents were super-purity quality from Romil
(Cambridge, England) or analytical-grade from Merck (Dietikon, Switzer-
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land). Stock solutions of both compounds were prepared in methanol.
3.2.2 Handling cytostatic drugs
Since cytostatic drugs are (geno)toxic, their handling requires a number
of organisational and technical precautions in order to guarantee the best
possible protection of research workers. The workers wore special protective
clothing (Chemoprotectr gloves and gowns from CODAN, Germany). All
stock solutions were prepared under a biological safety cabinet with laminar
airflow. An absorbent paper (BenchGuardr) was used to protect the work
surfaces. Waste materials were collected in appropriate sealed containers and
were disposed of as contaminated material from hospital pharmacies.
3.2.3 Tamoxifen (Extraction, Purification)
3.2.3.1 Method development
Several solid phase extraction (SPE) cartridges were tested with spiked
bi-distilled water (n=1) for the extraction of Tamoxifen: MCX and HLB
(OASISr), ENVI-18 (Supelco), C2 (Isolute), ENV + (Isolute). Many differ-
ent conditions of column conditioning, elution, sample pretreatment, sample
volumes and quantities of sorbent in the cartridge were tested (see Table C.3,
page 212).
MCX (OASISr) cartridge was tested with spiked and filtered (0.45 µm)
wastewater (n=1). Since Tamoxifen is lipophilic, the addition of methanol
(1%-2% of final volume) was tested to desorb this compound of wastewater
particles (see Table C.6, page 215).
Liquid-liquid extraction was performed on spiked bi-distilled water (n=1)
using both dichloromethane and diethyl ether (see Table C.10, page 220).
3.2.3.2 Final Method
100 g of sodium chloride was mixed with 1 l of raw wastewater in a LLE
separating funnel. The extraction was performed three times with 60 ml
of dichloromethane. The dichloromethane emulsion was centrifuged at 2500
rpm for 10 minutes. The dichloromethane phase (bottom layer) was passed
through a funnel filled with sodium sulfate and collected in a flask. Two ml
of methanol was added and the solution was evaporated to 0.2-0.4 ml in a
rotary evaporator (850 mbar, 40◦C). The addition of methanol is essential to
avoid losses of Tamoxifen during rotary evaporation.
The purification was performed on OASISr MCX (150 mg, 6 ml, 30 µm)
cartridge conditioned with 6 ml of methanol and 1 ml MQ water. Acidified
43
3.2. Experimental
water (10 ml at pH2) was added to the sample extract and was loaded onto
the cartridge at a flow rate of 1 drop/sec (5-10 minutes for 10 ml). The
flask was cleaned three times with 5 ml of acidified water, which was passed
through the cartridge. The cartridge was washed with 4 ml of 0.1N HCl
and dried for 2 minutes under vacuum. The cartridge was washed a second
time with 4 ml of Methanol and 4 ml of methanol:acetonirile (30:70, v:v).
The analyte was eluted (soak for 4 minutes and then dropwise) with 3 ml
of methanol:NH4OH (95:5, v:v) and collected in a SPE tube. The eluate
volume was evaporated to dryness under a gentle stream of nitrogen and
re-suspended in toluene.
3.2.4 5-Fluorouracil (Extraction, Derivatisation, Pu-
rification)
3.2.4.1 Method development
Several SPE cartridges were tested with spiked bi-distilled water for the
extraction of 5-Fluorouracil: ENVI-18 (Supelco), C2 (Isolute), MCX and HLB
(OASISr), ENV + (Isolute). Many different conditions of column condition-
ing, elution, sample pretreatment, sample volume and quantity of sorbent in
the cartridge were tested (see Appendix C.4, page 211).
Various conditions were tested to obtain an optimal and repeatable derivati-
sation. Three catalysts (triethylamine [Chapter 2; Matsushima et al., 1997],
K2CO3 [Plagellat et al., 2004] and K2HPO4 [Anderson et al., 1997]), various
final concentrations of pentafluorobenzyl bromide (PFBBr), different tem-
peratures (20-100◦C) and durations (0.5-3 h) of the reaction were tested (see
Appendix C.5, page 216).
3.2.4.2 Final Method
The pH of the raw wastewater sample (150 ml) was adjusted to 5 with
one (or two) drops of HCl (32%) and phosphate buffer (0.01 mol/l KH2PO4
adjusted with 0.1 mol/l phosphoric acid to pH3).
The cartridge (ENV +, 6 ml, 1 g) was conditioned with 12 ml of methanol
and 12 ml of phosphate buffer (0.01 mol/l KH2PO4 adjusted with 0.01 mol/l
KOH solution to pH5). The sample was loaded with a flow rate of 3-5 ml/min
(30-50 minutes for 150 ml) by applying a low vacuum. After drying the solid
phase for two to three hours under vacuum, the analyte was eluted dropwise
with 4x3 ml of methanol. The sorbent was soaked for 4 minutes with each 3
ml. The methanol extract was evaporated till dryness under a gentle stream
of nitrogen.
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The derivatisation was performed by adding 1 ml of acetonitrile and 100 µl
K2CO3 solution (25% in MQ-water; w/w). This solution was mixed (vortex)
for 30 sec, and 100 µl PFBBr solution in acetonitrile (20:80, v:v) was added.
The tube were capped and incubated at 80◦C for one hour.
1 ml of toluene was added. The solution was evaporated to 200 µl un-
der a stream of nitrogen before adding 1 ml of isooctane. Purification was
performed on a SiOH cartridge completed with 0.5 cm of Na2SO4 and condi-
tioned with 5 ml of hexane:acetone (80:20, v:v) followed by 5 ml of hexane. Af-
ter adding the extract, the cartridge was washed with 8 ml of toluene:hexane
(15:85, v:v). The cartridge was dried for 1 min under vacuum. Then, the
cartridge was washed with 2 ml of hexane:acetone (80:20, v:v). The analyte
was eluted dropwise with the next 2 ml of hexane:acetone (80:20, v:v) and
collected in a SPE tube. 0.7 ml of toluene was added, and the eluate volume
was reduced under a gentle stream of nitrogen to 100 µl.
3.2.5 Gas Chromatography and quantification
A GC/MS system (Varian CP 3800 gas chromatograph / Varian 1200L
mass spectrometer) was used for the quantitative analysis.
The gas chromatograph was equipped with a 60 m x 0.25 mm i.d. x 0.25
µm RTX-5 capillary column connected to a 5 m deactivated fused silica pre-
column. Constant column flow mode was chosen (1 ml/min).
GC injection parameters: 1 µl with a SPI - Septum-equipped Programmable
injector (on-column); injection port: 85◦C for 0.2 min; 100◦C/min to 250◦C.
GC oven temperature programm: 90◦C for 4 min; 50◦C/min to 180◦C for
1 min; 1.5◦C/min to 270◦C for 5 min; 50◦C/min to 300◦C; 300◦C isothermal
30 min.
MS parameters: Transfer line temperature: 250◦C; EI mode, electron en-
ergy: 70 eV; NCI mode, gas: methane. Tamoxifen was detected in the EI
mode. A mass spectra is shown in Figure 3.1. Derivative 5-Fluorouracil was
detected in NCI and EI mode. Figure 3.2 includes mass spectra in both
modes. For identification of the substance in SIM mode, three to four char-
acteristic ions were selected for each compound (see Table 3.2). External stan-
dards were used for quantification. Calibration curves were obtained with four
to seven standard concentrations (linear regression: R2 > 0.99). The identity
of substances in samples was confirmed by checking the relative abundances
of the characteristic ions.
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Table 3.2: GC/MS data for the detection of Tamoxifen and 5-Fluorouracil-
PFBBr
Substances Retention time Characteristic ions
[min] [m/z]
Tamoxifen 63.5 58 / 72 / 371
5-Fluorouracil-PFBBr (NCI) 42.9 308-311
5-Fluorouracil-PFBBr (EI) 114 / 181 / 266 / 490
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Figure 3.1: Structure and mass spectra of Tamoxifen (EI mode)
3.2.6 Reproducibility, determination of recoveries and
detection limits
To quantify the reproducibility of the whole method, a spiked sample was
analysed four times. The relative standard deviations are shown in Table 3.3.
To determine the recoveries, samples of wastewater were spiked with the
pharmaceutical substances at four concentrations: about 5, 10, 15 and 20
times the limit of detection. Samples were taken through the analytical pro-
cedure. The experimental quantities expressed as a function of the theoretical
quantities enabled to determine a regression line (see Figures B.7 and B.9;
pages 192 and 196). The recovery was then derived from the slope. Deviation
standards of slopes were calculated with the method of least squares and are
also shown in Table 3.3. Recoveries after SPE or LLE, derivatisation and
clean-up exceeded 70% for both compounds. Seeing that relative standard
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Figure 3.2: Structure and mass spectra of 5-Fluorouracil (EI mode) and
mass spectra of derivatised 5-Fluorouracil (EI and NCI mode)
47
3.2. Experimental
deviations on the reproducibility and standard deviations on recoveries var-
ied from 3% to 9%, the precision is sufficient. These results indicate that the
analytical procedures are suitable for the analyses of both substances.
Limits of detection (signal/noise ratio of 3) and limits of quantification
(s/n ratio of 10) of the entire analytical procedure were calculated from spiked
samples, and were corrected for recovery (Table 3.3).
Table 3.3: Relative standard deviations (RSD) of the method reproducibil-
ity (n = 4), recoveries and their standard deviations (SD), limits of detection
(LOD) and limits of quantification (LOQ) per liter of wastewater for Tamox-
ifen and 5-Fluorouracil
Substances Reproducibility Recovery LOD [ng/l] LOQ [ng/l]
(RSD) ± SD
Tamoxifen 3% 81% ± 4% 1 4
5-Fluorouracil 9% 73% ± 4% NCI: 15 50
EI: 30 90
3.2.7 Sampling
Thirty seven samples of wastewater were collected: in June and July 2004
at the University hospital (1200 beds) of Lausanne (CHUV) and at the STP of
Lausanne (220 000 equivalent inhabitants), in July 2004 at the STP of Morges
(29 000 equivalent inhabitants; Western Switzerland, on Lake Geneva) and
in July and August 2004 in a residential area (RA) of Lausanne. Both STPs
have a similar treatment process (activated sludge and chemical precipitation
with FeCl3 followed by a secondary clarifier). A more precise description of
these sewage treatment plants is presented in Chapter 2 (Table 2.3, page 26).
The samples (24h composites) were collected each day during 6-7 con-
secutive days, with a flow proportional automatic sampler for the STP of
Morges and with a time-related automatic sampler for the Lausanne STP
(30 ml every 15 minutes) and for the hospital and residential wastewaters
(70 ml every 15 min). The samples were analysed immediately.
From the STPs of Morges and Lausanne, two samples (influent and eﬄu-
ent) per day of the sampling period were analysed.
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3.2.8 Calculation of predicted environmental concen-
trations (PECs)
The estimation of environmental concentrations (PEC) in Switzerland
were calculated from the following equation, modified from several authors
[Chapter 2; EMEA, 2001; Stuer-Lauridsen et al., 2000; Ferrari et al., 2003]
PEC =
A× (100−R)× E
365× P × V ×D × 10000 (3.1)
where A is the predicted amount used per year (kg/yr) (Table 3.1), R the
removal rate in percent (due to loss by adsorption to sludge particles, by
hydrolysis, by biodegradation during sewage treatment, etc.), E the maximal
excretion of unchanged drug in percent (Table 3.5), P the number of inhabi-
tants of the geographic area considered (in Switzerland: 7 261 000 in 2001),
V the volume of wastewater per capita and day (0.3 m3/capita-day), and D
the factor for dilution of wastewater by surface water flow.
To estimate concentrations in wastewater (influent) and to be able to
compare with analytical measurements and limits of detection, two scenarios
were chosen:
PECinfa: Without metabolisation. The excretion (E) was set to 100, the
removal rate (R) to zero and the dilution factor (D) to 1.
PECinfb: Scenario considering the metabolisation rate (Excretion). We cal-
culated a more realistic influent concentration which was compared to
the measured influent concentrations.
3.3 Results and discussion
3.3.1 Method development
3.3.1.1 Tamoxifen
Solid phase extraction (SPE) cartridges were tested for the extraction of
Tamoxifen. ENV + (Isolute) gave a recovery below 5% (n=1). ENVI-18 (Su-
pelco) provided a slightly higher recovery (<30%, n=1). 80% of extraction
was achieved with a C2 cartridge (1 g, Isolute), but only with a mixture
of elution solvent (either Methanol:NH4OH or Methanol:NaCl). MCX car-
tridge (OASISr) gave a recovery up to 100% (n=1) in bi-distilled water with
methanol:NH4OH (95:5, v:v) elution. Due to the high lipophilicity of Tamox-
ifen, losses of 50% were observed with filtered (0.45 µm) wastewater, and the
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filtration step was absolutely necessary to avoid clogging of the cartridge.
The addition of methanol (1-2%) before filtration did not improve the recov-
ery. Thus SPE cartridges could not be adapted to get acceptable recovery
of Tamoxifen. For this reason, liquid-liquid extractions (LLE) were tested.
Seventy-five percent of Tamoxifen was extracted from bi-distilled water with
diethyl ether (1 x 120 ml and 2 x 60 ml) and 100% with dichloromethane (3
x 60 ml). Before injection into the GC/MS, the LLE extract needed a purifi-
cation step. Since wash steps could be introduced in the extraction with a
MCX cartridge (OASISr), we decided to combine the LLE and a SPE with
several washing steps. More details on the method development are available
in the Appendices C.4 to C.6 (pages 211 to 220).
The final conditions were applied to the wastewater samples and the whole
methodology was tested for reproducibility and recovery (see Table 3.3). The
recovery (81%±4%) and the reproducibility (RSD = 3%) are better than
previously published results [Ashton et al., 2004]. A mass spectrum (in EI
mode) is presented in Figure 3.1 and is similar to that previously published
[Mihailescu et al., 2000].
3.3.1.2 5-Fluorouracil
Most of the tested cartridges gave 0% recovery (n=1) with bi-distilled
water: ENVI-18 (Supelco), C2 (Isolute), MCX and HLB (OASISr). ENV
+ (Isolute) showed the highest recoveries (2-110%). Losses of 5-Fluorouracil
were observed with high sample volumes (see Figure 3.3). The sorption of
this drug on the sorbent was weak and even water could elute 5-Fluorouracil.
These losses could be reduced by using a cartridge with more sorbent. The
best compromise was to use a cartridge of 1 g with only 150 ml of water (see
Figure 3.3).
5-Fluorouracil can be detected without derivatisation, but the peak shape
is poor. Its mass spectra is provided in Figure 3.2.
Testing of derivatisation revealed that the quantity of PFBBr is a key pa-
rameter for a complete and repeatable derivatisation. 400 µl of the solution
of PFBBr (2%) was not sufficient. 600 µl of PFBBr (4%) showed a signifi-
cant amelioration. An increase of temperature was necessary for a complete
derivatisation. With the catalyst K2CO3 [Plagellat et al., 2004], 60
◦C could be
adequate with a reaction time of three hours. To decrease the duration of this
method, one hour of reaction was necessary at 80◦C or 100◦C. Derivatisation
with K2CO3 or K2HPO4 catalysts worked better than with triethylamine.
K2HPO4 seemed very efficient, but an impurity was detected very close to 5-
Fluorouracil in the GC/MS analysis. Mass spectra in EI and NCI modes are
presented in Figure 3.2. The one in NCI mode is similar to one previously
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Figure 3.3: Recoveries of 5-Fluorouracil using solid phase extraction with
ENV+ (200 mg , 500 mg and 1 g)
published [Kok et al., 1985]. The EI spectra demonstrated molecular and
fragment ions consistent with the addition of two PFB groups (CH2C6F5;
m/z=181). The NCI spectra showed one major fragment (M-C7H2F5).
Again, a detailed description of the method development results are avail-
able in the Appendices C.4 and C.5.
The selected conditions were applied to the wastewater samples and the
whole methodology was tested for reproducibility (RSD = 9%) and recovery
(73%±4%; Table 3.3). The sensitivity was better in NCI (LOD = 15 ng/l;
Table 3.3) than in EI mode (LOD = 30 ng/l), but this difference was lower
than expected. The signal was higher in NCI than in EI mode. Nevertheless
the noise was also more important in NCI mode that decreased the sensitivity
of this mode. The sensitivity of our method is a factor of one hundred times
more sensitive than that of a previously published method [Mahnik et al.,
2004].
3.3.2 Wastewater contamination
3.3.2.1 Tamoxifen
Tamoxifen was detected in the wastewaters from the hospital, residential
area and both STPs (see Table 3.4). The concentrations of this drug were
between the limit of quantification and the limit of detection (1 and 4 ng/l).
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Table 3.4: Percentage of wastewaters of hospital (CHUV) and of two sewage
treatment plants where Tamoxifen (TAM) and 5-Fluorouracil (5-FU) were
detected
Substances TAM (>1 ng/l; <4 ng/l) 5-FU
CHUV (7 samples) 70% (5/7) (sat, sun: ND) 0%
Lausanne influents (7 samples) 100% (7/7) 0%
Lausanne eﬄuents (7 samples) 0% 0%
Morges influents (6 samples) 100% (6/6) 0%
Morges eﬄuents (6 samples) 0% 0%
RA Lausanne (4 samples) 100% (4/4) 0%
ND: Not Detected
RA: residential area
This range of concentration is below the predicted environmental concentra-
tions PECinfa and PECinfb (see Table 3.5). This difference could be explained
in different ways. Firstly, Tamoxifen could be degraded before the analysis.
Indeed, Tamoxifen is sensitive to UV light and up to 90% is degraded in
five days [Jalonen, 1988]. Our analyses were performed as soon as possible
and were protected from light. But some degradation cannot be ruled out.
Secondly, Tamoxifen is adsorbed onto particles due to its high lipophilicity
(estimated value: Log Kow = 6.3 [Meylan & Howard, 1995]). These particles
could settle in sewer systems and would not be analysed. Another explana-
tion could be that the proposed value for excretion of unchanged drug is too
high, so the PECinfb value is overestimated.
Other authors have tried to detect this drug in wastewaters, but in most
samples concentrations were below the limit of detection, with the exception
of two samples [Ashton et al., 2004].
Our results indicate that the hospital eﬄuent samples for the Saturday
and Sunday were not contaminated by Tamoxifen, resulting probably from
a decrease of the hospital activity (work/treatment) during the weekend.
Indeed, patients were fewer during the weekend and only a small amount of
Tamoxifen was distributed by the hospital. Indeed, most of this substance
is sold by pharmacies (see Table 3.1) and patients ingest the drug at home.
On that account, we observed no difference in the contamination of hospital
wastewaters and municipal sewage.
52
CHAPTER 3. TRACE DETERMINATION OF TAMOXIFEN AND
5-FLUOROURACIL IN HOSPITAL AND URBAN WASTEWATERS
Table 3.5: Excretion in the urine and in the bile of unchanged drugs
and Predicted Environmentally Concentrations (PECs) [ng/l] estimated from
Equation 3.1, comparison of several cytostatic drugs
Substances Excretion PECinfa PECinfb
[% of the dose]c a b
[ng/l] [ng/l]
Tamoxifen 20% (F) 196 39
5-Fluorouracil < 20% (U) 675 < 23
Capecitabine 0.5% of 5-Fluorouracil (U)
Ifosfamide 12-90% dose-dependent (U) 15 2-14
Methotrexate 50-80% (U) 16 8-13
Hydroxycarbamide 30-60% (U) 443 133-266
Cyclophosphamide 50% (U) 43 22
a Without metabolism and STP removal
b With metabolism
c From rxlist (www.rxlist.com) or Swiss drug compendium (www.kompendium.ch)
F: Fecal excretion
U: Urinal excretion
Due to the high adsorption of Tamoxifen on particles, this drug was re-
moved from wastewater by both STPs (see Table 3.4), avoiding surface water
contamination. To our knowledge, no study is available on biodegradability
of this compound.
3.3.2.2 5-Fluorouracil
5-Fluorouracil was not detected in any of the wastewater samples (see
Table 3.4). Since only a small portion of this pharmaceutical is excreted in
the same form, the PECinfb was lower than the PECinfa (see Table 3.5).
The predicted environmental concentrations using excretion (PECinfb) were
in the range of the limit of detection of our method (PECinfb = 23 ng/l
and LOD = 15 ng/l; see Tables 3.5 and 3.3). Seeing that the calculation of
PEC used an approximated value of excretion, and that it did not take into
consideration the degradation, the real concentration is below the LOD of
the method.
PEC was also estimated for the wastewaters of the hospital (PECCHUV ).
These results are presented in Table A.6 of the Appendix A.18 (page 179).
Contradictory results have been published concerning the biodegradabil-
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ity of 5-Fluorouracil [Ku¨mmerer & Al-Ahmad, 1997; Kiffmeyer et al., 1998].
According to Ku¨mmerer & Al-Ahmad [1997], it is not biodegradable in the
closed bottle test (CBT) nor in the Zahn-Wellens test (ZWT). On the other
hand, Kiffmeyer et al. [1998] found that 5-Fluorouracil was completely re-
moved from the spiked influent in a laboratory sewage plant within a few
days, but the rate seemed dependent on the initial concentration. Neverthe-
less, this drug can be inactivated by ozonation [Rey et al., 1999].
5-Fluorouracil has been detected in eﬄuents of the oncologic department
in Vienna University Hospital [Mahnik et al., 2004]. Due to the absence of di-
lution with other sources of wastewaters (such as other medical departments),
the detected concentrations were high (20-122 µg/l).
3.3.2.3 Potential contamination by other anticancer drugs
PECs for the seven most used chemotherapeutic agents are presented
in Table 3.5. These estimations showed that Hydroxycarbamide could be a
substance with a high contamination potential. Nevertheless, this risk is de-
creased by the fact that this compound is labile in water [Elyazigi & Alraw-
ithi, 1992]. Cyclophosphamide PECinfb is the same level as 5-Fluorouracil,
which is in accordance with reported environmental concentrations (<6 ng/l
to 140 ng/l) [Steger-Hartmann et al., 1997]. Ifosfamide has also been de-
tected in few samples of wastewaters (<6 ng/l to 30 ng/l) and in the range of
the PECinfb [Ku¨mmerer & Al-Ahmad, 1997]. Methotrexate was not detected
in river and potable supply samples, but has been reported in one hospital
eﬄuent (1 µg/l) [Aherne et al., 1985]. As no STP sample was analysed, a
comparison with the calculated PECinfb is not possible.
The other antineoplastic drugs were administered in lower quantity in
Switzerland, and thus the risk of a detectable contamination in the environ-
ment is weak (see PECs in Appendices A.17 and A.18).
3.4 Conclusion
Cytostatic drugs are less used in comparison with other pharmaceutical
substances such as anti-inflammatory drugs. Predicted environmental concen-
trations (PEC) are very low. Powerful methods are necessary to detect these
compounds at such low concentrations (ng/l level). The methods developed
in our study showed good limits of detection and quantification, recoveries
and reproducibility.
Tamoxifen was detected in all wastewaters (hospital, residential area, and
STPs), but was not detected in treated wastewaters. Thus, both STPs effi-
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ciently removed Tamoxifen. 5-Fluorouracil was not detected in any of the
wastewater samples.
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Motivations
As genotoxic pharmaceutical compounds, including cytostatic agents, are
discharged in wastewaters, the mutagenic potential of wastewaters from var-
ious origins (hospital and municipal) was a domain of interest. The present
chapter discusses the mutagenicity and the bacterial toxicity of wastewaters
evaluated with Salmonella typhimurium (Ames test). As several strains can
be used with the Ames test, their sensitivity to wastewaters was interesting
to know. Since wastewater samples could also be toxic in addition to the
mutagenicity and that these toxicity could interfere with the results of the
mutagenicity, two methods to evaluate the survival of Salmonella were elab-
orated.
The protocol of the methods and of the solutions are available in the Ap-
pendices B.5 and B.4, respectively.
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Abstract
As pharmaceutical compounds, including cytostatic agents that are geno-
toxic, are discharged in wastewater, the mutagenic potential of wastewater
from various origins (hospital, two different sewage treatment plants (STP)
and a residential area) was evaluated using the Ames test. The samples were
not concentrated prior the analysis to determine the overall effects of these
waters. The survival and the reversion frequencies of strains TA98, TA100,
TA102 and TA1538 following treatment with the different wastewaters were
determined. Survival was obtained by two methods. The first method was by
comparing the number of reversions induced by a known mutagen in the pres-
ence and absence of wastewater. The second was by determining the colony
forming ability of dilutions of treated and non-treated cultures. The sam-
ples from the hospital were on the whole more toxic than samples from the
STPs and residential area. The different strains showed varying sensitivities
to the toxic effects of the wastewater, with TA98 exhibiting the highest sen-
sitivity (<5% survival). The results from the reversion assays indicated that
TA102 was the most sensitive, followed by TA1538 and TA100. More hospi-
tal wastewaters than influents of sewage treatment plants were mutagenic,
indicating a higher mutagenic activity in the wastewater of the hospital.
Comparison of the mutagenicity of the influents and eﬄuents of the STPs
showed that less eﬄuent samples were mutagenic. This result indicates that
biological treatments were relatively efficient in decreasing the mutagenicity
of wastewaters.
Keywords: Mutagenicity; Genotoxicity; Ames test; Salmonella typhimurium;
wastewater; sewage treatment plant.
4.1 Introduction
Due to human activity, many pollutants reach the aquatic environment.
The contamination of water by xenobiotics is a critical problem regarding
the water ecosystem and the human population exposed via drinking water.
Indeed, the presence of xenobiotic compounds or of hazardous waste sites
may increase the risk of human cancer [Koivusalo et al., 1994; Griffith et al.,
1989; Morris et al., 1992]. In addition, sufficient quantities of contaminants,
among them some genotoxic compounds [Stahl, 1991; Adams et al., 1992;
De Flora et al., 1991; Theodorakis et al., 2000] could result in adverse effects
on the ecosystem community. Most chemicals observed to be carcinogenic
in humans by clinical or epidemiological studies are genotoxic [Shelby &
Zeiger, 1990]. Mutations are implicated in carcinogenesis and the Salmonella
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mutagenicity assay (Ames test) is highly predictive for rodent carcinogens
[Zeiger, 1998; Zeiger et al., 1990; Tennant et al., 1987]. This assay is a short
term test used worldwide in more than 2000 laboratories [Edler, 1992]. In
addition, the Salmonella mutagenicity assay has been shown to be a useful
tool in the identification of important pollution sources [Umbuzeiro et al.,
2001].
The influence of bacteria survival and growth is seldom used in the quan-
tification of genotoxicity results. However, samples that contain mixtures,
such as wastewater or industrial eﬄuents can be toxic [Castillo et al., 2001;
Dizer et al., 2002; Giuliani et al., 1996]. This toxicity may mask the muta-
genic effect, especially if the sample is a weak mutagen. In addition, some
artifacts can occur for instance in the fluctuation assay [Harrington et al.,
1983], that could lead to false positive results, suggesting that survival de-
termination should be a routine part of this assay. The normalization of the
genotoxic response with toxicity has been proposed for the Ames assay [Kar-
galioglu et al., 2002] and for other genotoxic assays, such as the umuC test
[Baun et al., 1999].
Many studies have reported on the mutagenicity of wastewaters [Rappa-
port et al., 1979; Helma et al., 1996; Filipic & Toman, 1996b; Jolibois et al.,
2003; Jolibois & Guerbet, 2005], surface waters [Pelon et al., 1977; Cerna
et al., 1996; Umbuzeiro et al., 2001; Kutlu et al., 2004] and drinking waters
[Park et al., 2000]. The absence of mutagenic activity in eﬄuents has been
described in several studies [Shishida et al., 2000; Rappaport et al., 1979;
Monarca et al., 2000] and several authors had reported a partial removal of
mutagens by biological treatment [Hu et al., 2003; Ono et al., 1996]. Most
of the studies concentrate the samples through procedures such as resin col-
umn (XAD, Separon SE), or liquid/liquid extraction (methylene chloride,
dichloromethane), to increase the limit of detection. Nevertheless, the con-
centration of the samples results in a loss and/or modification of some com-
pounds [Filipic & Toman, 1996a; Filipic, 1995] and in an alteration of the
interaction among the substances [Filipic & Toman, 1996a]. Thus, analysis
of samples “as is” without any prior treatment is more representative of the
real environmental effect.
A variety of sewage sources enter into a municipal wastewater treatment
plant. For instance, municipal sewage can contain domestic, commercial, or
industrial wastewaters, as surface runoff. Some studies have suggested that
the genotoxicity of municipal wastewaters is proportional to the occurrence
of industries [Rappaport et al., 1979; Meier et al., 1987]. Nevertheless, seeing
that the results (umu-test during one week) were positive even on Sunday,
the origin of potency seems mainly not to come from industrial wastewater
but from human [Ono et al., 1996]. Moreover, other studies indicated that
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the mutagenic activity of sludge is independent of the percent of industrial-
ization [Babish et al., 1983] and that over 90% of the genotoxic loading of
the Montreal municipal wastewater had a nonindustrial origin [White & Ras-
mussen, 1998]. Since many chemicals used in hospitals, including cytostatic
substances [for review see Sorsa et al., 1985], antibiotics [Ehlhardt et al., 1988;
Giuliani et al., 1996], and disinfectants [Giuliani et al., 1996], are genotoxic or
carcinogenic, and since urine samples of patients undergoing chemotherapy
are also mutagenic [for review see Sorsa & Anderson, 1996], wastewaters of
hospitals could be an important source of mutagenic potency.
The first aim of our work was to include different ways to evaluate the
bacterial toxicity in the Ames test. The second aim was to compare the
sensitivity of different strains of Salmonella typhimurium to wastewaters.
The third aim was to compare the mutagenicity of hospital wastewaters with
municipal sewage treatment plant influents and eﬄuents.
4.2 Materials and methods
4.2.1 Materials
Agar and Benzo(a)pyrene were purchased from Sigma-Aldrich (Steinheim,
Germany), LB broth, histidine, biotin, sodium azide, all salts and nutrients
from Fluka (Buchs, Switzerland), and 2-nitrofluorene from Merck (Dietikon,
Switzerland).
4.2.2 Sampling of hospital and sewage treatment plant
(STP) wastewater
Forty-one samples of wastewater were collected: in June and July 2004
at the University hospital (1200 beds) of Lausanne (CHUV) and at the STP
of Lausanne (220 000 equivalent inhabitants), in July 2004 at the sewage
treatment plant (STP) of Morges (29 000 equivalent inhabitants; Western
Switzerland, on Lake Geneva) and in July and August 2004 in a residential
area of Lausanne. Both STPs have similar treatment processes (activated
sludge and chemical precipitation with FeCl3 followed by a secondary clari-
fier).
The samples (24h composite) were collected each day during 6-7 consecu-
tive days, with a flow proportional automatic sampler for the STP of Morges
and with a time-related automatic sampler for the Lausanne STP (30 ml
every 15 minutes) and for the hospital and residential wastewaters (70 ml
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every 15 min). The samples were immediately filtered (0.45 µm) and were
stored at -20◦C.
From the STPs of Morges and Lausanne, we analyse two samples (influent
and eﬄuent) per day of the sampling period.
4.2.3 Salmonella mutagenicity assay - Ames test
The Ames test was done with preincubation as previously described [Maron
& Ames, 1983; Mortelmans & Zeiger, 2000] with the following modifications
(see Figure 4.1 and Appendix B.5):
The mixture A was prepared with 1 ml of Mini A 10x (102.4 g Na2HPO4-
7H2O, 24 g KH2PO4, 4 g NaCl, 8 g NH4Cl and bi-distilled water to a final
volume of 800 ml), 20 µl of Growth supplement (200 mg of L-Proline, L-
Threonin, L-Arginine, 400 mg of L-Leucine, 10 mg of Thiamine HCl, 100 mg
of Biotin in 20 ml of sterile MQ-Water), 10 µl of CaCl2 0.1M, 10 µl of MgSO4
1M, 40 µl of glucose (50%), 50 µl of Histidine (20 mg/ml) and 8.8 ml of water
sample filtered with 0.22 µm sterile filter.
3 ml (in triplicate) of the mixture A was inoculated with 100 µl of the
bacteria culture. The inoculated wastewater were incubated at 37◦C for 3
hours with agitation and then centrifuged at 4000 rpm during 5 minutes.
The resulting pellet was re-suspended in 3 ml of sterile phosphate buffered
saline (PBS) and centrifuged another time to ensure removal of histidine.
This pellet was re-suspended in 0.3 ml of PBS (mixture B).
0.1 ml of mixture B was added to 2 ml of top agar (supplemented with
histidine and biotin) at 45◦C and mixed and poured onto minimal glucose
agar plates. The plates were inverted and placed in a 37◦C incubator for 48
h.
When the assay was performed with metabolic activation, 0.3 ml of the S9-
mix replaced 0.3 ml of wastewater sample in the mixture A. The S9-mix was
freshly prepared before each test using lyophilized Aroclor-1254-induced rat
liver S9 fraction (Moltox - Trinova Biochem GmbH, Giessen, Germany). S9-
mix was prepared with: S9 20%, nicotinamide adenine dinucleotide (NADP)
4mM, glucose-6-phosphae 5mM, sodium phosphate pH 7.4 100 mM, KCl 33
mM and MgCl2 8 mM.
Spontaneous reversion controls (sterile bi-distilled water) were used as
negative controls. Positive controls included 2-Nitrofluorene (5 µg/ml) for
TA98 and TA1538 strains without S9, Sodium azide (5 µg/ml) for TA100,
Benzo(a)pyrene (5 µg/ml) for TA98 and TA100 with S9.
TA98 and TA1538 strains detect frameshift mutagens, TA100 strain re-
sponds to base-pair substitution mutations and TA102 strain detects a large
variety of oxidative mutagens, active forms of oxygen and alkylating agents
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Figure 4.1: Ames test protocol
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and has intact excision repair mechanisms. The plasmid pKM101 is present
in the TA98 strain, that enhances chemical and UV-induced via an increase
in the error-prone recombination DNA repair pathway [Mortelmans & Zeiger,
2000].
4.2.4 Salmonella toxicity assay using induced rever-
tants - First method
The positive controls in DMSO were diluted to their respective concen-
trations specified in the tests in sterile bi-distilled water. To measure the
toxicity of the wastewater samples, the appropriate positive control for each
of the strains was added to wastewater samples (in mixture A) and the num-
ber of revertants obtained under these conditions was determined (see Figure
4.1). The toxicity of the water sample was obtained by comparing the num-
ber of revertants observed in the presence and absence of wastewater. Since
the positive control for TA102 (Mitomycin C) is very toxic and needs a lot
of precautionary work methods, the toxicity on this bacterial stain was not
evaluated with this method.
4.2.5 Salmonella toxicity assay by dilution - Second
method
0.05 ml of mixture B was diluted to 10−4 to 10−6 with PBS (see Figure
4.1). 0.1 ml of this dilution was used to inoculate LBM-Agar plate (12 g of
Agar and 20 g of LB broth in 1 l of bi-distilled water, autoclave and dispensed
20 to 25 ml in sterile petri plates). The plates were inverted and placed in a
37◦C incubator for 20 h.
4.2.6 Data and statistical analysis
For mutagenicity and toxicity (induced revertants), experiments were re-
peated 3 times with 2 plates per experiment. We obtained six replicate plates
per sample and per strain. For the determination of toxicity by the dilution
method, experiments were repeated only 2 times with 2 plates per experi-
ment.
All raw data are available in the Appendix C.7 (pages 221 to 230).
In the reversion assays, the data obtained were the average of six repli-
cates and were expressed as Mutation Ratio (MR), dividing the number of
revertants per plate in presence of the sample (spontaneous + induced rever-
tants) by the control number of revertant (spontaneous revertants).
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For toxicity, the data obtained were expressed as survival (in %). With
the first method of evaluation of the toxicity, the survival is the percentage
of the number of his+ colonies in the presence of sample and control positive
(spontaneous + induced revertants - revertants killed by sample) in com-
parison to number of his+ colonies in the positive control (spontaneous +
induced revertants). With the second method of evaluation of the toxicity,
the survival is the percentage of colonies in presence of sample in comparison
with the number of colonies in bi-distilled water.
Instead of using the twofold rule [Ames et al., 1975] according to which
a sample is mutagenic when an increase of the revertant number by a fac-
tor of two relative to the negative control is observed, the results have been
evaluated by the Mann-Whitney-Wilconxon U test as proposed by several
authors [Perez et al., 2003; Edler, 1992]. Differences with a probability (p) of
0.05 or less were considered as statistically significant. This non-parametric
test was used instead of parametric test (t-test), because most of mutagenic-
ity data do not meet assumptions of normality and homogeneous variance
[Callahan & Short, 1995]. Some authors have reported Ames colony counts
to be distributed according to Poisson statistics [Stead et al., 1981; Hamada
et al., 1994] and others have reported them to be more variable than would
be expected from the Poisson [Margolin et al., 1981; Callahan & Short, 1995].
For the toxicity, Mann-Whitney-Wilconxon U test was also used to evalu-
ate if the number of colonies observed in the samples and in the control were
different at α<0.05. If the toxic effect in the samples compared to the control
was significant, the reversion frequency was adjusted according to the sur-
vival. The corrected number of revertants in the sample and the number in the
negative control were compared using the Mann-Whitney-Wilconxon U test.
The calculation of an adjusted mutagenic potency value has been proposed
by several authors [Kargalioglu et al., 2002]. The data of mutagenicity cor-
rected with toxicity were expressed as adjusted Mutagenicity Ratio; MRadj1
corrected with the first method of toxic evaluation (induced revertants) and
MRadj2 corrected with the second method (see Appendix B.6 on page 206).
No adjustment was done when survival values were below 20%. The correc-
tion of MR with very low survival led to a very high Mutagenicity Ratio that
was easily significant and increased the risk of type I error (false positive).
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4.3 Results and discussion
4.3.1 Selection of strains
The aim of this first section was to select the strains that would be most
informative for our samples. The toxicity and the mutagenicity (Figure 4.2)
were first evaluated with several strains on samples of a hospital (CHUV)
and of a sewage treatment plant (STP).
Both methods that were used to evaluate the toxicity indicated that most
of the samples were very toxic. Comparison of the results from the two meth-
ods (Figure 4.2.A and B) showed lower toxicities when toxicity was deter-
mined with the first method (evaluation with induced revertants), the sec-
ond method (by dilution) often yielding survival of less than 5%. The latter
method could overestimate the toxicity due to the experimental protocol,
where dilutions are made in order to be able to count the number of colonies.
The lower cell density of bacteria could result in less efficient colony forming
abilities.
The use of several Ames strains showed that TA98 was most sensitive
to the toxic effects of hospital samples (Figure 4.2.A). TA1538 was slightly
less sensitive to the toxic activity (20-50% of survival), and two samples were
not toxic to this strain. TA100 exhibited a survival above 50%. Using the
second method (dilution) to determine toxicity, TA102 was found to be the
least sensitive (Figure 4.2.B). Based on these results, we analysed all samples
using TA102, TA100 and TA1538 since they showed relative resistance to the
wastewater samples.
Most of the hospital samples were mutagenic on TA102, even without
correction for toxicity (Figure 4.2.C). Two samples were also mutagenic on
TA1538. The wastewater of Monday was mutagenic on TA1538, but highly
toxic on TA102 and TA100 (significant decrease of number of revertants,
p<0.05). The hospital samples of Friday and Sunday were also toxic on
TA100 (Figure 4.2.C), but the toxic effects were eliminated when S9 was
added. Thus, transformation by a liver extract decreased the toxicity of both
samples. Those appeared to be examples of toxic compounds that are me-
tabolized predominately to nontoxic substances. Inactivation of mutagens by
liver enzymes has been reported previously [Grabow et al., 1980; Pelon et al.,
1977].
The adjusted Mutagenicity Ratio using the toxicity on induced revertants
(MRadj1) showed that most of the samples of hospital were mutagenic on at
least one strain (Figure 4.2.D). TA98 was the less sensitive, only one sam-
ple was mutagenic on this strain. Contradictory results have been reported
in the literature. Most of the studies showed that TA98 was more sensitive
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Figure 4.2: Sensitivity of different strains to wastewater - Toxicity with
induced revertants (A), Toxicity with the second method (B), Mutation ratio:
without correction (C) and corrected with toxicity first method (D). A sample
is considered toxic or mutagenic when the number of colonies observed in the
sample and in the control are different at α<0.05 (Mann-Whitney-Wilconxon
U test) as described in the Section 4.2.6 (page 63)
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than TA100, when sludge [Perez et al., 2003], concentrated lake water sam-
ples [Monarca et al., 1998], wastewater concentrates (XAD-2 and XAD-7)
[Rappaport et al., 1979], surface water (concentrated or not, 20-year sur-
vey) [Umbuzeiro et al., 2001] were studied. However, few studies found than
TA100 was more sensitive than TA98, for sludge [Babish et al., 1983], hospi-
tal laboratories wastewater [Gartiser et al., 1996] and drinking water [Park
et al., 2000].
Only two samples of hospital (Friday and Sunday) were tested on TA100
with metabolic activation (S9), but none were mutagenic. The results from
TA98 in the presence of S9 were the same order of magnitude as without
metabolic activation. S9 metabolic activation reduced genotoxic (SOS Chro-
motest) and mutagenic (TA98 and sometimes TA100) potency in several
studies of water or extract samples [Umbuzeiro et al., 2001; White et al.,
1996; Monarca et al., 1998; Park et al., 2000], suggesting a prevalence of
direct-acting mutagens in the sample analyzed. Nevertheless, mutagenicity
on TA100 was higher with metabolic activation in the first study [Um-
buzeiro et al., 2001], suggesting that there are some indirect-acting mutagens
that could induce base pair substitution mutations. In our study, the use of
metabolic activation (S9-mix) did not seem to influence our results (Figure
4.2), all other samples were analysed without metabolic activation.
The Mutagenicity Ratio was not adjusted for toxicity by the second
method (MRadj2). The correction of MR with so low survival values (often
below 5% or even below 1%) would yield a high and significant Mutagenicity
Ratio, increasing the risk of type I error (false positive). Thus, adjustment
with survival values below 20% was not appropriate.
4.3.2 TA 102
The results of toxicity (dilution method) on TA102 showed that 70% (29
out of 41) of samples tested were toxic (see Figure 4.3.A). Wastewaters of
hospital (six out of seven) were as toxic as those of residential area (seven out
of eight). Samples from STP of Morges (five out of six) were more toxic than
samples from Lausanne (three out of seven). For both STPs, the quantity of
eﬄuents showing toxic activity was similar to the influents indicating that the
toxicity of influent was not removed by treatments of STPs. It is interesting
to note that some influents that did not exhibit toxicity became toxic after
treatment of STPs, as was observed in Thursday’s sample of Morges and
Lausanne and Saturday’s sample of Lausanne. One wastewater of Morges and
two of Lausanne showed a decrease of toxicity with treatment. A decrease in
toxicity in eﬄuent compared to influent sampled from different plants and
measured with a bioluminescence assay, Daphnia magna, Microtoxr and/or
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ToxAlertr have been observed by several authors [Castillo & Schafer, 2000;
Monarca et al., 2000; Castillo et al., 2001; Dizer et al., 2002]. The plant
treatment studied by these authors were successful in respect to the toxicity
measured. Nevertheless, toxic activity were still measured in STP eﬄuents
for most of these studies.
Most of the samples that were mutagenic on TA102 were from the hos-
pital (see Figure 4.3.B). Only two wastewaters of the residential area and of
Lausanne STP were mutagenic. After the biological treatment of the STP,
none of the wastewaters of Lausanne were mutagenic. Toxicity was, however,
observed in two wastewaters of Lausanne (Thursday and Saturday) and could
have masked their mutagenicity. When toxicity of the samples was taken into
consideration, the two samples were found to be mutagenic (see MRadj2 on
Figure 3.C).
All samples showing a significant decrease in the number of revertants in
comparison with the control (◦ in Figure 4.3.B) were also found to be toxic
with the second method of toxicity evaluation (Figure 4.3.A). This implies
that the method is reliable for the evaluation of survival of this bacterial
strain.
The three mutagenic eﬄuents of Lausanne were slightly more mutagenic
than before the treatment, showing that the treatments were not able to
remove the mutagenic substances and probably responsible for an increase
of mutagenic activity (Figure 4.3.C). An increase in the mutagenicity of the
wastewater following secondary treatment has also been observed in several
studies [Meier et al., 1987; Helma et al., 1996]. Several possible explanations
have been proposed for this observation. Cytotoxic interferences with the
mutagenic response of the raw wastewaters may be a contributing factor,
since the toxicity of raw wastewater could be higher than the toxicity of
secondary eﬄuents. This hypothesis could not be verified as the toxicity was
not evaluated. Another explanation could be the formation of direct-acting
mutagens during activated sludge treatment. As our results are corrected
with the toxicity, they are consistent with the second hypothesis.
Nevertheless, treatments of Lausanne and Morges STPs were efficient for
two days (Wednesday and Sunday) and for one day (Monday), respectively
(Figure 4.3.C). During those days, the mutagenic activity found in the influ-
ent was not detected in the eﬄuent. Several authors had reported removal of
mutagens by biological treatment, a Pilot-Scale Integrated biological treat-
ment process was found to reduce TA98 mutagenicity of water samples by
50% [Hu et al., 2003]. In addition, the genotoxicity measured with the umu-
test (with S9) cannot be completely removed by biological treatment [Ono
et al., 1996]. According to several studies [Babish et al., 1983; Perez et al.,
2003], most of the sludge samples analysed showed mutagenic activity, sug-
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Figure 4.3: TA102 - Toxicity with the second method (A), Mutation ratio:
without correction (B) and corrected with toxicity (C). RA: Residential area.
Mutagenicity or toxicity are as described in the Section 4.2.6 (page 63)
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gesting a transfer of a portion of mutagenicity from wastewater to sludge.
TA102 was very sensitive to mutagenicity of wastewater (MR significative:
10 out of 41 samples; MRadj2: 18 out of 41 samples). This strain was also found
to be very sensitive in another study [Malik & Ahmad, 1995]. Thus TA102 is
a good indicator of potential risk of contamination by mutagenic substances
in wastewater samples.
4.3.3 TA 1538
28% of samples tested (11 out of 40) were found to be toxic (induced rever-
tant method) on TA1538 (see Figure 4.4.A). The dilution method of survival
evaluation (Figure 4.4.B) showed a higher toxicity (48%). The bacterial sur-
vivals of hospital wastewaters were below 20% with the second method and
between 25% to 65% with the induced revertant method. Two samples of
hospital (Monday and Friday) and five influents of Lausanne and Morges
were classified as toxic with the dilution method but not with the induced
revertant method. And five eﬄuents of Lausanne were toxic with the induced
revertant method but only one with the dilution method. Because different
results were obtained with the induced revertant and dilution methods, the
mutagenicity of samples expressed without correction for toxicity were the
only one with no ambiguity.
An increase in the number of revertant colonies was found following treat-
ment with several water samples under conditions to measure toxicity (in-
duced revertant method), (Figure 4.4.A). Most of these samples, except for
one influent of Morges and two samples of the RA of Lausanne (Figure 4.4.C-
E), did not by themselves induce an increase in the number of revertants. This
result can be due to an increase in colony forming ability or interaction be-
tween the positive control and waste water possibly leading to a potentiation
of the mutagenic effect of the positive control.
The results of mutagenicity without correction for toxicity showed that
18% of samples (7 out of 40) were mutagenic (Figure 4.4.C). A higher per-
centage (40%) was found for Mississipi River water samples with this strain
[Pelon et al., 1977], indicating that Swiss wastewaters from 2004 were less
mutagenic than river water from thirty years ago (1974).
Mutagenic activity was observed in Thursday and Wednesday influents
of Lausanne. During these two days, the samples from the hospital and the
residential area were not mutagenic, indicating that another source of release
contaminated the influents of Lausanne (Figure 4.4.C).
Lausanne eﬄuents did not show mutagenic activity on TA1538, suggest-
ing a removal of mutagenic substances for both mutagenic influents. Morges
eﬄuents were also not mutagenic on TA1538. The absence of mutagenic ac-
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tivity in concentrated eﬄuents has already been described in several studies
on TA98 and TA100 [Shishida et al., 2000; Rappaport et al., 1979; Monarca
et al., 2000]. As we have observed with TA102, other studies have found eﬄu-
ents to be mutagenic on TA98 and/or on TA100, but these eﬄuents contain
a high proportion of industrial wastewater [Grabow et al., 1980; Rappaport
et al., 1979].
Morges wastewaters were less mutagenic than Lausanne wastewaters.
Morges being a smaller city than Lausanne with less contaminants could
account for this variation. Other authors [White & Rasmussen, 1998] have
shown a correlation between surface water mutagenicity and population.
4.3.4 TA 100
The results from the studies of wastewaters on TA100 showed that 57%
(8 out of 14) of samples tested with induced revertants and that 64% (18
out of 28) of wastewater tested with dilution method were toxic (see Figure
4.5.A and B). All of the hospital samples were toxic with both methods of
evaluations (Figure 4.5.A and B). One out of seven wastewaters of Lausanne
STP was toxic with the induced revertants evaluation, but six were classified
as toxic with the second method. Three out of six wastewaters of Morges
were toxic with the second method. Toxicities were higher with the second
method, as shown above.
Comparison of the results using the dilution method with samples from
Morges and Lausanne showed a lower number of toxic samples from Morges
(Figure 4.5.B). Only one sample from the residential area was toxic. The
wastewater of this area did not appear to contribute to the toxic activity
of Lausanne STP wastewaters. A significantly higher number of bacterial
colonies was observed in the Wednesday sample of the residential area. We
postulate that this sample contained growth nutrients that could have in-
creased the growth efficiency of the bacteria. This artifact can induce a false
positive result in the mutagenicity evaluation. For this reason, we corrected
the mutagenicity ratio by this significant growth increase (MRadj1).
The results of mutagenicity (without correction: Figure 4.5.C) also showed
that samples of the hospital were toxic to this strain (four out of seven
samples showed a decrease of revertants). After correction for the toxicity
(induced revertant method), two samples could be classified as mutagenic
(Figure 4.5.D). With adjustment (MRadj1), our method improves the sensi-
tivity of the Ames test. Without correction, none of hospital wastewater were
mutagenic on TA100, as has been reported in another study [Gartiser et al.,
1996] on TA98 and TA100.
Three wastewaters of Lausanne were mutagenic on TA100. Mutagenic
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Figure 4.5: TA100 - Toxicity with induced revertants (A), Toxicity with
the second method (B), Mutation ratio: without correction (C) and corrected
with toxicity first method (D) and second method (E). RA: Residential area.
Mutagenicity or toxicity are as described in the Section 4.2.6 (page 63)
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samples from the STP and the hospital were not found to be from the same
days (Figure 4.5.D), suggesting that the hospital mutagenic activity was di-
luted in wastewater of the city and that other sources contributed to the
mutagenic activity of STP.
The adjustment with the toxicity (dilution method) of the MR (see MRadj2
on Figure 4.5.E) indicated that more wastewaters showed mutagenic activity
(six out of seven Lausanne STP; three out of six Morges STP; two out of
eight RA). For several samples, this activity was very low, but significant.
Indeed, the standard deviations were very low. Another study did not show
mutagenic activity on TA100 for wastewater of a residential area [Grabow
et al., 1980].
Figure 4.5.E shows that less Morges wastewaters (three out of six) were
mutagenic than Lausanne wastewaters (six out of seven). These results were
in accordance with non-adjusted results (Figure 4.5.C). The same result was
found for the mutagenic activity of these both STPs and for TA1538.
Several studies pointed out the mutagenic activity on TA100 of wastew-
aters or surface waters. For instance, a not-concentrated influent and cor-
responding eﬄuent of the Central municipal wastewater treatment plant in
Domzale (Slovenia) were mutagenic on TA100 (+/-S9) [Filipic & Toman,
1996a].
4.3.5 General discussion
85% (35 out of 41) of samples analysed were toxic in at least one strain
with the second method of evaluation (see Table 4.1). Though more samples
exhibited toxicity on TA102, the survival observed in the different samples
was however lower in TA98.
37% (15 out of 41) of samples were significantly mutagenic (without ad-
justment) in at least one strain (Table 4.1). Nevertheless, 54% (22 out of 41)
of samples showed a decrease in the number of revertants in the mutagenicity
assays. With the adjustment with toxicity as measured by induced revertants
(MRadj1), a small increase in the number of mutagenic samples was observed
(44%; 18 out of 41). However, after adjustment with the dilution method to
measure toxicity (MRadj2), 71% (29 out of 41) of samples could be classified
as mutagens. These percentages were the same order of magnitude as those
observed from a French hospital, where 55% (10 out of 18) were genotoxic
either on TA98/TA100 or on SOS chromotest [Jolibois et al., 2003]. Never-
theless, our percentages were high in comparison to most other studies. On
a study conducted by Giuliani et al. [1996], the UmuC assay detected geno-
toxic activity in 13% of samples of a hospital wastewater . As in our work,
these authors did not concentrate the samples. Two samples (8%, n=25) of
74
CHAPTER 4. MUTAGENICITY OF HOSPITAL AND SEWAGE
TREATMENT PLANTS WASTEWATERS
Table 4.1: Number of toxica and mutagenica samples on TA102, TA1538
or TA100 evaluated with the various methods described in our study
hhhhhhhhhhhhhhhhhhSamples (Total)
Methods Toxicity Toxicity MR MRadj1 MRadj2
1st b 2nd c
CHUV (7) 7 7 7 6 7
Lausanne Influent (7) 3 7 4 4 7
Lausanne Eﬄuent (7) 5 3 0 3 4
Morges Influent (6) 0 6 0 0 5
Morges Eﬄuent (6) 0 5 0 0 2
RA Lausanne (8) 0 7 4 2 4
a A sample is toxic or mutagenic when the number of colonies observed in the sample and
in the control are different at α<0.05 (Mann-Whitney-Wilconxon U test) as described in
the Section 4.2.6 (page 63)
b Induced revertant method
c Dilution method
German Hospital wastewaters were mutagenic on TA98 or TA100, but 40%
of these samples were genotoxic with the umuC test [Hartmann et al., 1999].
This difference could have resulted from toxicity of hospital samples which
masked the mutagenic activity in TA98. In a 20-year survey of water quality
with the Salmonella mutagenicity assay, 14% (137/1007) of surface water
and 18% of source water showed mutagenic activity [Umbuzeiro et al., 2001].
Strain TA102 was the most sensitive, 10 out of 15 (67%) of all the muta-
genic samples were found to be mutagenic on this strain without adjustment
with toxicity. When toxicity was taken into consideration, 18 out of 29 (62%)
of MRadj2 were mutagenic on TA102. TA1538 was more sensitive than TA100
with a MR significant for seven samples on TA1538 but only three samples
on TA100 and with a MRadj2 significant for 16 samples on TA1538 but only
11 samples on TA100.
4.4 Conclusion
The two methods used to evaluate bacterial toxicity showed different sen-
sitivities. Samples from the hospital were extremely toxic, survival was often
below 20%. Influents of STPs were less toxic than hospital wastewaters. For
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the mutagenicity assessment, TA102 strain was the most sensitive, followed
by TA1538 and TA100. TA98 showed the lowest survival with the hospital
samples, it is the reason why this strain is the less adapted for the evaluation
of mutagenic activity of this kind of samples. Most of the samples from the
hospital and from the larger STP studied showed mutagenic activities. More
hospital wastewaters were mutagenic even without correction with toxicity
than influents of STP, indicating a higher mutagenic activity in wastewater
of hospital. Since less eﬄuents were mutagenic than influents in both STPs,
biological treatments were relatively efficient.
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Chapter 5
General conclusion and
recommendations
5.1 Conclusion and outlook
The development of sensitive analytical methods allowed to evaluate the
contamination of wastewaters by seven pharmaceutical substances, some are
highly consumed and some are very toxic. The toxicity and genotoxicity
assays permitted to assess the mixture effect of all contaminants in hospital
and urban wastewaters.
5.1.1 Occurrence of pharmaceutical substances in the
environment
The concentrations of the highly consumed pharmaceuticals (NSAIDs)
were relatively important in the influents and eﬄuents of STPs, and thus the
substances in STP eﬄuents contaminated the surface waters.
This thesis allowed the analysis of two of the most used anticancer drugs,
that have never been detected. The concentrations of these toxic drugs were
very low, below the limit of quantification or below the limit of detection.
None of these drugs were detected in eﬄuents of STPs, indicating that the
surface water exposure was low.
A continue survey of the environmental concentrations of pharmaceutical
substances would be necessary to evaluate the evolution of this contamina-
tion.
In addition, for lipophilic substances as Tamoxifen, the measurement of
concentrations in sludge of STP would be interesting.
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5.1.2 Fate
None of the NSAIDs were well removed by STPs, except Ibuprofen in
only one STP. For Ibuprofen, the removal depends on the residence time of
wastewater in biological treatment of the STP. The removals of Ibuprofen
and Ketoprofen decreased during a raining period of winter, in comparison
to dry periods. Diclofenac and Clofibric acid were resistant to all studied
treatments, thus no removal was observed.
Due to its high lipophilic property, Tamoxifen was removed during the
treatment of both studied STPs.
The removal of pharmaceutical substances were dependent on the STPs
and on weather conditions, which can lead to increased aquatic exposures.
Additional research are needed to know why there is such differences between
STPs. A long-time survey (e.g. one year) would be useful to know the real
exposure of aquatic environment, even in bad weather conditions.
The degradation pathway and resultant metabolites can differ from those
observed in human metabolism [Winkler et al., 2001]. In addition, only few
research papers on the environmental degradability (e.g. photodegradation,
ozonation) are available [Rey et al., 1999; Andreozzi et al., 2003; Zwiener
& Frimmel, 2000; Werner et al., 2005]. It is the reason why, there is an
important need to elucidating the environmental transformation and fate of
pharmaceutical products.
5.1.3 Risk assessment and effects data
Mefenamic acid seems to present the most important risk, followed by
Ibuprofen, Clofibric acid, Diclofenac and Ketoprofen. But the risk ratio for
surface water calculated with a dilution factor was above one only for Mefe-
namic acid.
To our knowledge, chronic ecotoxicity data are available only for Di-
clofenac and Clofibric acid. These kind of data are needed for the other
chemicals to confirm our results. In addition, the risk evaluation was not
possible for the two anticancer drugs, since no ecotoxicity data (even acute
data) is available.
The knowledge on environmental toxicity of biologically active drugs is
generally limited. Evaluation of the ecotoxicity of all pharmaceutical com-
pounds and their metabolites have to be urgently performed, including phar-
maceuticals not frequently detected in the environment.
In addition, ecotoxicity tests need to better accommodate subtle end
points (e.g., genetic modifications, behavioral and endocrine effects) and to
take into consideration the modes of action of pharmaceutical substances. Ac-
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cording to Ferrari et al. [2004], the development of new endpoints related to
the known mode of action of pharmaceuticals should improve the suitability
of the acute ecotoxicity testing.
Mixture effects
Since the toxicity of a single drug might be enhanced by the occurrence
of other pharmaceuticals with similar activity [Cleuvers, 2003], the overall
risk of the NSAID drugs could be significant.
In the aquatic environment, most organisms are continually exposed to a
range of toxic pollutants. When determining environmental risk of substances
at low concentration, consideration must be given to both additive effects
(drugs of like-mode of action) and to synergistic effects (interactions between
drugs of different classes). Indeed, some compounds that have no inherent
risk on their own may contribute to risk by increasing the toxicity of others.
Considerable combination effects of substances can occur. Since theses
effects on aquatic life is little studied [see for instance Cleuvers, 2003; Brain
et al., 2004], further mixture toxicity testing is required to achieve a better
assessment of the ecotoxicological potential impact of drug residues in the
aquatic environment.
Adverse effect on human health
It is unknown what effects, if any, exposure to repeated doses of a mixture
of subtherapeutic amounts of drug compounds could have on human health.
Most likely they will be of little or no consequence in healthy people. Never-
theless, there is the possibility that the compounds may interact with other
medications that an individual may be taking. For instance, Ibuprofen has
been demonstrated to interfere with the cardioprotective properties of aspirin
[MacDonald & Wei, 2003], while caffeine can enhance the effects of certain
analgesics [Buerge et al., 2003]. Although it is doubtful that concentrations
would be high enough in drinking water to cause these effects.
According to several studies [Reddersen et al., 2002; Webb et al., 2003;
Christensen, 1998], there are no substantial concerns with regards to exposure
by pharmaceutical residues via drinking water. Nevertheless, further research
in this area would be useful [Jones et al., 2004].
5.1.4 Toxicity and genotoxicity of wastewaters
Samples from the hospital were extremely toxic. Influents of STPs were
less toxic than hospital wastewaters. Most of the samples from the hospital
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and from the larger STP studied showed mutagenic activities. More hospi-
tal wastewaters were mutagenic than influents of STP, indicating a higher
mutagenic activity in wastewaters of hospital. Thus, hospitals are an impor-
tant source of contamination by toxic and mutagenic substances, which could
be pharmaceutical substances as anticancer drugs, but also disinfectants or
cleaning products. The low contamination by anticancer drugs measured in
this thesis showed that the (geno)toxic effect of a pollutant alone is unlikely,
but the mixture effects of all pollutants from hospital were significant. Thus,
it is important that hospital wastewaters are not released into the aquatic
environment without an adequate treatment.
Toxicity or mutagenicity were often lower in eﬄuents than in influents,
indicating that biological treatments were relatively efficient. Nevertheless,
several eﬄuents were toxic or mutagenic, indicating that the surface waters
were exposed to toxic and mutagenic compounds.
Evaluations of the toxicity/mutagenicity and chemical analyses are com-
plementary. Toxicity/mutagenicity assays allow to evaluate the overall effect
of the occurrence of pollutants. And analytical analyses identify and quan-
tify compounds probably responsible for the genotoxicity and the toxicity
measured.
A wastewater survey (especially with TA102) of several hospitals will be
interesting to estimate if the dimension of hospital (number of beds) and the
available treatments influence the toxicity and the mutagenicity of wastewa-
ters.
A routine survey of the treated wastewaters of STPs will be useful to es-
timate the potential contamination of surface waters by toxic and mutagenic
compounds.
5.2 Recommendations
Several recommendations are presented here to decrease the environmen-
tal risk of human pharmaceuticals in the environment.
5.2.1 Sewage treatment plants
Since sewage treatment plants are likely to be the most significant and
continuous pathway of human medicinal compounds to surface water, an im-
provement of the efficiency of their treatments is needed. According to Larsen
et al. [2004], from the technical point of view there is a choice between end-of-
pipe technologies (e.g. ozonation of eﬄuents) and more fundamental changes
in wastewaters management (urine separation). In addition, the connection
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to all the population at a STP and a capacity increase of the existing STPs,
will prevent the direct discharge or the overflow of untreated sewage to the
environment and will increase the residence time of waters in the STPs. These
improvements would have a great impact on reducing the release of drugs.
Due to the high toxicity and mutagenicity of hospital wastewaters, it
would be useful to add specific and efficient treatments at the end of hospitals.
5.2.2 Reduction at source
Nevertheless end-of-pipe technologies will never be able to solve the prob-
lem entirely, it is better to focus on reduction at source. But it is a ticklish
task, due to the beneficial health effects and economic importance of these
compounds. The reduction at source can be performed by different ways: (1)
by decreasing the consumption and excretion of pharmaceutical substances,
mainly the ecotoxic one and (2) by eliminating the discharge of unused drugs
in the sewer or in the garbage. These changes would be possible with the
following recommendations.
Environmental approval sign/label
An environmental information system should be created with simple and
rapid accessibility. Such a system has to await the establishment of an envi-
ronmental classification system for drugs. This classification should be tack-
led on an international platform (e.g. EU or OECD). When such a system
is available, the doctors could be able to make an environmentally favorable
selection between drug alternatives that are medically equivalent.
Environmentally friendly drugs should be given an environmental ap-
proval sign in the package and sheets of the product, catalogues, and other
media in which the product is presented to doctors, pharmacists and patients.
The approval sign should only be allowed to be used on products with the
following characteristics which are favorable for the environment:
• The bio-availability, in terms of the percentage of the product that is
taken up systemically in the patient, must be high (e.g. 75%), to avoid
the direct elimination of the active compounds in urine and feces.
• The environmental adverse effects of the pharmaceutical compound and
their metabolites must be minimal.
• The (bio)degradability of the pharmaceutical compound and their metabo-
lites must be high.
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• The package should also be environmentally friendly (e.g. recycling
materials, optimisation of material quantities).
• Description on the package about the disposal of unwanted or expired
drugs must be clearly present.
To meet those requirements, the producers will be encouraged to develop
new or improved treatments, including the package, in accordance with the
guidelines for sustainable development.
As already used for business contribution to sustainable development, the
environmental approval sign/denomination could be “eco-efficiency”, a term
the World Business Council for Sustainable Development (WBCSD) invented
in 1992.
Awareness campaign
An awareness campaign, promoting healthy style of live and alternative
therapeutic treatments, would be efficient to reduce the consumption of sev-
eral pharmaceutical substances and their release in the environment.
As already performed in Sweden [Wennmalm, 2003], carrying out a cam-
paign informing patients about the environmental aspects of drugs is also
proposed. The campaign goal is that patients should not dispose unused
drugs in the garbage or in the sewer, but return it to the pharmacy. On that
account, to avoid unused drugs, prescriptions should be better correspond to
the duration of the treatment.
Education on the environmental aspects of pharmaceutical drugs should
be given to the personnel of the public health care system. The prescribers
should also be informed about the environmental consequences of released
drugs residues.
In our society, it is sure that too many people underestimate the risk for
human of drug consumption, maybe due to the pharmaceutical marketing and
to the high trust in our doctors. “Advertising” about the potential toxicity
of pharmaceuticals would be necessary to increase the awareness of adverse
effects of drug consumption, even at therapeutic doses. Pharmacists should
better inform the patients about the toxic effects of the products and about
the potential dangerous interactions with others drugs. These advices should
avoid a lot of drug poisoning and by this way decrease these emergency
patients in hospital.
Another problem is that the purpose of most medical treatments is to
control symptoms, but not actually to cure the patients. To be able to cure,
it is necessary to diagnose the origin of the symptoms (e.g. skin diseases are
often due to stress situations). Unfortunately, a lot of generalist practitioners
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are not interested, have not the ability or have not enough time to diag-
nose the origin of the patient diseases, specially psychosomatic diseases. The
formation of medical practitioners have to be improved in this way.
In summary, due to their beneficial health effects and economic impor-
tance, the actions taken to reduce inputs of drugs into the environment are
much debated. The use of pharmaceutical compounds is expected to grow
with the increasing age of the population. A solution for pollution control is
to add sewage treatments in hospital and to avoid that municipal wastew-
aters are released without any treatment. Another solution is to focus on
reduction at source, by developing a clear labelling on medicinal products,
guidelines for the disposal and awareness campaign. These recommendations
would have the potential benefit of improved consumer health (by minimizing
the intake of active substances), as well as reduced health care spending.
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Appendix A
Pharmaceutical substances
Most of the information in the Appendices A.1 to A.15 are from the
following databases:
• TOXNET, a cluster of databases on toxicology, hazardous chemicals,
and related areas (http://toxnet.nlm.nih.gov/). Hazardous Substances
Data Bank (HSDB) was specially used
• National Toxicology Program (NTP) Database
(http://ntp-apps.niehs.nih.gov/ntp tox/index.cfm)
• The Physical Properties Database (PHYSPROP) of Syracuse Research
Corporation (http://www.syrres.com/esc/physdemo.htm)
• RxList, the internet drug index (http://www.rxlist.com)
• Compendium of drugs, a Swiss database on drugs
(http://www.kompendium.ch)
• ChemFinder.com, a scientific databases
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A.1. Clofibric acid
A.1 Clofibric acid
Generality
Name 2-(4-chlorophenoxy)-2-methyl propionic acid
CAS RN 882-09-7
Molecular weight 214.6 (C10H11ClO3)
Melting point 120-122◦C
λmax (absorption) 225 nm in MeOH
Solubility in water (25◦C) 583 mg/l (estimation)
Solubility in methanol (22◦C) 1-5 mg/ml
Log Kow 2.57
OCl C
CH3
CH3
C
O
OH
 
Figure A.1: Structure of Clofibric acid
Clofibric acid is an active metabolite of clofibrate, etofibrate, etofyllinclofi-
brate wich are drugs used as blood lipid regulators. These substances are used
to decrease the plasmatic concentration of cholesterol and triglycerides. The
mechanism of action has not been established definitively.
Occurrence in the environment
Clofibric acid has already been detected in STP eﬄuents at concentrations
up to 1600 ng/l [Stumpf et al., 1996; Heberer et al., 2002]. In the aquatic
environment, it was detected in German river waters at concentrations up
to 550 ng/l [Ternes, 1998] and in Swiss lakes at concentrations up to 9 ng/l
[Buser et al., 1998b]. It was even found in samples of ground water wells at
a drinking water treatment plant (up to 7 300 ng/l) [Heberer et al., 1997].
Dosage
Patients ingest one capsule (500 mg) of clofibrate one to four times per
day.
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Metabolism and Elimination
After an oral administration, Clofibrate is quickly and completely reduced
of the gastro-intestinal tract and is degraded by hydrolysis in clofibric acid.
Between 95% and 99% of an oral dose of clofibrate is excreted in the urine
as free and conjugated clofibric acid.
Etofyllinclofibrate is well reduced after oral administration. It is not found
in the blood under unchanged shape, but under the shape of its two main
metabolites: etofylline and clofibric acid. The half-life of elimination is about
12-18 hours. Eight hours after the administration, 8.5% of the dose are elim-
inated in urine in the form of clofibric acid.
Toxicity
Ecotoxicity
Organisms Toxicity Ref.
Daphnia magna (Invertebrates) EC50 = 106 mg/l [Webb,
2001a]
Brachyderio rerio (Fish embryos) EC50 (48h) = 86 mg/l
Scenedesmus subspicatus (Algae) EC50 (72h) = 89 mg/l
Daphnia magna (Invert.) EC50 (48h) > 200 000 µg/l [Ferrari
et al.,
2003]
Ceriodaphnia dubia (Invert.) EC50 (48h) > 200 000 µg/l
P. subcapitata (Algae) NOEC (96h) = 75 000 µg/l
B. Calyciflorus (Invert.) NOEC (48h) = 246 µg/l
Ceriodaphnia dubia (Invert.) NOEC (7d) = 640 µg/l
Brachyderio rerio (Fish embryos) NOEC (10d) = 70 000 µg/l
EC50: median Effect Concentration or 50% effective concentration
NOEC: No Observed Effect Concentration
Carcinogenesis
Administration of clofibrate to mice and rats in long-term studies at 1
to 2 times the maximum recommended human dose (based on surface area,
mg/m2 ), resulted in a higher incidence of benign and malignant liver tumors
than in controls. There was an increase in benign Leydig cell tumors in male
rats treated at 400 mg/kg/day or 2 times the maximum recommended human
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dose in one study. A comparative carcinogenicity study was also done in rats
comparing three drugs in this class: fenofibrate (10 and 60 mg/kg; 0.3 and 1.6
times the human dose), clofibrate (400 mg/kg; 1.6 times the human dose),
and gemfibrozil (250 mg/kg; 1.7 times the human dose). Pancreatic acinar
adenomas were increased in males and females on fenofibrate; hepatocellular
carcinoma and pancreatic acinar adenomas were increased in males and hep-
atic neoplastic nodules in females treated with clofibrate; hepatic neoplastic
nodules were increased in males and females treated with gemfibrozil while
testicular interstitial cell tumors were increased in males on all three drugs.
Impairment of Fertility
Arrest of spermatogenesis has been seen in both dogs and monkeys at
doses approximately two times the maximum recommended human dose
(based on surface area).
Adverse effect on human
The treatment with these drugs can result in some gastro-intestinal con-
fusions, such as sickness, vomit and diarrhea. Very rare cases of fall of hair,
impotence and muscular pains were reported. Diseases of bile tract can arise
following a long treatment with blood lipid regulators.
Medicines on sale in Switzerland
Clofibrat Tripharmar, Lipo-Merzrretard, Duolipr
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A.2 Ibuprofen
Generality
Name 2-(4-isobutylphenyl)propionic acid
CAS RN 15687-27-1
Molecular weight 206.3 (C13H18O2 )
Melting point 75-77◦C
λmax (absorption) 223 nm in MeOH
Solubility in water (25◦C) 21 mg/l
Solubility in MeOH:water (1:99) 83 mg/l
Log Kow 3.97
pKa 4.91
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Figure A.2: Structure of Ibuprofen
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID). Ibupro-
fen possesses analgesic and antipyretic activities. Its mode of action, like
that of other NSAIDs, is not completely understood, but may be related to
prostaglandin synthetase inhibition.
Ibuprofen is indicated for relief of the signs and symptoms of rheumatoid
arthritis and osteoarthritis. Ibuprofen is also indicated for relief of mild to
moderate pain and for the treatment of primary dysmenorrhea.
It is on of the most important pharmaceuticals in term of quantities con-
sumed.
Occurrence in the environment
Ibuprofen was already detected in surface waters and sewage treatment
plant at concentrations up to 530 ng/l and 3400 ng/l, respectively [Buser
et al., 1998a; Stumpf et al., 1999; Ternes, 1998].
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Dosage
The suggested dosage is 1200-3200 mg daily, and do not exceed 3200 mg
total daily dose.
Metabolism and Elimination
Ibuprofen is rapidly absorbed when administered orally. Studies have
shown that following ingestion of the drug, 45% to 79% of the dose was
recovered in the urine within 24 hours as metabolite A (25%), (+)-2-4 -
(2-hydroxy-2-methylpropyl)-phenylpropionic acid and metabolite B (37%),
(+)-2-4 -(2-carboxypropyl)-phenylpropionic acid; the percentages of free and
conjugated ibuprofen were approximately 1% and 14%, respectively.
Toxicity
Ecotoxicity
Organisms Toxicity References
Daphnia magna (Invertebrates) EC50 (48h) = 9.06 mg/l [Webb, 2001a]
Lepomis macrochirus (Fish) EC50 (96h) = 173 mg/l
Skeletonema costatum (Algae) EC50 (96h) = 7.1 mg/l
EC50: median Effect Concentration or 50% effective concentration
Animal toxicity
Animals and absorption Toxicity References
LD50 (oral, mice) 1255 mg/kg Merck index
LD50 (i.p., mice) 495 mg/kg
LD50 (oral, rat) 1050 mg/kg
LD50 (i.p., rat) 626 mg/kg
LD50: lethal dose 50 percent kill; i.p: intraperitoneal.
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Adverse effect on human
The most frequent type of adverse reaction occurring with ibuprofen is
gastrointestinal (nausea, epigastric pain, heartburn, diarrhea, abdominal dis-
tress, nausea and vomiting, indigestion, constipation, abdominal cramps or
pain). Adverse reactions observed during controlled clinical trials at an in-
cidence greater than 1% are effects on central nervous system (dizziness,
headache, nervousness) and dermatologic effect (rash, pruritus).
Because of the known effects of Ibuprofen on the fetal cardiovascular
system (closure of ductus arteriosus), use during late pregnancy should be
avoided.
Medicines on sale in Switzerland
Algiforr, Dolocylr, Ecoprofenr, etc.
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A.3 Ketoprofen
Generality
Name 2-(meta-Benzoylphenyl) propionic acid
CAS RN 22071-15-4
Molecular weight 254.3 (C16H14O3 )
Melting point 94◦C
Max (absorption) 216 and 244 nm in MeOH
λmax 260 nm in acid solution
Solubility in MeOH:water (1:99) 220 mg/l
Solubility in water (pH=7) 0.3 g/ml
Log Kow 3.12
pKa 4.45
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Figure A.3: Structure of Ketoprofen
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) with anal-
gesic and antipyretic properties. In anti-inflammatory models ketoprofen has
been shown to have inhibitory effects on prostaglandin and leukotriene syn-
thesis, to have antibrady-kinin activity, as well as to have lysosomal membrane-
stabilizing action. However, its mode of action, like that of other nonsteroidal
anti-inflammatory drugs, is not fully understood.
Ketoprofen is indicated for the management of the signs and symptoms
of rheumatoid arthritis and osteoarthritis. Ketoprofen is indicated for the
management of pain and for treatment of primary dysmenorrhea.
Occurrence in the environment
Ketoprofen is detected in surface waters and sewage treatment plant at
concentrations up to 120 ng/l and 380 ng/l, respectively [Stumpf et al., 1996,
1999; Ternes, 1998]
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Dosage
The recommended starting dose of ketoprofen in otherwise healthy pa-
tients is 75 mg three times or 50 mg four times a day, or 200 mg administered
once a day. The recommended maximum daily dose of ketoprofen is 200-300
mg/day.
Metabolism and Elimination
The metabolic fate of ketoprofen is glucuronide conjugation to form an
unstable acyl-glucuronide. The glucuronic acid moiety can be converted back
to the parent compound. There are no known active metabolites of ketopro-
fen. Ketoprofen has been shown not to induce drug-metabolizing enzymes. In
a 24-hour period, approximately 80% of an administered dose of ketoprofen
is excreted in the urine, primarily as the glucuronide metabolite.
Toxicity
Ecotoxicity
Organisms Toxicity References
V. ficheri (ToxAlert 100) EC50 = 15.6 µg/ml [Farre´ &
Barcelo´, 2003]
V. ficheri (Microtoxr) EC50 = 27 µg/ml [Robin &
Soulet, 1999]
Daphnia magna(Invert.) EC50 (24h) = 101-138 µg/ml
Daphnia magna(Invert.) EC50 (48h) = 52-76 µg/ml
EC50: median Effect Concentration or 50% effective concentration
Animal toxicity
Animals and absorption Toxicity References
LD50 (oral, mice) 101 mg/kg Merck index
LD50: lethal dose 50 percent kill
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Carcinogenesis, Mutagenesis, Impairment of Fertility
Chronic oral toxicity studies in mice (up to 32 mg/kg/day; 96 mg/m2/day)
did not indicate a carcinogenic potential for ketoprofen. A 2-year carcino-
genicity study in rats, using doses up to 6.0 mg/kg/day (36 mg/m2/day),
showed no evidence of tumorigenic potential. Abnormal spermatogenesis or
inhibition of spermatogenesis developed in rats and dogs at high doses, and
a decrease in the weight of the testes occurred in dogs and baboons at high
doses.
Adverse effect on human
The most frequent type of adverse reaction occurring with ketoprofen is
gastrointestinal (nausea, abdominal pain, diarrhea, constipation, flatulence,
anorexia, vomiting). Adverse reactions observed during controlled clinical
trials at an incidence greater than 1% are effects on central nervous system
(dizziness, headache, excitation) and dermatologic effect (rash).
Medicines on sale in Switzerland
Fastumr
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A.4 Mefenamic acid
Generality
Name N-(2,3-Xylyl)anthranilic acid
CAS RN 61-68-7
Molecular weight 241.29 (C15H15NO2 )
Melting point 230-231◦C
λmax (absorption) 285, 340 nm in NaOH 0.1N
Solubility in water (pH=7.1; 25◦C) 0.004 g/100ml
Solubility in water (pH=7.1; 37◦C) 0.008 g/100ml
Log Kow 5.12
pKa 4.2
Few soluble in chloroform and in ether. Slightly soluble in ethanol.
N
H
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H3C CH3
Figure A.4: Structure of Mefenamic acid
Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) that
exhibits anti-inflammatory, analgesic, and antipyretic activities. The mecha-
nism of action of mefenamic acid, like that of other NSAIDs, is not completely
understood but may be related to prostaglandin synthetase inhibition.
Mefenamic acid is indicated for relief of mild to moderate pain, when
therapy will not exceed one week (7 days) and for treatment of primary
dysmenorrhea.
Occurrence in the environment
To our knowledge, no study has been conducted to detect mefenamic acid
in influent of sewage treatment plant. Mefenamic acid was measured in river
(with a very low recovery rate of 43.1%) [Ahrer et al., 2001] and in eﬄuent
of sewage treatment plants [Ashton et al., 2004].
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Dosage
The recommended dose is 500 mg as an initial dose followed by 250 mg
every 6 hours as needed, usually not to exceed one week.
Metabolism and Elimination
Mefenamic acid is metabolised by cytochrome P450 enzyme CYP2C9
to 3-hydroxymethyl mefenamic acid (Metabolite I). Further oxidation to a
3-carboxymefenamic acid (Metabolite II) may occur. The activity of these
metabolites has not been studied. The metabolites may undergo glucuronida-
tion and mefenamic acid is also glucuronidated directly. Approximately 52
percent of a mefenamic acid dose is excreted into the urine primarily as
glucuronides of mefenamic acid (6%), 3-hydroxymefenamic acid (25%) and
3-carboxymefenamic acid (21%). The proportion of free mefenamic acid in
the urine is lower than 5%. The fecal route of elimination accounts for up
to 20% of the dose, mainly in the form of unconjugated 3-carboxymefenamic
acid.
Toxicity
Ecotoxicity
None
Animal toxicity
Animals and absorption Toxicity References
LD50 (oral, mice) 630 mg/kg Merck index
LD50 (oral, rat) 790 mg/kg
LD50: lethal dose 50 percent kill
Adverse effect on human
The most frequently reported adverse experiences occurring in approxi-
mately 1-10% of patients are abdominal pain, constipation, diarrhea, dyspep-
sia, flatulence, gross bleeding/perforation, heartburn, nausea, GI ulcers (gas-
tric/duodenal), vomiting, abnormal renal function, anemia, dizziness, edema,
elevated liver enzymes, headaches, increased bleeding time, pruritus, rashes,
tinnitus.
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Medicines on sale in Switzerland
Me´fe´-basan, Ponstanr, Spiralginr, etc.
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A.5 Diclofenac
Generality
Name 2-[(2,6-dichlorophenyl)amino]
benzeneacetic acid
CAS RN 15307-86-5
Molecular weight 318,14 (C14H10Cl2NNaO2 )
Melting point 283-285◦C
λmax (absorption) 221 nm and 280 nm in MeOH
Solubility in MeOH/water (1/99) ∼ 7 760 mg/l
Log Kow 4.51
pKa 4.15
N 
H
Cl
Cl
H2C
C
O
OH(Na)
 
Figure A.5: Structure of Diclofenac
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID). In phar-
macologic studies, diclofenac has shown anti-inflammatory, analgesic, and
antipyretic activity.
Diclofenac is indicated for the acute and chronic treatment of signs and
symptoms of osteoarthritis and rheumatoid arthritis. In addition, diclofenac
are indicated for the treatment of ankylosing spondylitis and for the man-
agement of pain and primary dysmenorrhea.
As with other NSAIDs, its mode of action is not known; its ability to in-
hibit prostaglandin synthesis, however, may be involved in its anti-inflammatory
activity, as well as contribute to its efficacy in relieving pain related to in-
flammation and primary dysmenorrhea.
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Occurrence in the environment
Diclofenac was already detected in surface waters and sewage treatment
plant at concentrations up to 1200 ng/l and 2100, ng/l, respectively [Buser
et al., 1998a; Stumpf et al., 1999; Ternes, 1998].
Dosage
Diclofenac may be administered from 25 mg to 75 mg.
Metabolism and Elimination
Diclofenac is eliminated through metabolism and subsequent urinary and
biliary excretion of the glucuronide and the sulfate conjugates of the metabo-
lites. Approximately 65% of the dose is excreted in the urine, and approx-
imately 35% in the bile. Conjugates of unchanged diclofenac account for
5%-10% of the dose excreted in the urine and for less than 5% excreted in
the bile. Little or no unchanged unconjugated drug is excreted. Conjugates
of the principal metabolite account for 20%-30% of the dose excreted in the
urine and for 10%-20% of the dose excreted in the bile. Conjugates of three
other metabolites together account for 10%-20% of the dose excreted in the
urine and for small amounts excreted in the bile. Some of the metabolites
may have activity.
Toxicity
Animal toxicity
Animals and absorption Toxicity References
LD50 (oral, mice) 390 mg/kg Merck index
LD50 (oral, rat) 150 mg/kg
LD50 (oral, monkey) 3200 mg/kg HSBD
LD50 (oral, dog) 500 mg/kg
LD50: lethal dose 50 percent kill
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Ecotoxicity
Organisms Toxicity References
Daphnia magna EC50 = 106 mg/l [Webb,
2001a]
Brachydanio reria (embryos) 48h EC50 = 86 mg/l
Scenedesmus subspicatus 72h EC50 = 89 mg/l
Daphnia magna (Invert.) EC50 (48h) = 22 430 µg/l [Ferrari
et al., 2003]
Ceriodaphnia dubia (Invert.) EC50 (48h) = 22 704 µg/l
P. subcapitata (Algae) NOEC (96h) = 10 000 µg/l
B. Calyciflorus (Invert.) NOEC (48h) = 12 500 µg/l
Ceriodaphnia dubia (Invert.) NOEC (7d) = 1 000 µg/l
Brachyderio rerio (Fish em-
bryos)
NOEC (10d) = 4 000 µg/l
EC50: median Effect Concentration or 50% effective concentration
NOEC: No Observed Effect Concentration
Adverse effect on human
Incidence greater than 1% : Abdominal pain or cramps, headache, fluid re-
tention, abdominal distention. Digestive perturbation (diarrhea, indigestion,
nausea, constipation, flatulence, liver test abnormalities, peptic ulcer, with
or without bleeding and/or perforation, or bleeding without ulcer). Effect on
nervous system (dizziness). Etc.
Medicines on sale in Switzerland
Inflamar, Voltaren, Olfenr, etc.
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A.6 Hydroxycarbamide / Hydroxyurea
Generality
Name
CAS RN 127-07-1
Molecular weight 76.06 (CH4N2O2)
Melting point 141-146◦C
Solubility in water (21◦C) ≥100 mg/ml
Solubility in 95% ethanol, acetone (21◦C) <1 mg/ml
Log Kow -1.80
This chemical is hygroscopic and decomposes in the presence of moisture.
Solution of this chemical in water, DMSO, ethanol or acetone should be
stable for 24 hours under normal laboratory conditions.
Distribution: pharmacy (the most cytostatics sold in pharmacy, for instance:
∼500g/year for one pharmacy in Vevey).
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Figure A.6: Structure of Hydroxyurea
Hydroxyurea is used in the treatment of chronic myeloid leukemia, ma-
lignant melanomas and inoperable tumors of the ovary, and squamous cell
carcinomas of the head and neck (with radiotherapy).
The precise mechanism by which produces its cytotoxic and cytoreductive
effects is not really known. However, various studies support the hypothesis
that hydroxyurea causes an immediate inhibition of DNA synthesis by acting
as a ribonucleotide reductase inhibitor, without interfering with the synthesis
of ribonucleic acid or of protein.
Biodegradability
To our knowledge, no study has been conducted to evaluate the biodegrad-
ability of hydroxyurea.
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Occurrence in the environment
To our knowledge, no study has been conducted to detect hydroxyurea
in wastewaters or in the environment.
Detection methods
According to Tjaden & De Bruijn [1990], data are limited. One study de-
scribed an LC assay for the determination of hydroxyurea in pharmaceutical
formulation.
Dosage
The initial dose of hydroxyurea is 15 mg/kg/day as a single dose. If blood
counts are in an acceptable range, the dose may be increased by 5 mg/kg/day
every 12 weeks until a maximum tolerated dose (the highest dose that does
not produce toxic blood counts over 24 consecutive weeks), or 35 mg/kg/day,
is reached.
Metabolism and Elimination
Up to 50% of an oral dose undergoes conversion through metabolic path-
ways that are not fully characterised. In one minor pathway, hydroxyurea
may be degraded by urease found in intestinal bacteria. Acetohydroxamic
acid was found in the serum of three leukemic patients receiving hydroxyurea
and may be formed from hydroxylamine resulting from action of urease on hy-
droxyurea. Excretion of hydroxyurea in humans is a nonlinear process occur-
ring through two pathways. One is saturable, probably hepatic metabolism;
the other is first-order renal excretion. In adults, mean cumulative urinary
hydroxyurea excretion was 62% of the administered dose at 8-hours.
Toxicity
Ecotoxicity
None
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Animal toxicity
Animals and absorption Toxicity References
LD50 (ipr, mouse) 5800 mg/kg NTP
LD10 (scu, mouse) 2400 mg/kg
TDLo (oral, human) 80 mg/kg/d
TDLo (iv, human) 86 mg/kg
LD50: lethal dose 50 percent kill; LD10: lethal dose 10 percent kill; TDLo: lowest published
toxic dose; iv: intravenous; ipr: intraperitoneal; scu: subcutaneous.
Carcinogenicity and mutagenesis
Hydroxyurea is mutagenic and clastogenic, and causes cellular transfor-
mation to a tumorigenic phenotype. Hydroxyurea is thus unequivocally geno-
toxic and a presumed transspecies carcinogen which implies a carcinogenic
risk to humans. In patients receiving long-term hydroxyurea whether this
leukemogenic effect is secondary to hydroxyurea or is associated for myelo-
proliferative disorders, such as polycythemia vera and thrombocythemia, sec-
ondary leukemias have been reported.
Impairment of Fertility
Hydroxyurea administered to male rats at 60 mg/kg/day (about 0.3 times
the maximum recommended human daily dose on a mg/m2 basis) produced
testicular atrophy, decreased spermatogenesis, and significantly reduced their
ability to impregnate females.
Adverse effect on human
Treatment of patients with hydroxyurea may be complicated by severe,
sometimes life-threatening, adverse effects. Hematologic effects (neutrope-
nia), gastrointestinal symptoms (stomatitis, anorexia, nausea, vomiting, di-
arrhea, and constipation), and dermatological reactions such as maculopapu-
lar rash, skin ulceration, dermatomyositis-like skin changes, peripheral ery-
thema and facial erythema. Hyperpigmentation, atrophy of skin and nails,
scaling and violet papules have been observed in some patients after several
years of long-term daily maintenance therapy with hydroxyurea. Skin cancer
has been reported. Dysuria and alopecia occur very rarely. Large doses may
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produce moderate drowsiness. Neurological disturbances have occurred ex-
tremely rarely and were limited to headache, dizziness, disorientation, hallu-
cinations, and convulsions. Hydroxyurea occasionally may cause temporary
impairment of renal tubular function accompanied by elevations in serum
uric acid and creatinine levels. Fever, chills, malaise, edema, asthenia, and
elevation of hepatic enzymes have also been reported.
Medicines on sale in Switzerland
Litalirr
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A.7 Tamoxifen / Tamoxifen citrate
Generality
Name (Z)-2-[4-(1,2-diphenyl-1-butenyl)
phenoxy]-N,N-dimethylethanamine
CAS RN 10540-29-1/ 54965-24-1
Molecular weight 371.53 (C26H29NO) / 563.62 (C32H37NO8)
Melting point 97◦C / 140-142◦C
Solubility in water (37◦C) 0.5 mg/ml (Tamoxifen citrate)
Log Kow 6.3
Tamoxifen citrate is soluble in ethanol, methanol and acetone. Hygroscopic
at high relative humidity. Sensitive to UV light.
Distribution: pharmacy (Sold in most of the swiss pharmacies: 2-100 g per
pharmacy and per year)
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Figure A.7: Structure of Tamoxifen
Tamoxifen citrate is effective in the treatment of metastatic breast cancer
in women and men. Available evidence indicates that patients whose tumors
are estrogen receptor positive are more likely to benefit from tamoxifen citrate
therapy.
Tamoxifen citrate is a nonsteroidal agent that has demonstrated potent
antiestrogenic properties in animal test systems. The antiestrogenic effects
may be related to its ability to compete with estrogen for binding sites in tar-
get tissues such as breast. Tamoxifen inhibits the induction of rat mammary
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carcinoma induced by dimethylbenzanthracene (DMBA) and causes the re-
gression of already established DMBA-induced tumors. In this rat model,
tamoxifen appears to exert its antitumor effects by binding the estrogen re-
ceptors.
Biodegradability
To our knowledge, no study has been conducted to evaluate the biodegrad-
ability of tamoxifen.
Occurrence in the environment
Authors tried to detect this drug in wastewaters, but most of the samples
showed concentrations below the limit of detection, excepted two samples
[Ashton et al., 2004].
Detection methods
Biological matrice GC, GC-MS or HPLC method were developed for
the determination of tamoxifen and its metabolites in pharmaceuticals, hu-
man bile, rat uterine cytoplasm and in breast tumor from tamoxifen-treated
patients [Tjaden & De Bruijn, 1990].
Dosage
For patients with breast cancer, the recommended daily dose is 20-40
mg. Dosages greater than 20 mg per day should be given in divided doses
(morning and evening).
Metabolism and Elimination
Tamoxifen is extensively metabolized after oral administration. Studies
in women receiving 20 mg of 14C tamoxifen have shown that approximately
65% of the administered dose is excreted from the body over a period of 2
weeks with fecal excretion as the primary route of elimination. The drug is
excreted mainly as polar conjugates, with unchanged drug and unconjugated
metabolites accounting for less than 30% of the total fecal radioactivity. N-
desmethyl tamoxifen was the major metabolite found in patients’ plasma.
The biological activity of N-desmethyl tamoxifen appears to be similar to
tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative
of tamoxifen have been identified as minor metabolites in plasma.
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Toxicity
Ecotoxicity
None
Animal toxicity (Tamoxifen citrate)
Animals and absorption Toxicity References
LD50 (iv, mice) 62.5 mg/kg Merck index
LD50 (oral,mice) 3000-6000 mg/kg
LD50 (iv, rats) 62.5 mg/kg
LD50 (oral, rats) 1200-2500 mg/kg
LD50: lethal dose 50 percent kill; iv: intravenous
Carcinogenesis
A conventional carcinogenesis study in rats (doses of 5, 20, and 35 mg/kg/day
for up to 2 years) revealed hepatocellular carcinoma at all doses, and the in-
cidence of these tumors was significantly greater among rats given 20 or
35 mg/kg/day (69%) than those given 5 mg/kg/day (14%). The incidence
of these tumors in rats given 5 mg/kg/day (29.5 mg/m2) was significantly
greater than in controls. As with other additive hormonal therapy (estrogens),
an increased incidence of endometrial cancer has been reported in association
with tamoxifen citrate treatment. In a large randomized trial in Sweden of
adjuvant tamoxifen citrate 40 mg/day for 2 to 5 years, an increased incidence
of uterine cancer was noted. Tamoxifen is classified as human carcinogen.
Mutagenesis
Although no genotoxic potential was found in a conventional battery of in
vivo and in vitro tests with pro- and eukaryotic test systems with drug me-
tabolizing systems present, increased levels of DNA adducts have been found
in the livers of rats exposed to tamoxifen. Tamoxifen also has been found to
increase levels of micronucleus formation in vitro in human lymphoblastoid
cell line (MCL-5). Based on these findings, tamoxifen is genotoxic in rodent
and human MCL-5 cells.
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Impairment of Fertility
Fertility in female rats was decreased following administration of 0.04
mg/kg for two weeks prior to mating through day 7 of pregnancy. There was
a decreased number of implantations, and all fetuses were found dead.
Adverse effect on human
Adverse reactions to tamoxifen citrate are relatively mild and rarely se-
vere enough to require discontinuation of treatment in breast cancer pa-
tients. Increased bone and tumor pain and, also, local disease flare have
occurred. The most frequent adverse reaction to tamoxifen citrate is hot
flashes. Other adverse reactions which are seen infrequently are hypercal-
cemia, peripheral edema, distaste for food, pruritus vulvae, depression, dizzi-
ness, light-headedness, headache, hair thinning and/or partial hair loss, and
vaginal dryness.
Medicines on sale in Switzerland
Nolvadexr - Tamecr - Kessarr
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A.8 5-Fluorouracil
Generality
Name 5-fluoro-2,4(1H,3H)-Pyrimidinedione
CAS RN 51-21-8
Molecular weight 130.08 (C4H3FN2O2 )
Melting point 283 ◦C
λmax (absorption) 265-266 nm in NaOH 0.1N
Solubility in water (19◦C) <1 mg/ml
Solubility in methanol (22◦C) 1-5 mg/ml
Log Kow -0.89
pKa 8.02
This chemical may be sensitive to prolonged exposure to light. It undergoes
hydrolysis in alkaline solution. Hydrolysis is enhanced by increased pH and
temperature. The shelf-life of aqueous solutions is about 3 years at pH 9 and
at room temperature.
Distribution: Hospital (3.2 kg in 2001 CHUV) and pharmacy (cream and
capecitabin which is metabolized in 5-fluorouracil in the tumor).
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Figure A.8: Structure of 5-Fluorouracil
Fluorouracil is effective in the palliative management of carcinoma of the
colon, rectum, breast, stomach and pancreas. Fluorouracil is an antineoplastic
antimetabolite.
There is evidence that the metabolism of fluorouracil in the anabolic
pathway blocks the methylation reaction of deoxyuridylic acid to thymidylic
acid. In this manner 5-fluorouracil interferes with the synthesis of DNA and to
a lesser extent inhibits the formation of ribonucleic acid (RNA). Since DNA
and RNA are essential for cell division and growth, the effect of fluorouracil
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may be to create a thymine deficiency which provokes unbalanced growth and
death of the cell. The effects of DNA and RNA deprivation are most marked
in those cells which grow more rapidly and which take up fluorouracil at a
more rapid rate.
Biodegradability
5-fluorouracil was not biodegradable in the closed bottle test (CBT) nor
in the Zahn-Wellens test (ZWT) [Ku¨mmerer & Al-Ahmad, 1997]. According
to Kiffmeyer et al. [1998], 5-Fluorouracil was completely biodegraded within
a few days in a laboratory sewage plant. But the rate of biodegradation seems
depending on the initial concentration: the higher the initial concentration
the slower the degradation.
Occurrence in the environment
To our knowledge, no study has been conducted to detect 5-fluorouracil
in sewage treatment plant or in the environment. Nevertheless, in wastewater
from a 5-Fluorouracil plant, 900 ppm was measured [Anheden et al., 1996].
Detection methods
Environmental matrice Solid phase extraction (SPE) followed by
HPLC-UV was used by Kiffmeyer et al. [1998]. 5-Fluorouracil, methotrex-
ate, 7-hydroxymethotrexate ant etoposide can be detected in one chromato-
graphic run with HPLC-UV with a polystyrene-divinylbenzene (PS-DVB)
column with buffered superheated water as the mobile phase [Teutenberg
et al., 2001].
Dosage and administration
Twelve mg/kg are given intravenously once daily for four successive days.
The daily dose should not exceed 800 mg. If no toxicity is observed, 6 mg/kg
are given on the 6th, 8th, 10th and 12th days unless toxicity occurs. No ther-
apy is given on the 5th, 7th, 9th or 11th days. Therapy is to be discontinued at
the end of the 12th day, even if no toxicity has become apparent. In instances
where toxicity has not been a problem, it is recommended that therapy be
continued using either of the following schedules: 1. Repeat dosage of first
course every 30 days after the last day of the previous course of treatment. 2.
When toxic signs resulting from the initial course of therapy have subsided,
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administer a maintenance dosage of 10 to 15 mg/kg/week as a single dose.
Do not exceed 1 g per week.
Metabolism and Elimination
Seven to twenty percent of the parent drug is excreted unchanged in the
urine in six hours; of this over 90% is excreted in the first hour. The remaining
percentage of the administered dose is metabolized, primarily in the liver. The
catabolic metabolism of 5-fluorouracil results in degradation products (e.g.,
CO2 urea and -fluoro- -alanine) which are inactive. The inactive metabolites
are excreted in the urine over the next 3 to 4 hours. No intact drug can be
detected in the plasma three hours after an intravenous injection.
Toxicity
Ecotoxicity
None
Animal and human toxicity
Animals and absorption Toxicity References
LD50 (oral, rat) 230 mg/kg NTP
LD50 (oral, mouse) 115 mg/kg
TDLo (oral, human) 450 mg/kg/30d
TDLo (iv, human) 6 mg/kg/3d
TDLo (iv, man) 39 mg/kg/1d-I
LD50: lethal dose 50 percent kill; TDLo: lowest published toxic dose; I: intermittent; iv:
intravenous.
Carcinogenesis
Longterm studies in animals to evaluate the carcinogenic potential of 5-
fluorouracil have not been conducted. However, there was no evidence of
carcinogenicity in small groups of rats given 5-fluorouracil orally at doses of
0.01, 0.3, 1 or 3 mg per rat 5 days per week for 52 weeks, followed by a six-
month observation period. Also, in other studies, 33 mg/kg of 5-fluorouracil
was administered intravenously to male rats once a week for 52 weeks fol-
lowed by observation for the remainder of their lifetimes with no evidence of
carcinogenicity. Female mice were given 1 mg of 5-fluorouracil intravenously
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once a week for 16 weeks with no effect on the incidence of lung adenomas. On
the basis of the available data, no evaluation can be made of the carcinogenic
risk of 5-fluorouracil to humans.
Mutagenesis
Oncogenic transformation of fibroblasts from mouse embryo has been in-
duced in vitro by 5-fluorouracil, but the relationship between oncogenicity
and mutagenicity is not clear. 5-Fluorouracil has been shown to be mutagenic
to several strains of Salmonella typhimurium, including TA1535, TA1537
and TA1538, and to Saccharomyces cerevisiae, although no evidence of mu-
tagenicity was found with Salmonella typhimurium strains TA92, TA98 and
TA100. In addition, a positive effect was observed in the micronucleus test on
bone marrow cells of the mouse, and fluorouracil at very high concentrations
produced chromosomal breaks in hamster fibroblasts in vitro.
Impairment of Fertility
5-Fluorouracil has not been adequately studied in animals to permit an
evaluation of its effects on fertility and general reproductive performance.
However, doses of 125 or 250 mg/kg administered intraperitoneally, have been
shown to induce chromosomal aberrations and changes in chromosomal or-
ganization of spermatogonia in rats. Spermatogonial differentiation was also
inhibited by 5-fluorouracil, resulting in transient infertility. However, in stud-
ies with a strain of mouse which is sensitive to the induction of sperm head
abnormalities after exposure to a range of chemical mutagens and carcino-
gens, 5-fluorouracil did not produce any abnormalities at oral doses of up to
80 mg/kg/day. In female rats, 5-fluorouracil, administered intraperitoneally
at weekly doses of 25 or 50 mg/kg for three weeks during the pre-ovulatory
phase of oogenesis, significantly reduced the incidence of fertile matings, de-
layed the development of pre- and postimplantation embryos, increased the
incidence of preimplantation lethality and induced chromosomal anomalies
in these embryos. In a limited study in rabbits, a single 25 mg/kg dose of
5-fluorouracil or 5 daily doses of 5 mg/kg had no effect on ovulation, ap-
peared not to affect implantation and had only a limited effect in producing
zygote destruction. Compounds such as 5-fluorouracil, which interfere with
DNA, RNA and protein synthesis, might be expected to have adverse effects
on gametogenesis.
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Adverse effect on human
Stomatitis and esophagopharyngitis (which may lead to sloughing and
ulceration), diarrhea, anorexia, nausea and emesis are commonly seen during
therapy. Leukopenia usually follows every course of adequate therapy with
5-fluorouracil. The lowest white blood cell counts are commonly observed
between the 9th and 14th days after the first course of treatment, although
uncommonly the maximal depression may be delayed for as long as 20 days.
By the 30th day the count has usually returned to the normal range. Alopecia
and dermatitis may be seen in a substantial number of cases. The dermatitis
most often seen is a pruritic maculopapular rash usually appearing on the
extremities and less frequently on the trunk. It is generally reversible and
usually responsive to symptomatic treatment.
Medicines on sale in Switzerland
Efudixr, Fluoro-uracil ICN
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A.9 Ifosfamide
Generality
Name N,3-bis(2-chloroethyl)tetrahydro-
2H,1,3,2-oxazaphospharin-2-amine,2-oxide (9CI)
CAS RN 3778-73-2
Molecular weight 261.09 (C7H15Cl2N2O2P )
Melting point 39-41◦C
Solubility in water (25◦C) 3780 mg/l (estimation)
Log Kow 0.86
Distribution Hospital (1.3 kg in 2001 CHUV)
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Figure A.9: Structure of Ifosfamide
Ifosfamide used in combination with certain other approved antineoplastic
agents, is indicated for germ cell testicular, ovarian, bronchial, breast, liver
cancer.
Ifosfamide is an alkylating agent. Ifosfamide has been shown to require
metabolic activation by microsomal liver enzymes to produce biologically
active metabolites. The alkylated metabolites of ifosfamide have been shown
to interact with DNA.
Biodegradability
Ifosfamide was not biodegradable in the Zahn-Wellens test and the sewage
treatment plant simulation test [Ku¨mmerer et al., 1997]. Ifosfamide was not
biodegraded at a concentration of 5 mg/l in the Closed Bottle Test within 28
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days (“not readily biodegradable”) [Ku¨mmerer et al., 1996]. Ifosfamide was
not adsorbed into the sewage sludge [Ku¨mmerer et al., 1997].
Occurrence in the environment
Ifosfamide was detected in hospital eﬄuents and in communal sewage
treatment plant up to 2.9 µg/l [Ku¨mmerer et al., 1997; Ternes, 1998].
Detection methods
Environmental matrice Solid phase extraction (SPE) followed by
HPLC-MS-MS or GC-MS were used by several studies [Ku¨mmerer et al.,
1997; Sacher et al., 2001; Steger-Hartmann et al., 1996; Ternes, 1998]. These
study show recovery rates which are very low (<51%), excepted for ground-
water.
Dosage
Ifosfamide should be administered intravenously at a dose of 1.2 g/m2
per day for 5 consecutive days. Treatment is repeated every 3 weeks or af-
ter recovery from hematologic toxicity (Platelets = 100 000/µl, WBC = 4
000/µl).
Metabolism and Elimination
Ifosfamide has been shown to require metabolic activation by microsomal
liver enzymes to produce biologically active metabolites. Activation occurs
by hydroxylation at the ring carbon atom 4 to form the unstable intermediate
4-hydroxyifosfamide. This metabolite rapidly degrades to the stable urinary
metabolite 4-ketoifosfamide. Opening of the ring results in formation of the
stable urinary metabolite, 4-carboxyifosfamide. These urinary metabolites
have not been found to be cytotoxic. N, N- bis (2-chloroethyl)-phosphoric
acid diamide (ifosphoramide) and acrolein are also found. Enzymatic oxi-
dation of the chloroethyl side chains and subsequent dealkylation produces
the major urinary metabolites, dechloroethyl ifosfamide and dechloroethyl
cyclophosphamide.
After administration of doses of 5 g/m2 of 14 C-labeled ifosfamide, from
70% to 86% of the dosed radioactivity was recovered in the urine, with
about 61% of the dose excreted as parent compound. At doses of 1.6-2.4
g/m2 only 12% to 18% of the dose was excreted in the urine as unchanged
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drug within 72 hours. Two different dechloroethylated derivatives of ifos-
famide, 4-carboxyifosfamide, thiodiacetic acid and cysteine conjugates of
chloroacetic acid have been identified as the major urinary metabolites of
ifosfamide in humans and only small amounts of 4-hydroxyifosfamide and
acrolein are present. Small quantities (nmole/ml) of ifosfamide mustard and
4-hydroxyifosfamide are detectable in human plasma. Metabolism of ifos-
famide is required for the generation of the biologically active species and
while metabolism is extensive, it is also quite variable among patients.
Toxicity
Ecotoxicity
None
Animal toxicity
Animals and absorption Toxicity References
LD50 (ip, rats) 150-160 mg/kg Merck index
LD50 (oral, rats) 143 mg/kg HSDB
LD50 (iv, rats) 190 mg/kg
LD50 (oral, mouse) 1005 mg/kg
LD50 (ip, mouse) 397 mg/kg
LD50 (iv, mouse) 338 mg/kg
LD50: lethal dose 50 percent kill; ip: intraperitoneal; iv: intravenous;
Carcinogenesis
Ifosfamide has been shown to be carcinogenic in rats, with female rats
showing a significant incidence of leiomyosarcomas and mammary fibroade-
nomas.
Mutagenesis
The mutagenic potential of ifosfamide has been documented in bacterial
systems in vitro and mammalian cells in vivo. In vivo, ifosfamide has induced
mutagenic effects in mice and Drosophila melanogaster germ cells, and has
induced a significant increase in dominant lethal mutations in male mice as
well as recessive sex-linked lethal mutations in Drosophila.
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Impairment of Fertility
In pregnant mice, resorptions increased and anomalies were present at
day 19 after a 30 mg/m2 dose of ifosfamide was administered on day 11 of
gestation. Embryolethal effects were observed in rats following the adminis-
tration of 54 mg/m2 doses of ifosfamide from the 6th through the 15th day
of gestation and embryotoxic effects were apparent after dams received 18
mg/m2 doses over the same dosing period. Ifosfamide is embryotoxic to rab-
bits receiving 88 mg/m2/day doses from the 6th through the 18th day after
mating. The number of anomalies was also significantly increased over the
control group.
Adverse effect on human
In patients receiving ifosfamide as a single agent, the dose-limiting toxi-
cities are myelosuppression and urotoxicity. Dose fractionation, vigorous hy-
dration, and a protector such as mesna can significantly reduce the incidence
of hematuria, especially gross hematuria, associated with hemorrhagic cys-
titis. At a dose of 1.2 g/m2 daily for 5 consecutive days, leukopenia, when
it occurs, is usually mild to moderate. Other significant side effects include
alopecia, nausea, vomiting, and central nervous system toxicities.
Medicines on sale in Switzerland
Holoxanr
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A.10 Cyclophosphamide
Generality
Name 1-(bis(2-chloroethyl)amino)-1-oxo-
2-aza-5-oxaphosphoridine
CAS RN 50-18-0
Molecular weight 261.09 (C7H15Cl2N2O2P )
Melting point 41-51◦C
Solubility in water (23◦C) 10-50 mg/ml
Solubility in acetone (23◦C) 50-100 mg/ml
Log Kow 0.63
Distribution Hospital (0.6 kg in 2001 CHUV) and
pharmacy
This compound is sensitive to exposure to light. Hydrolysis occurs at tem-
peratures above 30◦C. Solution of this chemical in DMSO, 95% ethanol or
acetone should be stable for 24 hours under lab conditions.
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Figure A.10: Structure of Cyclophosphamide
Cyclophosphamide, although effective alone in susceptible malignancies,
is more frequently used concurrently or sequentially with other antineoplastic
drugs. The following malignancies are often susceptible to cyclophosphamide
treatment: 1. Malignant lymphomas, Hodgkin’s disease, lymphocytic lym-
phoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lym-
phoma. 2. Multiple myeloma. 3. Leukemias. 4. Mycosis fungoides (advanced
disease). 5. Neuroblastoma (disseminated disease). 6. Adenocarcinoma of the
ovary. 7. Retinoblastoma. 8. Carcinoma of the breast.
Cyclophosphamide is an alkylating agents. Cyclophosphamide is biotrans-
formed principally in the liver to active alkylating metabolites by a mined
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function microsomal oxidase system. These metabolites interfere with the
growth of susceptible rapidly proliferating malignant cells. The mechanism
of action is thought to involve cross-linking of tumor cell DNA.
Biodegradability
Cyclophosphamide exhibited only poor degradability in the Zahn-Wellens
test and the sewage treatment plant simulation test [Steger-Hartmann et al.,
1997]. Cyclophosphamide was not biodegraded at a concentration of 5 mg/l
in the Closed Bottle Test within 28 days (“not readily biodegradable”) [Ku¨m-
merer et al., 1996].
Occurrence in the environment
Cyclophosphamide was detected in hospital eﬄuents and in communal
sewage treatment plant up to 4.5 µg/l [Steger-Hartmann et al., 1996, 1997;
Ternes, 1998].
Detection methods
Environmental matrice Solid phase extraction (SPE) followed by
HPLC-MS-MS or GC-MS were used by several studies [Sacher et al., 2001;
Steger-Hartmann et al., 1996, 1997; Ternes, 1998]. These studies show very
low recovery rates (<60%), excepted for groundwater.
Dosage
When used as the only oncolytic drug therapy, the initial course of cy-
clophosphamide for patients with no hematologic deficiency usually consists
of 40 to 50 mg/kg given intravenously in divided doses over a period of 2 to 5
days. Other intravenous regimens include 10 to 15 mg/kg given every 7 to 10
days or 3 to 5 mg/kg twice weekly. Oral cyclophosphamide dosing is usually
in the range of 1 to 5 mg/kg/day for both initial and maintenance dosing.
Many other regimens of intravenous and oral cyclophosphamide have been
reported. Dosages must be adjusted in accord with evidence of anti-tumor
activity and/or leukopenia.
Metabolism and Elimination
Cyclophosphamide is well absorbed after oral administration with a bioavail-
ability greater than 75%. The unchanged drug has an elimination half-life of
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3 to 12 hours. It is eliminated primarily in the form of metabolites, but from
5 to 25% of the dose is excreted in urine as unchanged drug. Several cytotoxic
and noncytotoxic metabolites have been identified in urine and in plasma.
Concentrations of metabolites reach a maximum in plasma 2 to 3 hours af-
ter an intravenous dose. Plasma protein binding of unchanged drug is low
but some metabolites are bound to an extent greater than 60%. It has not
been demonstrated that any single metabolite is responsible for either the
therapeutic or toxic effects of cyclophosphamide. Although elevated levels of
metabolites of cyclophosphamide have been observed in patients with renal
failure, increased clinical toxicity in such patients has not been demonstrated.
Toxicity
Ecotoxicity
None
Animal or human toxicity
Animals and absorption Toxicity References
LD50 (oral, rat) 350 mg/kg Merck index
LD50 (oral, mouse) 137 mg/kg NTP
TDLo (oral, woman) 45 mg/kg
TDLo (oral, human) 20 mg/kg
LDLo (oral, woman) 16 mg/kg/4d-I
TDLo (oral, man) 56 mg/kg/26d-I
TDLo (oral, man) 56 mg/kg/4w-I
LD50: lethal dose 50 percent kill; TDLo: lowest published toxic dose; LDLo: lowest published
lethal dose; I: intermittent.
Carcinogenesis
Second malignancies have developed in some patients treated with cy-
clophosphamide used alone or in association with other antineoplastic drugs
and/or modalities. Most frequently, they have been urinary bladder, myelo-
proliferative, or lymphoproliferative malignancies. Second malignancies most
frequently were detected in patients treated for primary myeloproliferative or
lymphoproliferative malignancies or nonmalignant disease in which immune
processes are believed to be involved pathologically. There is sufficient animal
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and human evidence for this compound. Cyclophosphamide is classified as
human caricnogen.
Impairment of Fertility
Cyclophosphamide can cause fetal harm when administered to a preg-
nant woman and such abnormalities have been reported following cyclophos-
phamide therapy in pregnant women. Cyclophosphamide interferes with oo-
genesis and spermatogenesis. It may cause sterility in both sexes.
Adverse effect on human
The adverse reactions are listed in order of decreasing incidence
• Reproductive System: impairment of fertility.
• Digestive System: nausea and vomiting commonly occur. Anorexia and,
less frequently, abdominal discomfort or pain and diarrhea may occur.
• Skin and its Structures: alopecia. Skin rash occurs occasionally in pa-
tients receiving the drug.
• Hematopoietic System: leukopenia. Fever without documented infec-
tion has been reported in neutropenic patients. Thrombocytopenia or
anemia.
• Urinary System: cystitis and urinary bladder fibrosis. Hemorrhagic ureteri-
tis and renal tubular necrosis.
• Infections: reduced host resistance to infections.
Medicines on sale in Switzerland
Endoxan-Astar
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A.11 Carmustine
Generality
Name Bis(chloroethyl)nitrosourea
CAS RN 154-93-8
Molecular weight 214.05 (C5H9Cl2N3O2)
Melting point 31◦C
Solubility in water (18◦C) <1 mg/ml
Solubility in 95% ethanol, acetone (18◦C) > 100 mg/ml
Log Kow 1.53
Distribution Hospital (15 g in 2001 CHUV)
This compound is stable under normal laboratory conditions. This com-
pound decomposes rapidly in acid and in solutions above pH7; most stable
in petroleum ether or aqueous solution at pH4.
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Figure A.11: Structure of Carmustine
Carmustine belongs to the group of medicines known as alkylating agents.
It is used to treat cancer of the lymph system, cancerous brain tumors, and
a certain type of cancer in the bone marrow.
Although it is generally agreed that carmustine alkylates DNA and RNA,
it is not cross resistant with other alkylators. As with other nitrosoureas, it
may also inhibit several key enzymatic processes by carbamoylation of amino
acids in proteins.
Biodegradability
To our knowledge, no study has been conducted to evaluate the biodegrad-
ability of carmustine.
156
APPENDIX A. PHARMACEUTICAL SUBSTANCES
Occurrence in the environment
To our knowledge, no study has been conducted to detect carmustine in
sewage treatment plant or in the environment.
Detection methods
Environmental matrice Solid phase extraction (SPE) followed by
HPLC-UV is used by Kiffmeyer et al. [1998].
Dosage
The recommended dose of carmustine as a single agent in previously un-
treated patients is 150 to 200 mg/m2 intravenously every 6 weeks.
Metabolism and Elimination
It is thought that the antineoplastic and toxic activities of carmustine
may be due to metabolites. Approximately 60% to 70% of a total dose is
excreted in the urine in 96 hours and about 10% as respiratory CO2. The
fate of the remainder is undetermined. Because of the high lipid solubility
and the relative lack of ionization at physiological pH, carmustine crosses the
blood-brain barrier quite effectively.
Toxicity
Ecotoxicity
None
Animal and human toxicity
Animals and absorption Toxicity References
LD50 (oral, mouse) 19 mg/kg NTP
LD50 (oral, rat) 20 mg/kg
TDLo (iv, human) 125 mg/kg
TDLo (iv, human) 6 mg/kg
LD50: lethal dose 50 percent kill; TDLo: lowest published toxic dose; iv: intravenous.
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Carcinogenesis, Mutagenesis, Impairment of Fertility
Carmustine is carcinogenic in rats and mice, producing a marked in-
crease in tumor incidence in doses approximating those employed clinically.
Nitrosourea therapy does have carcinogenic potential in humans. There is
sufficient animal evidence, but human limited evidence of carcinogenicity.
Carmustine is classified as probable human carcinogen (IARC: 2A).
Impairment of Fertility
Carmustine also affects fertility in male rats at doses somewhat higher
than the human dose.
Adverse effect on human
Pulmonary Toxicity (characterized by pulmonary infiltrates and/or fibro-
sis). Hematologic toxicity (myelosuppression, thrombocytopenia, leukopenia,
acute leukemia and bone marrow dysplasias, anemia), gastrointestinal toxic-
ity (nausea and vomiting), nephrotoxicity (renal abnormalities consisting of
progressive azotemia, decrease in kidney size and renal failure). Accidental
contact of reconstituted carmustine with skin has caused burning and hy-
perpigmentation of the affected areas. Neuroretinitis, chest pain, headache,
allergic reaction, hypotension and tachycardia have been reported as part of
ongoing surveillance.
Medicines on sale in Switzerland
BiCNUr
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A.12 Cisplatin
Generality
Name 2’-Deoxycytidine diphosphate
CAS RN 15663-27-1
Molecular weight 300.06 (H6Cl2N2Pt)
Melting point 270◦C
Solubility in water, 95% ethanol
or acetone (19◦C) <1 mg/ml
Log Kow -2.19
Distribution Hospital (57 g in 2001 CHUV)
This compound is stable under normal laboratory conditions.
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Figure A.12: Structure of Cisplatin
Cisplatin is widely prescribed for a variety of tumors (germ-cell, advanced
bladder carcinoma, adrenal cortex carcinoma, breast cancer, head and neck
carcinoma, lung carcinoma).
Cisplatin is believed to kill cancer cells by binding to DNA and interfering
with its repair mechanism, eventually leading to cell death.
Biodegradability
Cisplatin is not biodegraded in a laboratory sewage plant [Kiffmeyer et al.,
1998].
Occurrence in the environment
The average daily concentrations in the hospital eﬄuents were apporxi-
mately <10-601 ng/l Pt [Ku¨mmerer et al., 1999].
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Detection methods
Environmental matrice Platin was detected with HPLC-ICP-MS
[Ku¨mmerer et al., 1999]. Solid phase extraction (SPE) followed by HPLC-
UV was used by Kiffmeyer et al. [1998].
Dosage and administration
Cisplatin is administered intravenously for one (50-120 mg/m2) to 5 days
(15-20 mg/m2) in a row, followed by a rest period of 2-4 weeks.
Metabolism and Elimination
The metabolic fate of cisplatin has not been completely elucidated. There
is no evidence to date that the drug undergoes enzymatic biotransformation;
the chloride ligands of the cisplatin complex are believed to be displaced
by water, forming positively charged platinum complexes that react with
nucleophilic sites. The chemical identities of platinum-containing products of
the drug that are formed in vivo have not been definitely determined. Intact
cisplatin and its platinum-containing product(s)are excreted principally in
urine (27-43% during 5 first days1); fecal elimination of platinum appears to
be insignificant.
Toxicity
Ecotoxicity
None
1compendium
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Animal toxicity
Animals and absorption Toxicity References
LD50 (oral, mouse) 32.7 mg/kg NTP
LD50 (iv, mouse) 11 mg/kg
LD50 (oral, rat) 25.8 mg/kg
LD50 (iv, rat) 8 mg/kg
TDLo (iv, human) 1.5 mg/kg/6d-I
TDLo (iv, human) 0.5 mg/kg/13d-I
TDLo (iv, human) 2.5 mg/kg
TDLo (iv, human) 72 mg/kg/25d-I
LD50: lethal dose 50 percent kill; I: intermittent; iv: intravenous; TDLo: lowest published
toxic dose.
Carcinogenesis
There is sufficient animal evidence, but human inadequate evidence. Cis-
platin is classified as probable human carcinogen.
Adverse effect on human
There are serious side effects associated with cisplatin, notably renal tox-
icity, emesis, neurotoxicity, bone marrow suppression and hearing loss.
Medicines on sale in Switzerland
Platiblastinr - Platinolr
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A.13 Doxorubicin / Adriamycin
Generality
Name 10-((3-Amino-2,3,6-trideoxy-alpha-L-lyso-hexopyranosyl)oxy)
-7,8,9,10-tetrahydro-6,8,11-trihydroxy-
8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
Adriamycin : hydrochlorid form (C27H30ClNO11)
CAS RN 23214-92-8
Molecular weight 543.53 (C27H29NO11)
Melting point 229-231◦C
Solubility in water (25◦C) 92.8 mg/l (estimation)
Log Kow 1.27
Distribution Hospital (15 g in 2001 CHUV)
Adriamycin is pratically insoluble in acetone, benzene and ethyl ether. Aque-
ous solution unchanged after one month at 5◦C, but unstable at higher tem-
perature or at either acid or alkaline pHs.
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Figure A.13: Structure of Doxorubicin
Doxorubicin HCl is used for various tumor (breast cancer, pulmonary
cancer, sarcomas of bones, genital cancers, cancer of the bladder, cancer of
testicles, etc.).
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from Strep-
tomyces peucetius (var. caesius). The mechanism of action of doxorubicin
HCl is thought to be related to its ability to bind DNA and inhibit nucleic
acid synthesis. Cell structure studies have demonstrated rapid cell penetra-
tion and perinuclear chromatin binding, rapid inhibition of mitotic activity
and nucleic acid synthesis, and induction of mutagenesis and chromosomal
aberrations.
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Biodegradability
To our knowledge, no study has been conducted to evaluate the biodegrad-
ability of doxorubicin.
Occurrence in the environment
To our knowledge, no study has been conducted to detect doxorubicin in
sewage treatment plant or in the environment.
Detection methods
Biological matrice HPLC is generally accepted for anthracycline
pharmacokinetic analysis, since it permits sufficient selectivity and sensitivity
for the parent coumpounds and their metabolites. Derivatisation was required
for GC analysis [Tjaden & De Bruijn, 1990].
Dosage
For ovarian cancer patients, doxorubicin HCl should be administered in-
travenously at a dose of 50 mg/m2 (swiss compenium: 75 mg/m2 every three
week).
Metabolism and Elimination
Doxorubicine is quickly (in one hour) metabolised in the liver in its main
active metabolite, the doxorubicinol. The biliary excretion represents the
main way of elimination: 40-50% of the administered dose are eliminated in
7 days by biliary way. The renal excretion is unimportant: about 4-5% of the
dose injected by way i.v. are eliminated by kidneys in 5 days.
Toxicity
Ecotoxicity
None
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Animal toxicity
Animals and absorption Toxicity References
LD50 (iv, mouse) 21.1 mg/kg Merk index - Adriamycine
LD50 (iv, rat) 12.6 mg/kg HSDB
LD50 (iv, mouse) 9.4 mg/kg
LD50 (iv, rabbit) 6 mg/kg
LD50: lethal dose 50 percent kill; iv: intravenous.
Carcinogenesis
There is sufficient animal evidence, but human inadequate evidence. Car-
mustine is classified as probable human carcinogen (IARC: 2A).
Mutagenesis
Although no studies have been conducted with doxorubicin HCl, but re-
lated compounds have been shown to have mutagenic and carcinogenic prop-
erties when tested in experimental models.
Impairment of Fertility
The possible adverse effects on fertility in males and females in humans
or experimental animals have not been adequately evaluated. However, Dox-
orubicin resulted in mild to moderate ovarian and testicular atrophy in mice
after a single dose of 36 mg/kg (about twice the 50 mg/m2 human dose on
a mg/m2 basis). Decreased testicular weights and hypospermia were present
in rats after repeat doses 0.25 mg/kg/day (about one thirtieth the 50 mg/m2
human dose on a mg/m2 basis), and diffuse degeneration of the seminiferous
tubules and a marked decrease in spermatogenesis were observed in dogs af-
ter repeat doses of 1 mg/kg/day (about one half the 50 mg/m2 human dose
on a mg/m2 basis).
Adverse effect on human
Irreversible myocardial toxicity leading to congestive heart failure often
unresponsive to cardiac supportive therapy may be encountered as the total
dosage of doxorubicin HCl approaches 550 mg/m2. Acute infusion-associated
reactions (flushing, shortness of breath, facial swelling, headache, chills, back
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pain, tightness in the chest or throat, and/or hypotension) have occurred in
about 5% to 10% of patients. Severe myelosuppression may occur.
Medicines on sale in Switzerland
Adriblastinr - Caelyxr
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A.14 Melphalan
Generality
Name 4-[bis(2-chloroethyl)amino]-
L- Phenylalanine
CAS RN 148-82-3
Molecular weight 305.21 (C13H18Cl2N2O2)
Melting point 177-182.5 ◦C
Solubility in water, 95% ethanol,
acetone (22◦C) <1 mg/ml (estimation)
Log Kow -0.52
Distribution Hospital (13 g in 2001 CHUV) and
pharmacy
This chemical is sensitive to light. It decomposes on storage. It also hydrolyzes
in water. Stability increases in acidic solutions and higher temperatures accel-
erate the hydrolysis. Solutions in methanol were found to retain full integrity
for >12 hours at room temperature and for at least 4 weeks at 20◦C.
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Figure A.14: Structure of Melphalan
Melphalan tablets are indicated for the palliative treatment of multiple
myeloma and for the palliation of non-resectable epithelial carcinoma of the
ovary.
Melphalan is an alkylating agent of the bischloroethylamine type. As a
result, its cytotoxicity appears to be related to the extent of its interstrand
cross-linking with DNA, probably by binding at the N 7 position of guanine.
Like other bifunctional alkylating agents, it is active against both resting and
rapidly dividing tumor cells.
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Biodegradability
To our knowledge, no study has been conducted to evaluate the biodegrad-
ability of melphalan.
Occurrence in the environment
To our knowledge, no study has been conducted to detect melphalan in
sewage treatment plant or in the environment.
Detection methods
Environmental matrice Solid phase extraction (SPE) followed by
HPLC-fluorescence was used by Kiffmeyer et al. [1998].
Dosage
For multiple myeloma, the usual oral dose is 6 mg daily. The entire daily
dose may be given at one time. One commonly employed regimen for the
treatment of ovarian carcinoma has been to administer melphalan at a dose
of 0.2 mg/kg daily for 5 days as a single course. Courses are repeated every
4 to 5 weeks depending upon hematologic tolerance.
Metabolism and Elimination
Melphalan is eliminated from plasma primarily by chemical hydrolysis to
monohydroxymelphalan and dihydroxymelphalan. Aside from these hydroly-
sis products no other melphalan metabolites have been observed in humans.
The 24-hour urinary excretion of parent drug was 10% ± 4.5%, suggest-
ing that renal clearance is not a major route of elimination of parent drug.
One study using universally labeled 14C melphalan, found substantially less
radioactivity in the urine of patients given the drug by mouth (30% of ad-
ministered dose in 9 days) than in the urine of those given it intravenously
(35% to 65% in 7 days).
Toxicity
Ecotoxicity
None
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Animal toxicity
Animals and absorption Toxicity References
LD50 (iv, mouse) 23 mg/kg NTP
LD50 (oral, rat) 11.2 mg/kg
LD50 (iv, rat) 4.1 mg/kg
TDLo (oral, human) 1.2 mg/kg/5d-I
TDLo (oral, human) 700 mg/kg/7d
TDLo (iv, man) 8140 mg/kg
LD50: lethal dose 50 percent kill; TDLo: lowest published toxic dose; I: intermittent; iv:
intravenous.
Carcinogenesis
Secondary malignancies, including acute nonlymphocytic leukemia, myelo-
proliferative syndrome, and carcinoma have been reported in patients with
cancer treated with alkylating agents (including melphalan). Adequate and
well controlled carcinogenicity studies have not been conducted in animals.
However, intraperitoneal administration of melphalan in rats (5.4 to 10.8
mg/m2) and in mice (2.25 to 4.5 mg/m2) three times per week for 6 months
followed by 12 months post dose observation produced peritoneal sarcoma
and lung tumors respectively.
There is sufficient animal and human evidence of carcinogenicity. Mel-
phalan is classified as human carcinogen (IARC: 1).
Mutagenesis
Melphalan has been shown to cause chromatid or chromosome damage
in humans. Intramuscular administration of melphalan at 6 and 60 mg/m2
produced structural aberrations of the chromatid and chromosomes in bone
marrow cells of Wistar rats.
Impairment of Fertility
Melphalan causes suppression of ovarian function in premenopausal women,
resulting in amenorrhea in a significant number of patients. Reversible and
irreversible testicular suppression have also been reported.
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Adverse effect on human
Hematologic (the most common side effect is bone marrow suppression).
Gastrointestinal disturbances such as nausea and vomiting, diarrhea, and
oral ulceration occur infrequently. Hepatic toxicity has been reported rarely.
Other reported adverse reactions include: pulmonary fibrosis and interstitial
pneumonitis, skin hypersensitivity, vasculitis, alopecia, and hemolytic ane-
mia.
Medicines on sale in Switzerland
Alkeranr
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A.15 Methotrexate
Generality
Name (+)-4-Amino-10-methylfolic acid
CAS RN 59-05-2
Molecular weight 454.45 (C20H22N8O5)
Melting point 185-204◦C
λmax (absorption) 244 and 307 nm in NaOH 0.1N
Solubility in water, 95% ethanol,
methanol, acetone or toluene (19◦C) <1 mg/ml
Log Kow -1.85
pKa 4.7
Distribution Hospital (0.6 kg in 2001 CHUV)
and pharmacy
This compound is sensitive to hydrolysis, oxidation and light. Solution of this
chemical in DMSO, 95% ethanol or acetone should be stable for 24hours at
pH 7.
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Figure A.15: Structure of Methotrexate
Methotrexate (formerly Amethopterin) is an antimetabolite used in the
treatment of certain neoplastic diseases (gestational carcinoma, leukemia,
breast cancer, epidermoid cancers of the head and neck, lung cancer), severe
psoriasis, and adult rheumatoid arthritis.
Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must
be reduced to tetrahydrofolates by this enzyme before they can be utilised as
carriers of one-carbon groups in the synthesis of nucleotides and thymidylate.
Therefore, methotrexate interferes with DNA synthesis, repair, and cellular
replication. Actively proliferating tissues such as malignant cells, bone mar-
row, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder
are in general more sensitive to this effect of methotrexate. When cellular
proliferation in malignant tissues is greater than in most normal tissues,
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methotrexate may impair malignant growth without irreversible damage to
normal tissues.
Biodegradability
The biodegradation of methotrexate increase continuously during the first
week and reached a constant value of 95% after about eight days. Little
dependence on the initial concentration was observed. On the second day
of the biodegradation experiments a metabolite of methotrexate appeared:
7-hydroxymethotrexate. The concentration of this degradation product in-
creases in the same rate as the methotrexate concentration decreases, indi-
cating that the 7-hydroxymethotrexate does not undergo further biodegra-
dation. [Kiffmeyer et al., 1998]
Occurrence in the environment
A concentration of 1 µg/l of methotrexate was found in a sample of hos-
pital eﬄuent [Aherne et al., 1985].
Detection methods
Environmental matrice Radioimmunoassay with or without concen-
tration by lyophilization [Aherne et al., 1985].
Laboratory surface contamination Solid phase exctraction (SPE)
followed by HPLC-UV was used by Floridia et al. [1999].
Dosage
Methotrexate is administered orally or intramuscularly in doses of 15 to
30 mg daily for a five-day course. Such courses are usually repeated for 3 to 5
times as required, with rest periods of one or more weeks interposed between
courses, until any manifesting toxic symptoms subside.
Metabolism and Elimination
After absorption, methotrexate undergoes hepatic and intracellular metabolism
to polyglutamated forms which can be converted back to methotrexate by
hydrolase enzymes. These polyglutamates act as inhibitors of dihydrofolate
reductase and thymidylate synthetase. Small amounts of methotrexate polyg-
lutamates may remain in tissues for extended periods. The retention and
prolonged drug action of these active metabolites vary among different cells,
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tissues and tumors. A small amount of metabolism to 7-hydroxymethotrexate
may occur at doses commonly prescribed. Accumulation of this metabolite
may become significant at the high doses used in osteogenic sarcoma. The
aqueous solubility of 7-hydroxymethotrexate is 3 to 5 fold lower than the
parent compound. Methotrexate is partially metabolized by intestinal flora
after oral administration. Renal excretion is the primary route of elimination
and is dependent upon dosage and route of administration. With intravenous
administration, 80% to 90% of the administered dose is excreted unchanged
in the urine within 24 hours. There is limited biliary excretion amounting to
10% or less of the administered dose.
Toxicity
Ecotoxicity
Organisms Toxicity References
Daphnia magna (Invert.) EC50 > 1000 mg/l [Webb, 2001a]
Brachydanio reria (Fish embryos) 48h EC50 = 85 mg/l
Scenedesmus subspicatus (Algae) 72h EC50 = 260 mg/l
EC50: median Effect Concentration or 50% effective concentration
Animal toxicity
Animals and absorption Toxicity References
LD50 (iv, rat) 14 mg/kg (Merck index)
LD50 (oral, mouse) 146 mg/kg NTP
LD50 (iv, mouse) 50 mg/kg
TDLo (oral, child) 2 mg/kg/12d
TDLo (iv, child) 100 mg/kg/4h
TDLo (oral, human) 43 mg/kg/5y
TDLo (iv, human) 4.6 mg/kg/4w-I
TDLo (im, human) 200 mg/kg/5y
LD50: lethal dose 50 percent kill; TDLo: lowest published toxic dose; I: intermittent; iv:
intravenous; im: intramuscular.
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Carcinogenesis and mutagenesis
No controlled human data exist regarding the risk of neoplasia with
methotrexate. Methotrexate has been evaluated in a number of animal stud-
ies for carcinogenic potential with inconclusive results. Although there is evi-
dence that methotrexate causes chromosomal damage to animal somatic cells
and human bone marrow cells, the clinical significance remains uncertain.
Impairment of Fertility
Methotrexate causes embryotoxicity, abortion, and fetal defects in hu-
mans. It has also been reported to cause impairment of fertility, oligospermia
and menstrual dysfunction in humans, during and for a short period after
cessation of therapy.
Adverse effect on human
The most frequently reported adverse reactions include ulcerative stom-
atitis, leukopenia, nausea, and abdominal distress. Other frequently reported
adverse effects are malaise, undue fatigue, chills and fever, dizziness and de-
creased resistance to infection.
Medicines on sale in Switzerland
Methotrexat Farmos, Me´thotrexate “Ebewe”, Me´thotrexate Lederle,
Me´thotrexate Proreo.
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A.16 Consumption of the acidic drugs in Switzer-
land
Table A.1: Quantity of substances sold from July 2001 to June 2002 by
hospitals, pharmacies and selfdispensing doctors
Substances Amount sold [kg/year]a
Total Hospitals Pharmacies Doctors
Ibuprofen 17982 551 13028 4404
Mefenamic acid 17276 1652 10367 5257
Diclofenac 3884 204 2342 1338
Ketoprofen 254 2 157 96
Etofibrate 67 0.22 49 18
Clofibrate 41 0.25 35 6
Etofylline clofibrate 34 16 17
a From Institut fu¨r Haushaltsanalysen (IHA) - IMS in Switzerland
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A.17 Consumption and prediction of environ-
mental concentrations (PECs) of anti-
cancer drug in Switzerland
Table A.2: Quantity of anticancer drugs sold from July 2001 to June 2002
and PECs calculated as described in the Section 3.2.8. The data of consump-
tion were kindly supplied by the Institut fu¨r Haushaltsanalysen (IHA) - IMS
HEALTH, Switzerland
Substances Total [kg] PECinfa [ng/l]
Capecitabine 455.484 572.879
Hydroxycarbamide 352.245 443.031
Tamoxifen 155.734 195.872
5-Fluorouracil 81.137 102.049
Cyclophosphamide 34.364 43.221
Gemcitabine 32.411 40.765
Imatinib 22.973 28.894
Estramustine 21.744 27.349
Methotrexate 12.960 16.300
Ifosfamide 12.275 15.439
Cytarabine 8.454 10.634
Carboplatin 7.094 8.922
Mercaptopurine 5.992 7.537
Etoposide phosphate 3.503 4.405
Temozolomide 3.185 4.006
Rituximab 2.553 3.211
Paclitaxel 2.312 2.908
Irinotecan 1.973 2.481
Dacarbazine 1.914 2.407
Etoposide 1.845 2.321
Epirubicin 1.247 1.569
Trastuzumab 1.226 1.542
Mitotane 1.200 1.509
Cisplatin 1.092 1.373
Doxorubicin 0.909 1.143
Docetaxel 0.719 0.904
Procarbazine 0.700 0.880
continued
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of anticancer drug in Switzerland
Substances Total [kg] PECinfa [ng/l]
Vinorelbine 0.646 0.813
Oxaliplatin 0.618 0.777
Chlorambucil 0.487 0.613
Lomustine 0.364 0.458
Fludarabine 0.256 0.323
Melphalan 0.213 0.268
Tretinoin 0.201 0.253
Tioguanine 0.163 0.205
Bleomycin 0.142 0.178
Pancreatin 0.114 0.143
Pegylated liposomal doxorubicin 0.069 0.087
Amsacrine 0.069 0.087
Mitoxantrone 0.058 0.073
Carmustine 0.057 0.072
Thymus gland 0.057 0.072
Mitomycin 0.041 0.052
Daunorubicin 0.041 0.052
Papain 0.028 0.036
Vinblastine 0.025 0.031
Viscum album 0.022 0.028
Thiotepa 0.021 0.027
Idarubicin 0.020 0.025
Vincristine 0.019 0.023
Busulfan 0.017 0.022
Cladribine 0.012 0.015
Topotecan 0.010 0.012
Raltitrexed 0.004 0.004
Chlormethine 0.002 0.003
Vindesine 0.001 0.002
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A.18 Consumption of anticancer drugs in CHUV
Table A.4: Quantity of anticancer drugs prepared by the pharmacy of
CHUV (hospital in Lausanne) during one year (2001). These data were kindly
supplied by Marc Voeffray (CHUV pharmacist)
Substances Abbreviation 2001 [mg]
5-Fluorouracil 5-FU 3 243 595
Ifosfamide IFOS 1 270 655
Cytarabine ARAC 682 866
Cyclophosphamide CYCL 638 937
Methotrexate MTX 607 790
Etoposide phosphate ETOP 162 101
Carboplatin CBDCA 104 421
Gemcitabine GEM 77 850
Cisplatin CDDP 56 846
Taxol TAX 49 875
Etoposide VP16 21 029
Dacarbazine DTIC 17 940
Taxotere TXT 17 072
Mitoguazone Me-GAG 15 870
Carmustine BCNU 15 492
Adriblastine ADM 14 916
Melphalan L-PAM 13 388
Fotemustine FOTE 6 040
Vinorelbine 4 955
Daunorubicin DAUN 4 829
Busulfan 4 258
Thiotepa THIO 3 995
Amsacrine m-AMSA 3 855
Epirubicin 4-EPI 3 503
Fludarabine FAMP 1 560
Idarubicin IDA 1 204
Mitoxantrone MITOX 976
Vincristine VCR 554
Bleomycin BLEO 514
Irinotecan CPT11 373
Cladribine 2-CDA 177
continued
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Substances Abbreviation 2001 [mg]
Oxaliplatin 120
Vinblastine VLB 84
Vindesine VDS 81
Topotecan TOPO 45
Actinomycine D DACT 27
Mitomicine C MMC 16
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Figure A.16: Quantity of anticancer drugs (total of all substances and 5-
Fluorouracil in mg) prepared each day by the pharmacy of CHUV during the
sampling period (June 29 to July 5 2004). These data were kindly supplied
by Gre´gory Podilsky (CHUV pharmacist)
Table A.6: Predicted Environmentally Concentrations in wastewaters of
CHUV (PECCHUV ) estimated with the quantity of drugs prepared for injec-
tion by the pharmacy of CHUV during the sampling period (June 29 to July
5 2004) and with the average of water consumption (703 m3/d), comparison
of several cytostatic drugs
Substances PECCHUV PECCHUV
a b
[ng/l] [ng/l]
5-Fluorouracil 0 - 76 000 0 - 15 000
Ifosfamide 0 - 17 000 0 - 2 000
Methotrexate 0 - 1 560 0 - 1 250
Cyclophosphamide 0 - 7 200 0 - 3 600
a Without metabolism
b With metabolism
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Appendix B
Protocols of analysis
B.1 Protocol for the analysis of NSAIDs and
Clofibric acid in wastewaters
B.1.1 Principle
250 ml 
Waste 
water 
Filtration 0.45 um
pH 2
Solide Phase
Extraction
ENVI-18
Derivatisation
  PFBBr
Clean up
SiOH cartridge
GC/MS
Figure B.1: Protocol principle of the acidic drugs analysis
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B.1. Protocol for the analysis of NSAIDs and Clofibric acid in wastewaters
B.1.2 Materials washed with acetone and hexane
1 funnel, n SPE tubes, n Erlenmeyer flasks of 300 ml, n+1 Becher flasks
of 350 ml.
B.1.3 Materials
Membrane filters (ME 25, 0.45 µm) from Schleicher & Schuell (Dassel
Germany); 6 ml Supelclean ENVI-18 from Supelco (Bellefonte, USA); 3 ml
SiOH cartridges containing 500 mg of unmodified silica from Macherey-Nagel
Chromabond (Du¨ren, Germany).
B.1.4 Solutions
MilliQ water, acid water (pH2, with HCl), acetone, methanol, toluene,
hydrochloric acid (32%), pentafluorobenzyl bromide solution (2% in toluene),
standard solution for the 5 substances in methanol.
B.1.5 Equipment
Millipore HazardousWaste Filtration System; Supelco Visiprep DL; stream
of nitrogen; drying oven.
B.1.6 Filtation and Extraction
Weigh 250 ml of wastewater. Add the wastewater through the Millipore
Hazardous Waste Filtration System previously well washed with water and
alcohol. Add HCl to obtain a pH of 2.
Prepare the SPE Cartridge (ENVI-18) on the Visiprep. Conditionne the
cartridge with 3 ml of acetone, 3 ml of methanol and 3 ml of acid water
(pH2).
Pass the sample through the cartridge at a flow rate of approximately 3
ml/min by applying a low vacuum. Dry the solid phase for one hour under
vacuum. Elute the analytes with 6 ml of methanol. Evaporate the methanol
extract till dryness under a gentle stream of nitrogen.
For the sample of surface water, one liter of water was used. It was passed
through four cartridges (250 ml per cartridge) and the methanol extract was
collected together.
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B.1.7 Derivatisation and purification
Add 400 µl of pentafluorobenzyl bromide (2% in toluene) and 4 µl of
triethylamine. Incubate the solution at 90◦C for one hour. The derivatised
extract is passed through a SiOH cartridge conditioned with toluene. Elute
the analytes with 15 ml of toluene. Reduce the eluate volume under a gentle
stream of nitrogen to 100-1500 µl, to be inside the range of concentration
tested in the calibration curve. If higher/smaller concentration were found,
the samples were diluted/concentred and analysed a second time.
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Figure B.2: Structures of derivatised substances
B.1.8 Detection
GC/MS system was used for quantitative analysis: a Varian CP 3800 gas
chromatograph coupled with a Varian 1200L mass spectrometer.
GC Parameters
The gas chromatograph was equipped with a 60 m x 0.25 mm i.d. x 0.25
µm RTX-5 capillary column connected to a 5 m deactivated fused silica pre-
column. Constant column flow mode was chosen (1 ml/min).
GC injection parameters: 1 µl with a SPI - Septum-equipped Programmable
injector (on-column); injection port: 85◦C for 0.2 min; 100◦C/min to 250◦C.
GC oven temperature programm: 80◦C for 1 min; 30◦C/min to 150◦C;
3.5◦C/min to 280◦C; 280◦C isothermal 30 min.
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B.1. Protocol for the analysis of NSAIDs and Clofibric acid in wastewaters
MS Parameters
Transfer line temperature: 250◦C; EI or NCI mode, electron energy: 70
eV. For SIM mode, two to four characteristic ions were selected for each
compound (see Table B.1 for EI mode and Table B.2 for NCI mode) and
scanned using corresponding time windows.
Table B.1: GC/MS data of the PFB derivatives in EI mode
Substances Retention time Characteristic ions
(min) (relative abundance)
Clofibric acid 24.9 130 (100), 169 (47),394 (37)
Ibuprofen 26.0 118 (30),161 (100),386 (15)
Ketoprofen 40.3 105 (32), 209 (100), 434 (6)
Mefenamic acid 40.9 194 (80), 223 (100), 421 (74)
Diclofenac 42.5 214 (100), 242 (22), 476 (19)
In italic and bold: ions chosen for the quantification
Table B.2: GC/MS data of the PFB derivatives in NCI mode
Substances Characteristic ions
(relative abundance)
Clofibric acid 213 (100), 214 (22), 215 (43), 286 (80)
Ibuprofen 181 (1), 205 (100), 206 (66)
Ketoprofen 209 (2), 210 (3), 253 (100), 254 (24)
Mefenamic acid 181 (1), 240 (100), 241 (33)
Diclofenac 258 (11), 260 (6), 294 (100), 296 (60), 439 (3)
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B.1.8.1 Chromatograms
40.3
Clofibric acid
Ibuprofen
Ketoprofen
Mefenamic acid
Diclofenac
Figure B.3: Chromatogram of a standard solution injected in GC/MS
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40.3
24.9
Clofibric acid
Ibuprofen
Ketoprofen
Mefenamic acid
Diclofenac
Figure B.4: Chromatogram of a wastewater extract injected in GC/MS
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B.1.9 Method validation
B.1.9.1 Recovery evaluations: Linear regressions
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Figure B.5: Determination of the recoveries; samples of wastewaters were
spiked with the pharmaceutical substances at four concentration. Linear re-
gressions between the theoretical quantities and the measured quantities [ng].
The recovery rates were derived from the slopes. See Section 2.2.4 (page 24)
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B.1.9.2 Limits of detection
Table B.3: Limits of detection (LOD) per liter of wastewater in EI mode
and per liter of surface water in NCI mode
Substances LOD in EI mode [ng/l] LOD in NCI mode [ng/l]
Wastewater (0.25 l) Surface water (1 l)
Clofibric acid 15 0.3
Ibuprofen 8 0.4
Ketoprofen 8 0.06
Mefenamic acid 5 0.03
Diclofenac 6 0.04
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B.2 Protocol for the analysis of 5-Fluorouracil
(5-FU) in wastewaters
B.2.1 Principle
150 ml 
Waste 
water 
pH 5
Solide Phase
Extraction
ENV+ 1g (6ml)
Derivatisation
  PFBBr +
     K2CO3
Clean up
SiOH cartridge
GC/MS
Figure B.6: Protocol principle of 5-Fluorouracil analysis
B.2.2 Materials
ENV+ cartridges: 1g, 6ml (Isolute); SiOH cartridges of 500 mg (Chromabond);
10 ml SPE tubes (previously washed with acetone and hexane); 150 ml Er-
lenmeyer flasks (washed with acetone and hexane).
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B.2.3 Solutions
P3: phosphate buffer, 0.01 mol/l KH2PO4 (0.136 g in 100 ml) adjusted
with 0.1 mol/l phosphoric acid to pH3,
P5: phosphate buffer, 0.01 mol/l KH2PO4 adjusted with 0.01 mol/l KOH
solution to pH5,
PFBBr/ACN (20/80, v/v), 25% of K2CO3 in water (w/w), Hexane/Acetone
(80/20), Toluene/Hexane (15/85), hexane, acetonitrile, pentofluoroBenzyl
bromide, methanol, toluene.
B.2.4 Equipment
SPE Visiprep Vacuum Manifold (Supelco); stream of nitrogen; drying
oven.
B.2.5 Extraction
Pre-treatment of 150 ml samples
Add one (or two) drop of HCl (32%) and adjust the pH to 5 with P3.
Extraction with cartridge ENV+ (1g, 6ml)
Conditione the cartridge with 12 ml MeOH and 12 ml P5.
Load the sample to a flow rate of 3-5 ml/min (30-50 minutes for 150 ml).
Dry the cartridge for 2 to 3 hours under vacuum.
Elute the analyte with 4 x 3 ml of MeOH. Lets soak during 4 minutes
each 3 ml and then elute the analyte dropwise in a SPE tube.
B.2.6 Derivatisation and purification
• Evaporate till dryness under a stream of nitrogen.
Then add:
• 1 ml Acetonitrile
• 100 µl K2CO3 solution
• Vortex during 30 sec and add
• 100 µl PFBBr solution (20% in ACN)
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• 1 hour at 80◦C (incubation)
• Add 1 ml Toluene
• Evaporated to 200 µl under a stream of nitrogen and add
• 1 ml Isooctane
• In the SiOH cartridge, add 0.5 cm of Na2SO4. Then condition the car-
tridge with:
• 5 ml of Hexane/Acetone (80/20) and
• 5 ml of Hexane
• Add the extract in the SiOH cartridge.
• Wash the SPE tube with 3x1 ml of Toluene/Hexane (15/85), and pass
through the cartridge
• And pass 5 ml of Toluene/Hexane (15/85) (with low vacuum) through
the cartridge
• Dry the cartridge for 1 min under vacuum
Then pass through the cartridge:
• 2 ml Hexane/Acetone (80/20) (pass with low vacuum, do not let dry
the cartridge), and
• 2 ml Hexane/Acetone (80/20) (pass dropwise, without vacuum) and
collect in a SPE tube
• Add 0.7 ml of toluene in the SPE tube and evaporate to 200 µl under
a stream of nitrogen
• Transfer into a vial for GC/MS and wash the SPE tube with 3 x 0.5
ml of toluene.
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B.2.7 Detection
See Section 3.2.5 (page 45).
B.2.8 Method validation
B.2.8.1 Recovery evaluation: Linear regression
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Figure B.7: Determination of the recoveries; samples of wastewaters were
spiked with 5-Fluorouracil at four concentration. Linear regression between
the theoretical quantities and the measured quantities [ng]. The recovery rate
was derived from the slope. See Section 3.2.6 (page 46)
B.2.8.2 Limit of detection
See Section 3.2.6 (page 46).
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B.3 Protocol for the analysis of Tamoxifen
(TAM) in wastewaters
B.3.1 Principle
   1 L 
Waste 
water 
100 g NaCl
Liquid Liquid
Extraction
3 x 60 ml 
dichloromethane
Evaporate 
+ disolution 
in MQ water
   pH 2
Clean up
OASIS MCX 
cartridge
GC/MS
Figure B.8: Protocol principle of Tamoxifen analysis
B.3.2 Materials washed with acetone and hexane
n Erlenmeyer flasks of 1 l; n Balloons of 250 ml; n LLE separating funnel
of 2 l; n small funnels fulled with sodium sulfate; n Becher flasks of 150 ml;
1 graduated cylinder of 100 ml; n 10 ml SPE tubes, n tubes (100-200 ml) for
centrifuge.
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B.3. Protocol for the analysis of Tamoxifen (TAM) in wastewaters
B.3.3 Materials
n OASIS MCX cartridges: 150 mg, 6 ml, 30 µm (Waters).
B.3.4 Solutions
Sodium chloride, dichloromethane, MilliQ water, acid water (pH2, with
HCl), hydrochloric acid (32%), methanol, 0.1 N HCl (10.6 g of HCl 32%
in 100 ml of MQ water), Methanol/Acetonirile (30/70), Methanol/NH4OH
(95/5), toluene.
B.3.5 Equipment
SPE Visiprep Vacuum Manifold (Supelco); rotary evaporator system;
stream of nitrogen.
B.3.6 Liquid-Liquid Extraction
Weigh 1 l of wastewater.
Add 100 g of sodium chloride.
Mix and pour in the LLE separating funnel.
To do three times:
• Add 60 ml of dichloromethane.
• Shake vigorously during 2 minutes.
• Wait 15 minutes (30 minutes the last extraction).
• Collect the dichloromethane emulsion in a tube for centrifuge.
• Centrifugation: 2500 t/min during 10 minutes.
• Pass the dichloromethane phase (bottom layer) in the funnel fulled with
sodium sulfate and collect in a balloon.
Add 2 ml of Methanol.
Evaporate to 0.2-0.4 ml in a rotary evaporator system (850 mbar, 40◦C).
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B.3.7 Purification
Condition the cartridge (OASISr MCX) with 6 ml MeOH and 1 ml MQ
water.
Mix 10 ml of Acid water (pH2) with the extract and load it through the
cartridge to a flow rate of 1 drop/sec (5-10 minutes for 10 ml).
Wash three times the balloon with 5 ml of acid water, and pass through
the cartridge.
To wash the cartridge, pass 4 ml of 0.1N HCl through the cartridge.
Dry the cartridge during 2 minutes under vacuum.
Wash the cartridge with 4 ml of Methanol.
Wash the cartridge with 4 ml of Methanol/Acetonirile (30/70).
Elute with 3 ml of Methanol/NH4OH (95/5): lets soak during 4 minutes
and then collect the analyte dropwise in a SPE tube.
Evaporate to dryness under a stream of nitrogen.
Add 0.7 ml of Toluene. Transfer into a vial for GC/MS and wash the SPE
tube with 3 x 0.5 ml of toluene.
B.3.8 Detection
See Section 3.2.5 (page 45).
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B.3.9 Method validation
B.3.9.1 Recovery evaluation: Linear regression
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Figure B.9: Determination of the recoveries; samples of wastewaters were
spiked with Tamoxifen at four concentration. Linear regression between the
theoretical quantities and the measured quantities [ng]. The recovery rate
was derived from the slope. See Section 3.2.6 (page 46)
B.3.9.2 Limit of detection
See Section 3.2.6 (page 46).
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B.4 Preparation of the solutions for the Ames
Test
B.4.1 Min A 10X
This is made by dissolving the following salts in bi-distilled water to a
final volume of 800 ml. Autoclave the salt solution for 30 minutes at 121◦C.
Salts Quantitiy [g]
Na2HPO4-7H2O 102.4
KH2PO4 24
NaCl 4
NH4Cl 8
B.4.2 Growth supplement mixture
Dissolve the following substances in 20 ml of sterile MQ water, and ster-
ilize by filtering using 0.22 µm sterile filter. Store at 4◦C.
Substance Quantitiy [mg]
L-Proline 200
L-Threonine 200
L-Arginine 200
L-Leucine 400
Thiamine HCL (stocked at 4◦c) 10
Biotin 100
B.4.3 50% Glucose
Dissolve 15 g of glucose in 30 ml of sterile MilliQ Water, and sterilize by
filtering using 0.22 µm sterile filter. Store at 4◦C.
B.4.4 Histidine 20 mg/ml
Dissolve 0.2 g of histidine in 10 ml of sterile MilliQ Water, and sterilize
by filtering using 0.22 µm sterile filter. Store at 4◦C.
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B.4.5 CaCl2 0.1M
Dissolve 0.73 g of CaCl2-2H2O in 50 ml of sterile MilliQ Water, and
sterilize by filtering using 0.22 µm sterile filter. Store at 4◦C.
B.4.6 MgSO4 1M
Dissolve 7.38 g of MgSO4-7H2O in 30 ml of sterile MilliQ Water, and
sterilize by filtering using 0.22 µm sterile filter. Store at 4◦C.
B.4.7 Phosphate-Buffered saline (PBS)
This is made by dissolving the following salts in bi-distilled water to a final
volume of 800 ml. Adjust the pH to 7.4 with HCl (normally not necessary).
Autoclave the salt solution for 30 minutes at 121◦C.
Salts Quantitiy [g]
NaCl 6.4
KCl 0.16
Na2HPO4 1.15
KH2PO4 0.19
B.4.8 Biotine/Histidine 5mM
Dissolve 50 mg of biotin and 50 mg of histidine in 50 ml of nearly boiling
sterile MilliQ Water. Sterilize by filtering using 0.22 µm sterile filter. Store
up to one year at 4◦C.
B.4.9 LB
Dissolve 4 g of LB Broth in 200 ml of MilliQ Water, and autoclave for 30
minutes at 121◦C.
B.4.10 Top Agar
This is made by dissolving the agar and salt in 396 ml of bi-distilled
water. Autoclave the solution for 30 minutes at 121◦C. Then, 4 ml of the
biotin/histidine 5mM solution is added.
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Salts Quantitiy
Agar 2.4 g
NaCl 2.4 g
Distilled water 396 ml
Biotin/histidine 5mM 4 ml
B.4.11 Top Agar 10X
This is made by dissolving the agar and salt in 180 ml of bi-distilled
water. Autoclave the solution for 30 minutes at 121◦C. Then, 20 ml of the
biotin/histidine 5 mM solution is added.
Salts Quantitiy
Agar 12 g
NaCl 12 g
Distilled water 180 ml
Biotin/histidine 5mM 20 ml
B.4.12 LBM-Agar petri boxes
This is made by adding the following substances in 800 ml of bi-distilled
water. Autoclave the solution for 30 minutes at 121◦C. And directly flushed
in the plates (about 30 ml per plate). Let dried the plates during 12-24 hours
and store in a plastic bag up to several months at 4◦C.
Salts Quantitiy [g]
Agar 9,6
LB 16 g
B.4.13 Agar petri boxes
Dissolve 12 g of Agar in 800 ml of bi-distilled water. Autoclave the solution
for 30 minutes at 121◦C. Then the following solutions are added. The petri
boxes are directly filled with the final solution (about 20-30 ml per plate). Let
dried the plates during 12-24 hours and store in a plastic bag up to several
months at 4◦C.
199
B.4. Preparation of the solutions for the Ames Test
Salts Quantitiy
Mini a 10x 100 ml
Growth supplement mixture 2 ml
CaCl2 0.1M 1 ml
MgSO4 1M 1 ml
50% Glucose 4 ml
B.4.14 Overnight culture
Add about 1 ml of the fizzed bacteria culture or some bacteria of a LBM-
Agar plate to 5 ml of LB. The culture is incubated at 37◦C in a shaking
incubator during the night before the Ames Test.
B.4.15 Bacteria conservation
Put 1 ml of the “overnight culture” in an ependorf tube. Add 150 µl of
autoclaved glycerol. Store at -20◦C.
B.4.16 S9 20%
Mix the following solutions and sterilize by filtering using 0.22 µm sterile
filter. Store all the solutions in ice. Store the mix solution up to one year at
-20◦C.
Salts Quantitiy Stock concentration Final conc
Mg-KCl 0.2 ml 400 mM - 1.65 M 8 mM - 33 mM
Phosphate buffer 5 ml 200 mM 100 mM
NADP 0.8 ml 50mM 4 mM
Glucose-6-Phosphate 0.8 ml 62.5 mM 5 mM
Milli-Q Water 1.4 ml
Dissolve the S9 powder with 2 ml of Milli-Q water. And add S9 solution
to the previous mix solution.
MgCl2 400 mM - KCl 1.65 M
Dissolve 0.81 g of MgCl2-6H2O and 1.23 g of KCl in 10 ml of sterile MilliQ
Water. Sterilize by filtering using 0.22 µm sterile filter. Store at ambiante
temperature.
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Phosphate buffer
Solution A: 0.2 M NaH2PO4-H2O (1.05 g in 38 ml of MQ Water)
Solution B: 0.2 M Na2HPO4-2H20 (5.77 g in 162 ml of MQ Water)
Mix 38 ml of solution A with 162 ml of Solution B, adjust to pH 7.4.
Store at ambiante temperature.
NADP
Dissolve 0.3827 g of NADP in 10 ml of sterile MilliQ Water. Store up to
one year at -20◦C.
Glucose-6-Phosphate
Dissolve 0.19 g of Glucose-6-Phosphate in 10 ml of sterile MilliQ Water.
Store up to one year at -20◦C.
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B.5 Protocol of preincubation Ames Test in-
cluding toxicity
B.5.1 Principle
8.8 ml Waste water or water
 1.1 ml Growth factor (glucose,  histidine,  etc.)
0.1 ml 
Incubation 
48h at 37˚C
Transfer
GM Agar
Control - Wastewater
Overnight 
culture
of TA 98, 
100, etc.
(his -) 
Incubation 3h at 37˚C
Removal of histidine by centrifugation
Resuspended in a PBS solution (0.3ml)
3 ml
2 ml Top 
Agar
0.1 ml
0.05 ml
Dilution 
5 ml
PBS
0.05 ml 0.05 ml
100 ul 
Incubation 
20h at 37˚C
LBM - Agar
Control - Wastewater
spontaneous 
revertants
(his +)
spontaneous 
+ 
induced 
revertants
Control +
Wastewater
+ Control +
spontaneous 
+ 
induced  
revertants
spontaneous 
+ 
induced revertants
-
dead revertants
his -  + his + his -  + his +
affected 
MUTAGENICITY
TOXICITY - 1st   
Induced revertants
TOXICITY - 2nd
Dilution method
   
Figure B.10: Ames test principle
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B.5.2 Sterile Materials
50 ml tubes, 13 ml tubes, 15 ml tubes, tips for pipettes, serological pipettes
(5 ml, 10 ml and 25 ml), etc.
B.5.3 Solutions
Min A 10X, Growth supplement mixture, 50% Glucose, Histidine 20mg/ml,
CaCl2 0.1M, MgSO4 1M, PBS, Top Agar, LBM-Agar petri boxes, Agar petri
boxes, S9 20%. (See Appendix B.4; page 197)
B.5.4 Equipment
Incubator at 37◦C with agitation; incubator at 37◦C; centrifuge.
B.5.5 Storage of wastewater samples
All the samples of wastewater were filtered (0.45 µm) with a Millipore
Hazardous Waste Filtration System immediately after the sampling and kept
frozen until tested, as proposed by several authors [Davidov et al., 2000;
Hartmann et al., 1999; Naudin et al., 1995].
B.5.6 Pretreatment
The evening before the test, an overnight culture (see section B.4.14, page
200) of the selected bacterial strain is prepared.
B.5.7 Treatment
Mixture A; add in a 50 ml tube (one tube per each samples and control):
• 2 ml Mini A10x
• 40 µl Growth supplement
• 20 µl MgSO4 1M
• 20 µl CaCl2 0.1M
• 80 µl Glucose (50%)
• 100 µl Histidine (20 mg/ml)
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• 17.6 ml of water (MQ or wastewater)
Concentration Sterile MQ water Wastewaters (+/- filtered 0.22 µm)
Control 17.6 ml
25% 13.2 ml 4.4 ml
50% 8.8 ml 8.8 ml
100% 17.6 ml
When we have not enough wastewaters, half of these solutions was pre-
pared to obtain a final volume of 10 ml instead of 20 ml.
Without S9
3 ml of this preparation (Mixture A) is put in a tube of 15 ml (in trip-
licate). And 100 µl of the overnight bacteria culture is added in these tubes
and 15-20 µl Ampicillin (if the samples are not filtered and if the bacterial
strain is resistant).
2% S9
2.7 ml of this preparation is put in a tube (in triplicate). 100 µl of the
overnight bacteria culture and 0.3 ml of S9 solution are added in these tubes.
4% S9
2.4 ml of this preparation is put in a tube (in triplicate). 100 µl of bacteria
and 0.6 ml of S9 solution are added in these tubes.
To do with the inoculated Mixture A:
• The inoculated sample are incubated at 37◦C for 3 hours with agitation.
• Top agar is heated in a boiling water bath. Petri boxes are identified
with the names of samples or control and with the bacterial strain. 5
ml of PBS are added in all tubes for the dilution in the toxicity test.
• After 3 hours of incubation, the samples are centrifuged (4000 rpm for
5 minutes).
• Supernatant are removed.
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• Re-suspended the pellet in 3 ml of phosphate buffered saline (PBS) to
ensure removal of histidine.
• Second centrifugation: 4000 t/min during 5 minutes.
• Supernatant are well removed, with aspiration.
• Re-suspended in 0.3 ml of PBS (Mixture B).
B.5.8 Mutagenicity
Add in a 13 ml tube: (To do 2 times per 3 ml tube)
• 2 ml of Top Agar (at 45◦C)
• 0.1 ml of the Mixture B
• 5-10 µl of ampicillin (only if necessary: if the samples is not filtered and
if the bacterial strain is resistant)
The contents of test tubes are poured onto the surface of Agar petri
plates. When the Top Agar has hardened, the plate are incubated in an
inverted position in a 37◦C incubator for 48 hours at which time the histidine
revertant colonies are counted.
B.5.9 Toxicity assay using induced revertants - First
method
Proceed as in the Section B.5.7 and B.5.8, but add 100 µl of the positive
control (0.5 mg/ml in DMSO) in 10 ml of the Mixture A to get a final solution
of 5 µg/ml.
This is made for sterile bi-distilled water (control+) and for the samples
(wastewaters + control+).
B.5.10 Toxicity assay by dilution - Second method
To prepare in advance (during the previous treatment): the adequate
number of tube with 5 ml of PBS (3 tubes per each 3 ml tubes, that means
9 tubes per sample)
Make the following dilution in 5 ml of PBS:
• Mix 50 µl of the Mixture B with 5 ml of PBS (1st tube).
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• Mix 50 µl (or 100 µl when the bacteria concentrations are low) of the
1st tube with 5 ml of PBS (2nd tube).
• Mix 50 µl (or 100 µl when the bacteria concentrations are low) of the
2nd tube with 5 ml of PBS (3th tube).
Inoculate (in duplicate) a LBM-Agar petri box with 100 µl of the 3th PBS
tube. Spread with sterile little balls. The plate are incubated in an inverted
position in a 37◦C incubator for 18 to 20 hours.
B.6 Mutagenicity ratio
MR =
spontaneous+ induced revertants
spontaneous revertants
MRadj1 =
MR
survival (induced revertants method)
MRadj2 =
MR
survival (dilution method)
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Complementary results
C.1 Correlation between the removal of Ibupro-
fen and the residence time
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Figure C.1: Correlation between the removal of Ibuprofen and the residence
time of wastewaters in the STPs (See Section 2.3.2 on page 30)
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C.2 Acidic and alkaline hydrolysis of conju-
gated NSAIDs
C.2.1 Abstract
Besides alkaline and acidic hydrolysis of wastewaters was studied. Alkaline
hydrolysis did not increase the concentration of these drugs, indicating that
glucuronide metabolites are hydrolysed in parent drugs before the sewage
treatment plant.
C.2.2 Introduction
For many acidic NSAIDs, it is well known that urinary excretion of the
parent drugs is very low (about 5% of the administered dose, see Table 2.1
on page 21). For the substances studied here, conjugation of parent com-
pounds and their phase I metabolites to their corresponding glucuronides or
sulfates is frequent. For instance, after the administration of Ibuprofen, 13%
of the dose is excreted in urine as its acyl glucuronide metabolite [Geisslinger
et al., 1989], but only 1% of free Ibuprofen. Several methods have been pub-
lished for the indirect analysis of acyl glucuronide in plasma and urine, by
measuring Ibuprofen prior to and after hydrolysis [Castillo & Smith, 1993;
El Haj et al., 1999; Bauza et al., 2001]. Hirai et al. [1997] describe three
kinds of hydrolysis: (1) enzymatic, (2) acidic and (3) alkaline. These hydrol-
ysis are commonly used for the quantification of glucuronide metabolites of
NSAIDs in urine. To our knowledge, none of these hydrolysis was tested with
wastewaters. Therefore, the aim of this study was to test acidic and alkaline
hydrolysis to quantify the glucuronide metabolites of the four substances
studied (Ibuprofen, Ketoprofen, Mefenamic acid and Diclofenac).
C.2.3 Experimental section
Hydrolysis was carried out at the beginning of the analytical procedure,
just after the filtration. Two types of acidic and alkaline hydrolysis were
tested on an influent of Mittleres Emmental STP. Enzymatic hydrolysis was
not tested. Indeed, the results of Hirai et al. [1997] showed that this hydrolysis
can be employed only for one NSAID (Sulindac).
The first acidic hydrolysis, based on El Haj et al. [1999], was performed
by adding 50 ml of HCl (32%) to obtain a ∼2M HCl solution which was
heated at 80◦C for 30 minutes. For the second acidic hydrolysis, the pH was
adjusted to ∼2 with HCl and heated at 80◦C for one hour. In the first alkaline
hydrolysis, the sample was adjusted to pH 12 with 5M NaOH, then heated at
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80◦C for one hour [Castillo & Smith, 1993]. The second alkaline hydrolysis,
which was based on Bauza et al. [2001], was performed by adding 20 ml
of 1M NaOH and heating at 80◦C for 30, 60 or 90 minutes. After alkaline
hydrolysis, pH was adjusted to 2 with HCl.
Table C.1: Various hydrolysis tested
Hydrolysis Acid or base Final concentration or Temp. Duration
adjustment of pH
Acidic 50 ml of HCl ∼2M HCl 80◦C 30 min.
Acidic HCl pH2 80◦C 60 min.
Alkaline 5M NaOH pH12 80◦C 60 min.
Alkaline 20 ml of 1M
NaOH
80◦C 30, 60 and
90 min.
C.2.4 Results and discussion
Both methods of acidic hydrolysis showed a decrease of concentrations
for the four substances measured in the test sample. When acidic hydrolysis
was conducted according to the conditions proposed by El Haj et al. [1999],
concentrations of Mefenamic acid and Diclofenac were below the limit of
detection. Hirai et al. [1997] also pointed out that recoveries of Mefenamic
acid were decreased and that Diclofenac disappeared with acidic hydrolysis.
This shows that these methods of hydrolysis are not suitable to analyze
glucuronide metabolites in wastewaters.
The alkaline hydrolysis did not seem to degrade the parent substances,
and the process of hydrolysis did not increase the concentrations of all of
substances in the sample. Unlike urine, where Ibuprofen concentrations were
five times higher after hydrolysis [Hirai et al., 1997], influents of Mittleres
Emmental STP did not seem to contain glucuronide metabolites. According
to Heberer [2002a], the conjugated metabolites can easily be cleaved during
sewage treatment and parent compounds will be released into the aquatic
environment. According to our results, such metabolites have probably been
naturally hydrolyzed before the Mittleres Emmental STP. Indeed, wastew-
aters are rarely at neutral pH and, for instance, the half-life of Mefenamic
acid glucuronide under alkaline condition is lower than at pH 7.4 [McGurk
et al., 1996]. This hypothesis is confirmed by the fact that influent concen-
trations are close to the PECinf calculated with excretion of conjugated and
unchanged compounds (see Table 2.4 on page 31).
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Lake Geneva
C.3 Analysis of the NSAIDs and clofibric acid
in a surface water sample: Lake Geneva
C.3.1 Experimental section
The analysis of the sample (1l) was performed as described in the Ap-
pendix B.1 on page 181.
C.3.2 Results and discussion
Table C.2: Concentration [ng/l] of NSAIDs and Clofibric acid in a sample of
Lake Geneva and comparison with the literature data and the contamination
of STPs
Substances Lake Geneva
[ng/l]
Literature results
[ng/l]
Treated waters
of studied STPs
(min-max) [ng/l]
Clofibric acid 5 <1 - 9 (Lakes)a nd - 270
Ibuprofen 3 nd - 4 (Lakes)b 150 - 2500
Ketoprofen 0.4 nd- 200 (Rivers) c 100 - 340
Mefenamic acid 5 ∼10 (Rivers) d 470 - 3000
Diclofenac 1 <1 - 3 (Lakes) e 600 - 2500
aBuser et al. [1998b]
bBuser et al. [1999]
cStumpf et al. [1999]
dAhrer et al. [2001]
eBuser et al. [1998a]
The results presented in Table C.2 show that the concentrations in the
sample of Lake Geneva was well correlated with the concentrations in treated
wastewaters. Indeed, for the highly concentrated substances in wastewaters
(also the highly used: Ibuprofen and Mefenamic acid), the concentrations in
the Lake were high. The concentration of Clofibric acid was also relatively
important. This contamination was not due to the treated wastewaters where
the concentration of clofibric acid was low, but due to the persistent behavior
of this substance, which is also detected far away of the population (North
Sea up to 7.8 ng/l [Buser et al., 1998b]).
The measured concentrations in this sample was the same order of mag-
nitude than in the literature data.
210
APPENDIX C. COMPLEMENTARY RESULTS
C.4 Conditions for SPE Extractions of 5-Fluo-
rouracil and Tamoxifen
Table C.3 (page 212) shows the results of several extractions with ENVI-
18 (Supelclean; Supelco), Isolute 101 (Separtis), C2 (Isolute; Separtis) and
LC-NH2 (Supelclean; Supelco).
Tables C.4 and C.5 (pages 213-214) shows the results of extractions with
ENV+ (200mg, 500mg, 1g; ISOLUTE) of 5-Fluorouracil in different volumes
of MQwater.
Table C.6 (page 215) shows the results of extractions with MCX and HLB
plus (OASIS) of Tamoxifen with different wash steps.
Legends: P1: Phosphate Buffer pH=3; P2: Phosphate Buffer pH=5 (See
Appendix B.2, page 189).
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C.5. Conditions for 5-Fluorouracil derivatisations
C.5 Conditions for 5-Fluorouracil derivatisa-
tions
Table C.7 (page 217) shows the results of several tests of derivatisation of
5-Fluorouracil. Various catalysts (triethylamine and K2CO3), durations (0h
to 3h) and temperatures (20◦C to 100◦C) were tested.
Table C.8 (page 218) shows the results of several tests of derivatisation
of 5-Fluorouracil. Subtle changes in concentrations of Pentafluorobenzyl bro-
mide (PFBBr), in durations (1h-3h) and temperatures (80◦C to 150◦C) were
tested.
Table C.9 (page 219) shows the results of several repeatability tests of
derivatisation of 5-Fluorouracil. Most of the changes were in concentrations
of Pentafluorobenzyl bromide (PFBBr), in solvents and catalysts (triethy-
lamine, K2CO3 and K2HPO4) used.
The results show that for a complete and repeatable derivatisation, the
quantity of PFBBr have to be relatively important. 400 µl of the solution
of PFBBr (2%) was not enough. 600 µl of PFBBr (4%) showed a significant
improvement.
The catalysts were in enough quantity, indeed no significant increase of
the area were observed with 15 µl of triethylamine (triet.) instead of 7.5 µl.
An increase of temperature was necessary for a complete derivatisation,
indeed even with 20% of PFBBr (at 20◦C) only 40% of substance was de-
tected. With acetonitrile (ACN), evaporation (and sometimes losses) ap-
peared with a temperature higher than 80◦C.
No loses were observed when 5-FU-PFBBr was evaporated till dryness
under a gentle stream of nitrogen.
Derivatisation with K2CO3 or K2HPO4 worked better than with triethy-
lamine, 240% and 315% respectively. K2HPO4 seemed very efficient, but an
impurity was detected very close to 5-Fluorouracil in GC/MS.
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Table C.7: Conditions for 5-Fluorouracil derivatisations
Quantity of
Pentafluorobenzyl bromide
(PFBBr)
Catalyst Time and
Temperature
% Area
15 µl PFBBr in 400 µl TOL 6 µl triet. 1 h - 100◦C 100%
10 µl PFBBr in 800 µl TOL 4 µl triet. 1 h - 90◦C 90%
10 µl PFBBr in 800 µl TOL 4 µl triet. 1 h - 60◦C 0%
10 µl PFBBr in 800 µl TOL 4 µl triet. 1 h - 20◦C 0%
15 µl PFBBr in 400 µl TOL 6 µl triet. 1 h - 100◦C 100%
15 µl PFBBr in 400 µl TOL 6 µl triet. 1 h - 90◦C 95%
15 µl PFBBr in 400 µl TOL 6 µl triet. 1 h - 60◦C 20%
15 µl PFBBr in 400 µl TOL 6 µl triet. 1 h - 20◦C 3%
600 µl PFBBr/TOL (2%) 6 µl triet. 1 h - 90◦C 100%
600 µl PFBBr/TOL (2%) 6 µl triet. 3 h - 60◦C 80%
480 µl PFBBr/ACN (15%) 120 µl triet. 0.5 h - 20◦C gelatin
40 µl PFBBr/ACN (15%) +
560 µl ACN
- direct inj 0%
100 µl PFBBr/ACN (2%) +
1 ml ACN
100 µl K2CO3 3 h - 60
◦C 200%
600 µl PFBBr/TOL (2%) 6 µl triet. 1 h - 90◦C 100%
40 µl PFBBr/ACN (15%) +
560 µl ACN
6 µl triet. 1 h - 90◦C gelatin
40 µl PFBBr/ACN (15%) +
560 µl ACN
- 1 h - 90◦C 0%
600 µl PFBBr/TOL (2%) 6 µl triet. 1 h - 90◦C 100%
600 µl PFBBr/TOL (2%) 6 µl triet. 3 h - 60◦C 84%
100 µl PFBBr/ACN (15%) +
1 ml ACN
100 µl K2CO3 3 h - 60
◦C 170%
100 µl PFBBr/ACN (15%) +
1 ml ACN
100 µl K2CO3 1 h - 90
◦C 180%
TOL: Toluene; ACN: Acetonitrile; triet: triethylamine
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Table C.8: Duration and Temperature of derivatisations
Quantity of
Pentafluorobenzyl
bromide (PFBBr)
Catalyst Time and
Temperature
% Area
400 µl PFBBr/TOL
(2%)
5 µl triet. 1 h - 100◦C 100%
idem 5 µl triet. 1.5 h - 100◦C 100-135%
(Mean: 117%)
idem 5 µl triet. 2 h - 100◦C 117-125%
(Mean: 121%)
idem 5 µl triet. 3 h - 100◦C 111-121%
(Mean: 116%)
100 µl PFBBr/ACN
(20%) + 1 ml ACN
100 µl K2CO3 1 h - 90
◦C 100%
200 µl PFBBr/ACN
(20%) + 1 ml ACN
100 µl K2CO3 1 h - 90
◦C 100%
100 µl PFBBr/ACN
(20%) + 1 ml ACN
100 µl K2CO3 2 h - 90
◦C 100%
idem 100 µl K2CO3 2.5 h - 90
◦C 90%
idem 100 µl K2CO3 1 h - 100
◦C 95%
idem 100 µl K2CO3 2 h - 100
◦C 95%
idem 100 µl K2CO3 1 h - 80
◦C 120%
idem 100 µl K2CO3 2 h - 80
◦C 120%
400 µl PFBBr/TOL
(2%)
5 µl triet. 1 h - 100◦C High variation, but
a higher area was
never observed in
the samples with
higher temperature
than 100◦C.
idem 5 µl triet. 1 h - 110◦C
idem 5 µl triet. 1 h - 120◦C
idem 5 µl triet. 1 h - 150◦C
TOL: Toluene; ACN: Acetonitrile; triet: triethylamine
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C.6. Conditions for LLE Extractions of Tamoxifen and 5-Fluorouracil
C.6 Conditions for LLE Extractions of Ta-
moxifen and 5-Fluorouracil
Table C.10: Conditions for LLE extractions of Tamoxifen and 5-
Fluorouracil in bi-distilled water (n=1)
Solvent Volume of water Volume of sol-
vent
Recovery (n=1)
5-FU TAM
Ethyl acetate 0.25 l 2 x 120 ml 0% 15%a
Dichloromethane 1 l (+ 100g NaCl) 3 x 60 ml - 100-110%b
Diethyl ether 1 l (+ 100g NaCl) 1 x 120 ml and
2 x 60 ml
- 73-77%b
aLosses during the rotary evaporation
b2 ml of methanol was added to increase the stability of TAM during the rotary evap-
oration
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C.7 Raw data of the Ames test including tox-
icity assays
All raw data of the results presented in Chapter 4 are shown here. See
Section 4.2 on page 60 for a description of the assays and Section 4.2.6 on
page 63 for a description of statistical analysis.
TA102 - Toxicity (dilution method)
0
200
400
600
800
1000
1200
Control RA -
MON
RA -
TUE
RA -
WED
RA -
WED
(D)
RA -
THU
RA -
FRI
RA -
SAT
RA -
SUN
C
o
lo
n
ie
s
 (
N
B
)
TA102 - Mutagenicity
0
100
200
300
400
500
600
700
800
Control RA -
MON
RA -
TUE
RA -
WED
RA -
WED
(D)
RA -
THU
RA -
FRI
RA -
SAT
RA -
SUN
R
e
v
e
r
ta
n
ts
 (
N
B
)
TA102 - Mutagenicity adj2
0
500
1000
1500
2000
2500
3000
3500
Control RA -
MON
RA -
TUE
RA -
WED
RA -
WED
(D)
RA -
THU
RA -
FRI
RA -
SAT
RA -
SUN
R
e
v
e
r
ta
n
ts
 (
N
B
)
TA102 - Toxicity (dilution method)
0
100
200
300
400
500
600
Control CHUV
- MON
CHUV
- TUE
CHUV
- WED
CHUV
- THU
C
o
lo
n
ie
s
 (
N
B
)
TA102 - Mutagenicity
0
100
200
300
400
500
600
700
Control CHUV
- MON
CHUV
- TUE
CHUV
- WED
CHUV
- THU
R
e
v
e
r
ta
n
ts
 (
N
B
)
TA102 - Mutagenicity adj2
0
200
400
600
800
1000
1200
1400
1600
1800
2000
Control CHUV
- MON
CHUV
- TUE
CHUV
- WED
CHUV
- THU
R
e
v
e
r
ta
n
ts
 (
N
B
)
0
200
400
600
800
1000
1200
1400
1600
1800
Control CHUV -
FRI
CHUV -
SAT
CHUV -
SUN
0
500
1000
1500
2000
2500
3000
3500
4000
4500
Control CHUV -
FRI
CHUV -
SAT
CHUV -
SUN
0
100
200
300
400
500
600
700
800
900
Control CHUV -
FRI
CHUV -
SAT
CHUV -
SUN
< < < < < <
< < < < < < <
< < < <
< > > > > > >
> >
> > > > > >
> > > >
Figure C.2: TA102 - Raw data results of the mutagenicity and toxicity
assays for the hospital (CHUV) and the Residential area of Lausanne (RA).
<: statistically significant lower than in the control. >: statistically significant
higher than in the control. D: sampling from 7am to 9pm
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Figure C.3: TA102 - Raw data results of the mutagenicity and toxicity
assays for Lausanne (Vidy) influents and eﬄuents. <: statistically significant
lower than in the control. >: statistically significant higher than in the control
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Figure C.4: TA102 - Raw data results of the mutagenicity and toxicity
assays for Morges influents and eﬄuents. <: statistically significant lower
than in the control. >: statistically significant higher than in the control
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Figure C.5: TA1538 - Raw data results of the mutagenicity and toxicity
assays for the hospital (CHUV) and the Residential area of Lausanne (RA).
<: statistically significant lower than in the control. >: statistically significant
higher than in the control. D: sampling from 7am to 9pm
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Figure C.6: TA1538 - Raw data results of the mutagenicity and toxicity
assays for Lausanne (Vidy) influents and eﬄuents. <: statistically significant
lower than in the control. >: statistically significant higher than in the control
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C.7. Raw data of the Ames test including toxicity assays
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Figure C.7: TA1538 - Raw data results of the mutagenicity and toxicity
assays for Morges influents and eﬄuents. <: statistically significant lower
than in the control. >: statistically significant higher than in the control
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APPENDIX C. COMPLEMENTARY RESULTS
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Figure C.8: TA100 - Raw data results of the mutagenicity and toxicity
assays for the hospital (CHUV) with and without enzymatic activation (S9).
<: statistically significant lower than in the control. >: statistically significant
higher than in the control
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C.7. Raw data of the Ames test including toxicity assays
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Figure C.9: TA100 - Raw data results of the mutagenicity and toxicity
assays for Lausanne (Vidy) and Morges influents. <: statistically significant
lower than in the control. >: statistically significant higher than in the control
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Figure C.10: TA100 - Raw data results of the mutagenicity and toxicity
assays for the Residential area of Lausanne (RA). <: statistically significant
lower than in the control. >: statistically significant higher than in the con-
trol. D: sampling from 7am to 9pm
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C.7. Raw data of the Ames test including toxicity assays
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Figure C.11: TA98 - Raw data results of the mutagenicity and toxicity
assays for the hospital (CHUV) with and without enzymatic activation (S9).
<: statistically significant lower than in the control. >: statistically significant
higher than in the control
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